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Abstract
The application of medicinal chemistry drug design and development principles has
been undertaken in the current thesis towards the development of antivirals,
fluorescent anion transporters and carbonic anhydrase inhibitors.
Chikungunya viral infection is an increasing concern with no current treatments
available beyond supportive measures. In the absence of detailed viral molecular
information, phenotypic screening of compounds has provided leads for antichikungunya agents. Chapter 2 discusses the application of hybridization of two
fragments, namely pyrimidine and thiazolidine, with reported anti-CHIKV activity.
Convergent and convenient regioselective synthesis of novel thiazolo[2,3a]pyrimidine derivatives was accomplished using the one-pot reaction of 6ethylthiouracil, bromoacetic acid, anhydrous sodium acetate, acetic anhydride,
acetic acid and a suitable aldehyde. X-ray crystallographic studies reveal the
presence of the Z configuration of only one regioisomer confirmed by
computational studies as being the most likely isomer present. Anti-CHIKV
activity evaluation showed the tailed thiazolopyrimidine (Z)-7-ethyl-2-((4'-methyl[1,1'-biphenyl]-4-yl)methylene)-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)-dione as a
candidate for future development with EC50 = 42 μM, and IC50 > 250 μM against
the breast cancer cell line MCF-7 and the endothelial human sapiens cell line
EA.hy926.
Chapter 3 reports the synthesis and chikungunya antiviral activity of 1-aryl[1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-ones as bioisosteres for the 5-ethyl-3-(3isopropoxyphenyl)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one related
antiviral series. Importantly, this new scaffold features increased scope for
ix

derivatisation, exhibits low cytotoxicity, is efficiently and scalably synthesised and
is relatively inexpensive. Compound, 3-acetyl-5-ethyl-1-(3-isopropoxyphenyl)[1,2,4]triazolo[4,3-a]pyrimidin-7(1H)-one 3.33, being the 3-acetyl analogue of the
protype 3.1 emerged as having the most promising antiviral activity among the
tested series 3.29-3.39 with EC50 = 38 μM, and IC50 > 300 μM against breast cancer
cell lines, MCF-7 and MDA-MB-231 and normal cell line EA.hy926. Analysis of
the bioactivities of several compounds including the related 2-anilino-pyrimidones
using Density-Functional Theory (DFT) modelling provides insights into salient
ligand-target interactions necessary for antiviral activity and allows for the drafting
of a general pharmacophore
Chapter 4 discusses the development and derivatization of the hit compound
NCI_37168 (3-hydroxy-N-(3-nitrophenyl)-2-naphthamide) discovered from virtual
screening search using the NCI Diversity Set II database (1541 compounds). A
small library of 3-hydroxy-N-(3-nitrophenyl)-2-naphthamides were synthesized
and biologically evaluated for their anti-CHIKV activity. These compounds were
toxic to Vero cells at the tested concentration (20 µg/mL). Further development and
anti-CHIKV testing at lower concentration are planned be done to investigate their
antiviral activity, while lowering their cytotoxic effect.
The second part of this dissertation was the development of fluorescent anion
transporters for pharmacological evaluation. Anionophores are small organic
molecules that facilitate anion transport across lipid bilayer membranes. Chapter
5 discusses developing a method to switch on the anion transport function under
specific conditions that would dramatically widen the scope of compounds.
Therefore, they could be employed as potential therapeutics. This chapter presents
the design, synthesis of fluorescent anion transporters and investigation of their
x

anion transporter and binding properties. Further, we developed four switchable
complexes that are switched on in the presence of the physiologically reducing
agent GSH and non-physiological reducing agents DTT and TCEP.
In chapter 6, a series of coumarin-based bisureas have been synthesised and their
anion transport properties studied. The transporters function as highly potent HCl
co-transport agents in lipid bilayer membranes. These compounds elicited a H+/Clco-transport activity and a superior Cl-/NO3- exchange ability in ISE-based affinity
than the previously reported fluorescent anion transporters. The fluorescence nature
of these compounds will allow them to be localised within cells. A study of their
potential cellular localisation, partitioning, and action using fluorescence imaging
techniques is currently undergoing.
The third part of this thesis (Chapter 7) is the development of potent dual-tailed
benzenesulfonamide inhibitors of human carbonic anhydrases implicated in
glaucoma. The study investigated the in vivo profiling of their intraocular pressure
lowering action. The design and synthesis of three dual-tailed sulfonamide series
as carbonic anhydrase inhibitors are presented. All synthesized compounds were
evaluated for their inhibitory action against pharmacologically relevant human (h)
CAs

isoforms

(I,

II,

IV,

and

VII).

The

(E)-2-arylidene-3-oxo-N-(4-

sulfamoylphenyl)butanamides emerged as the most potent CA inhibitors against
the four tested isoforms with a significant selectivity to CA II, which is implicated
in glaucoma (Ki values spanning the range 0.36 - 6.9 nM). X-ray crystallographic
analysis of three compounds bound to CA II showed the validity of the adopted
drug design strategy as specific moieties within the ligand structure interacted
directly with the hydrophobic and hydrophilic halves of the CA II active site
enhancing the inhibition efficiency. Compounds (E)-2-(4-chlorobenzylidene)-3xi

oxo-N-(4-sulfamoylphenyl)butanamide and (E)-2-(4-methoxybenzylidene)-3-oxoN-(4-sulfamoylphenyl)butanamide showed significant anti-glaucoma efficacy
when compared to the clinically used drug dorzolamide, presenting potential for
the development of new therapeutic options against glaucoma.

xii

List of publications arising from this thesis (to date)
a- Journal articles:
1. Fares, M.; McCosker, P. M.; Alsherbiny, M. A.; Willis, A. C.; Clark, T.;
Neyts, J.; Jochmans, D.; Keller, P. A., Regioselective convergent synthesis of
2-arylidene thiazolo[3,2-a]pyrimidines as potential anti-chikungunya agents.
RSC Adv. 2020, 10, 5191-5195 (doi: 10.1039/D0RA00257G). Described in
Chapter 2.
2. Fares, M.; Canfield, P.; Alsherbiny, M. A.; Lewis W.; Willis, A. C.; Li, C. G.;
Neyts, J.; Jochmans, D.; Gale, P. A.; Keller, P. A., 1-Aryl-[1,2,4]triazolo[4,3a]pyrimidines, a synthetically facile scaffold for chikungunya antiviral agents,
reveals insights into the viral target-binding site. Submitted to RSC Med. Chem.
Described in Chapter 3.
3. Fares, M.; Wu, X.; Soto-Cerrato, V.; Lewis W.; Keller, P. A.; Howe, E. N. W.;
Pérez-Tomás, R.; Gale, P. A., Stimuli-responsive cycloaurated ‘OFF-ON’
switchable fluorescent anion transporters. Angew. Chem. 2020, (doi:
10.1002/anie.202006392 and 10.1002/ange.202006392). Described in Chapter
5.
4. Fares, M.; Wu, X.; Soto-Cerrato, V.; Lewis W.; Keller, P. A.; Pérez-Tomás,
R.; Gale, P. A., Coumarin-bisurea hybrids as potent fluorescent transmembrane
anion transporters. Prepared a communication for submission to Chem. Comm.
Described in Chapter 6.
5. Fares, M.; Eldehna, W. M.; Bua, S.; Lanzi, C.; Lucarini, L.; Masini, E.; Peat,
T. S.; Abdel-Aziz, H. A.; Nocentini, A.; Keller, P. A.; Supuran C. T., Discovery
of potent dual-tailed benzenesulfonamide inhibitors of human carbonic
anhydrases implicated in glaucoma and in vivo profiling of their intraocular
xiii

pressure

lowering

action,

J.

Med.

Chem.

2020

(doi:

10.1021/acs.jmedchem.9b02090). Described in Chapter 7.
6. Fares, M.; Abd El Hadi, S. R.; Eladwy, R. A.; Shoun A. A.; Abdel-Aziz, M.
M.; Abdel-Aziz, H. A.; Keller, P. A., An improved synthesis of pyrido[2,3d]pyrimidin-4(1H)-ones and their antimicrobial activity, Org. Biomol. Chem.
2018, 16, 3389-3395 (doi: 10.1039/C8OB00627J).
7. Fares, M.; Eladwy, R. A.; Nocentini, A.; Abd El Hadi, S. R.; Ghabbour, H. A.;
Abdel-Megeed, A.; Eldehna, W. M.; Abdel-Aziz, H. A.; Supuran, C. T.,
Synthesis

of

bulky-tailed

sulfonamides

incorporating

pyrido[2,3-

d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl) moieties and evaluation of their
carbonic anhydrases I, II, IV and IX inhibitory effects. Bioorg. Med. Chem.
2017, 25, 2210-2217 (doi: 10.1016/j.bmc.2017.02.037).

b- Conference Abstracts (presenter underlined)
Oral presentations:
1. Fares, M.; Willis, A. C.; Neyts, J.; Jochmans, D.; Keller, P. A., “Medicinal
Chemistry Towards Anti-CHIKV Agents” UOW Annual Chemistry
Conference 2017, Blue Mountains, Australia, 1st–3rd November 2017.
Presentation awarded highly commended talk by a second-year PhD
student.
2. Fares, M.; Willis, A. C.; Neyts, J.; Jochmans, D.; Keller, P. A., “Drug Design
Development Targeting Chikungunya Virus” UOW Annual Chemistry
Conference 2016, Blue Mountains, Australia, 2nd–4th November 2016.
Presentation awarded highly commended talk by a first-year PhD student.

xiv

Oral presentations:
1. Fares, M.; Howe, E. N. W.; Wu, X.; Keller, A. P.; Gale, A. P., “Development
of “Switch-on” Fluorescent Anionophores”, 14th International Symposium on
Macrocyclic and Supramolecular Chemistry (ISMSC2019), Lecce, Italy,
2019, 2nd June-6th June.

xv

Context Statement
This thesis is presented as a compilation of manuscripts from published and
unpublished work. The science is both multi-disciplinary and collaborative in
nature. Chapters either stand separately or together to present the science achieved
in the field of drug design and development of antivirals targeting chikungunya
virus, anion transporters and carbonic anhydrase inhibitors. At the start of each
chapter is a foreword with references added at the end of each chapter.
The outcomes of this dissertation are presented in Chapters 2-7 with overarching
conclusions and future directions in Chapter 8. Appendices are provided at the end
of this thesis including NMR spectra of the synthesized compounds, Figures of
NMR binding and anion transport studies, and protein X-ray crystallography data.
From the beginning of the project it was thought that the anti-chikungunya virus
project (Chapters 1-4) was challenging, and therefore a component of the
dissertation plan was to investigate alternative topics. To this end, an internship at
the University of Sydney was available in the fields of supramolecular chemistry
and anion transporters. The outcomes from this internship are described in
Chapters 5 and 6. Further, arising from an established collaboration in the design
of carbonic anhydrase inhibitors, this dissertation also explored a new direction in
this area (Chapter 7).

A detailed description of each topic follows:
A)

Anti-chikungunya virus agents:

Chikungunya virus (CHIKV) (alphavirus genus, family Togaviridae) is one of the
prevalent arboviruses that is implicated in high fever and severe persistent joint
pain that may last for weeks to years. In the view of absence of anti-CHIKV and
xvi

the reported multiple re-emergent epidemic outbreaks of the CHIKV in the last 70
years, there is a pressing need to discover new anti-CHIKV agents. A literature
review of the chikungunya virus biology and previous approaches used towards the
development of anti-chikungunya agents is presented in Chapter 1.
In this dissertation, considerable efforts were directed towards the development of
potential anti-CHIKV therapeutics via applying medicinal chemistry concepts
(Chapter 2 and 3) and structure-based drug design approaches (Chapter 4).
Chapter 2 describes the application of the hybridization of existing CHIKV
inhibitors towards the development of unprecedent anti-CHIKV agents. Molecular
hybridization is fundamentally based on the fusion of two or more pharmacophoric
moieties. Recently, hybridization of two or more bioactive fragments has emerged
as a concept for the exploration of novel multitarget acting inhibitors as well as
novel anti-CHIKV agents. This chapter discusses a molecular hybridization
approach with the fusion of uracil and rhodanine pharmacophoric moieties and
investigation of the biological activity against CHIKV. Uracil-rhodanine hybrids
were synthesized using the state-of-art organic chemistry starting from 6-ethyl-2thiouracil and by optimization of the multi-component collective reaction
conditions via replacing chloroacetic acid with the more regioselective bromoacetic
acid, lowering reaction temperature and changing the mode of addition. X-ray
crystal structure analysis and computational studies showed that only one
regioselective isomer formed with the Z configuration that is potentially stabilized
by two intramolecular hydrogen bonds. The synthetic phase was followed by
biological evaluation of the compounds as anti-CHIKV agents. The compounds
demonstrated different percentages of viral replication inhibition at 20 µg/mL-1
with (Z)-7-ethyl-2-((4`-methyl-[1,1`-biphenyl]-4-yl)methylene)-5H-thiazolo[3,2xvii

a]pyrimidine-3,5(2H)-dione showing the best activity with 58% inhibition of
CHIKV replication. Anti-CHIKV activity evaluation showed the (Z)-7-ethyl-2((4`-methyl-[1,1`-biphenyl]-4-yl)methylene)-5H-thiazolo[3,2-a]pyrimidine3,5(2H)-dione as a promising lead compound for future development with EC50 =
42 μM, with IC50 > 250 μM against the breast cancer cell line MCF-7 and the
endothelial human sapiens cell line EA.hy926. This compound is bearing pmethylbiphenyl tail functionality which might interact favourably with the target.
This chapter is published in RSC Adv. 2020, 10, 5191-5195 (doi:
10.1039/D0RA00257G).
Chapter 3 discusses drug design and development of potential antiviral agents
using synthetic modification including lead simplification and bioisosteric
replacement. Using 6-ethyl-2-thiouracil as a starting material, two series of fused
1-aryl-[1,2,4]triazolo[4,3-a]pyrimidines and 2-anilinopyrimidines were designed
and synthesized using the state-of-art organic chemistry. Single X-ray crystal
structure of two target compounds confirmed the formation of the desired isomer.
Tested compounds showed promising in silico pharmacokinetic properties
calculation and drug likeness scores. Compounds [1,2,4]triazolo[4,3-a]pyrimidin7(1H)-ones and 2-anilinopyrimidin-4(3H)-one were screened for their antiviral
activities in a viral-cell based assay against chikungunya virus (Indian Ocean strain
899). The most active compounds were further tested for their cytotoxic activity
against the normal cell line, EA.hy926, the endothelial human cell line, and two
human breast cancer cell lines, namely, MCF-7 and MDA-MB-231. Whilst the
series 2-anilinopyrimidines, proved to only exhibit weak anti-CHIKV activity,
derivative

3-acetyl-5-ethyl-1-(3-isopropoxyphenyl)-[1,2,4]triazolo[4,3-

a]pyrimidin-7(1H)-one emerged as the most active antiviral agent (EC50 = 38 μM)
xviii

and the least cytotoxic with IC50 > 300 μM against breast cancer cell lines, MCF-7
and MDA-MB-231 and normal cell line EA.hy926. Comparisons of the geometries
and electrostatic potential-mapped surfaces (EPS) of the active CHIKV inhibitors
has allowed for a consensus model for effective target binding. A manuscript based
on the results from Chapter 3 is in preparation for submission to RSC Med. Chem.
Chapter 4 presents the application of structure-based drug design concepts towards
anti-CHIKV agents. In silico screening of the NCI Diversity set II database (1541
compounds) in our laboratory against three viral proteins, namely nsP2, nsP3 and
envelope glycoproteins identified eleven potential inhibitors. The selected ligands
were requested from Developmental Therapeutics Program Databases and Search
Tools, National Cancer Institute, USA and were tested in Rega Institute, KU
Leuven, Belgium for their anti-CHIKV activity. Three CHIKV agents were
identified possessing naphthalene and quinoline scaffolds. A small library of
molecules based on the naphthalene scaffold was synthesized and tested for its antiCHIKV activity. The naphthalene scaffold showed considerable toxicity to Vero
cells, which might impede the antiviral activity. Further development of the
quinoline scaffold could be undertaken with planned iterative cycles of
optimization.

B) Fluorescent anion transporters:
The transport of ions via phospholipid bilayer membranes is involved in diverse
physiological functions including, neuroexcitation, muscle contraction, cell
migration and proliferation, and maintaining cellular pH, membrane potential and
cellular secretions. Channelopathies are a group of diseases characterised with ionchannel impairment, including cystic fibrosis, epilepsy and cancer. For example,
xix

cystic fibrosis transmembrane regulator (CFTR) is a protein responsible for
maintaining cellular chloride and bicarbonate levels and is implicated with cystic
fibrosis, while impairment of sodium, potassium and T-type calcium channels is
linked with epilepsy. Ionophores are transmembrane ion transporters that have
been recognised for diverse applications in ion sensing, catalysis and in medicinal
chemistry. Anionophores are a subclass of the ionophores that are capable of
transporting anions and they demonstrated a cytotoxic effect against stem cancer
cells by facilitating the transport of chloride and bicarbonate anions so changing
cellular pH, causing cellular differentiation and death.
One of primary aims of this PhD work was to design and synthesise fluorescent
anionophores and to investigate the mechanism of action of their cytotoxic effect
in living cells. A literature review of the fluorescent anion transporters (Chapters
5 and 6) is included in the beginning of these chapters.

Chapter 5 describes the development of stimuli-responsive cycloaurated ‘OFFON’ switchable fluorescent anion transporters. Inspired by the high affinity of
thiols, such as GSH, for gold, and by the reported efficient anion transport activity
of 1,3-bis(benzimidazol-2-yl)benzenes, we designed and synthesized new
switchable cycloaurated anion transporters that could be switched under
physiological conditions such as high levels of GSH. Five 1,3-bis(benzimidazol-2yl)benzenes anion transporters have been synthesized by condensation of
dipicolinic acid or 2,6-pyridinedicarboxaldehyde and phenylenediamine derivative
under acidic conditions. The structure of one derivative was confirmed by single
crystal X-ray diffraction. These transporters have been shown to bind Cl- in
solution with moderate affinity in DMSO-d6/0.5%H2O and CD3CN. A single

xx

crystal of anionophore 2,6-bis(5(6)-(trifluoromethyl)-1H-benzo[d]imidazol-2yl)pyridine with chloride ion was obtained for X-ray and interestingly showed that
Cl- is sandwiched between two molecules of the compound. Transporters 1,3bis(benzimidazol-2-yl)benzenes were investigated for their chloride transport
property via Cl-/NO3- exchange assay using a chloride ion selective electrode (ISE),
cationophore coupled-KCl assay and 8-hydroxypyrene-1,3,6-trisulfonic acid
(HPTS) assay. At the same concentration, they showed better transport properties
when transporter loading volume increased from 10 μL to 40 μL. Transporter 2,6bis(5(6)-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridine was the most active
with EC50 = 0.42 mol%. A cationophore coupling assay, using valinomycin (Vln)
or monensin (Mon) was used to investigate whether these compounds are
functioning as Cl- uniporter or H+/Cl- symporter. Generally, these transporters can
facilitate the transport of H+, Cl- and NO3- in liposomal models. Four switchable
cycloaurated complexes were constructed from the two most potent anion
transporters. Single X-ray crystal structure of three cycloaurated complexes
confirmed their structure. The switch-off the four gold III complexes demonstrated
higher affinity to DTT, followed by GSH, while TCEP emerged as the weakest
reducing agent. Finally transport studies showed that these switchable anion
transporters are highly efficient and can be switched on by all tested reducing
agents with different rates. DTT emerged as the most potent reducing agent
followed by GSH and TCEP. This chapter is just accepted in Angew. Chem. 2020,
(doi: 10.1002/anie.202006392 and 10.1002/ange.202006392) and describes the
development stimuli-responsive cycloaurated ‘OFF-ON’ switchable fluorescent
anion transporters.
Fluorescent labelling of the sub-cellular organelles has become an indispensable

xxi

tool of our understanding of the biological functions and it can shed the light on
the mechanism of action at a cellular level. Chapter 6 describes the development
of efficient fluorescent anion transporters for biological evaluation. The
development of these fluorescent anionophores was achieved by linking the
bisureas-anion transporter moiety and the fluorescent 4-methylcoumarin. Four
bisurea-coumarin transporters were prepared by nucleophilic addition of the 6,7diamino-4-methylcoumarin with the corresponding aryl isocyanate in DCM or in
absence of solvent. The structure of one derivative was confirmed by single crystal
X-ray diffraction. The fluorescent anion receptors were tested for their anion
binding properties in solution and elicited a relatively strong chloride binding
affinity in DMSO-d6/0.5%H2O with Ka = 81 - 177 M-1.
The four receptors were investigated for their chloride transport properties across
the lipid bilayer via liposome-based techniques using a chloride ion selective
electrode (ISE), cationophore coupled-KCl assay and 8-hydroxypyrene-1,3,6trisulfonic acid (HPTS) assay. These receptors showed a superior Cl-/NO3exchange ability in ISE-based affinity and H+/Cl- co-transport activity than the
previously reported fluorescent anion transporters. These transporters could be
considered as better candidates for cellular fluorescent imaging. Chapter 6 is a
manuscript in preparation for submission to the journal Chem. Comm.

C) Design and synthesis of tailed carbonic anhydrase inhibitors:
Carbonic anhydrases (CAs, EC 4.2.1.1) constitute a superfamily of ubiquitous
metalloenzymes which principally act as catalysts in the CO2 hydration reaction.
Abnormal expression of CAs is implicated in some diseases such as cancer,
glaucoma and arthritis. A literature review of carbonic anhydrase inhibitors is

xxii

included at the beginning of Chapter 7.

Chapter 7 describes the design and synthesis of three series of dual-tailed
sulphonamides CA inhibitors using accessible and low-cost starting materials
including, sulfanilamide, acetyl acetone and ethyl acetoacetate. The newly
synthesized compounds were evaluated for their inhibitory profiles against four
carbonic anhydrase isoforms: hCA I, II, IV, and VII. The tested compounds showed
selectivity to CA II and one series emerged as the most potent CA II inhibitors with
low to sub nanomolar Ki values (0.36-6.9 nM). X-ray crystallographic studies of
the compounds against CA II were performed to further understand and rationalize
their strong CA II inhibitory profile. X-ray co-crystallographic analysis of the
adducts of hCA II with three derivatives was achieved at resolutions of 1.32-1.67
Å. The X-ray crystallographic studies showed defined moieties within the ligand
structures specifically interact with the hydrophobic and hydrophilic halves of the
CA II active site. As CA II up-regulation is implicated with glaucoma, four of the
most active CA II inhibitors (Ki values of 0.36-2.9 nM) were evaluated for their
IOP lowering action against DRZ as the standard. Compound (E)-3-oxo-N-(4sulfamoylphenyl)-2-(thiophen-2-ylmethylene)butanamide showed a comparable
IOP lowering effect to DRZ (IOP reduction = 8.5 mmHg), while compounds (E)2-(4-chlorobenzylidene)-3-oxo-N-(4-sulfamoylphenyl)butanamide and (E)-2-(4methoxybenzylidene)-3-oxo-N-(4-sulfamoylphenyl)butanamide were more potent
than DRZ with IOP reduction of 12.8 and 12.3 mmHg, respectively. Therefore, this
study

presents

compounds

sulfamoylphenyl)butanamide and

(E)-2-(4-chlorobenzylidene)-3-oxo-N-(4(E)-2-(4-methoxybenzylidene)-3-oxo-N-(4-

sulfamoylphenyl)butanamide as promising candidates for the development of

xxiii

therapeutic anti-glaucoma strategies. Chapter 7 has been accepted to J. Med.
Chem. (doi: 10.1021/acs.jmedchem.9b02090).
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Chapter 1:
Introduction

Introduction Chapter 1

1.1 Biology, re-emergence and pathogenesis of chikungunya
virus
1.1.1

Taxonomy of the chikungunya

Arboviruses that mainly use arthropod vectors for transmission between hosts are
known as arthropod-borne viruses.1,

2

They are classified into five distinctive

classes: the three major classes are the Flaviviridae, Bunyaviridae or Togaviridae
families, and the remaining two are members of the Reoviridae and
Orthomyxoviridae families (Figure 1.1).3 Figure 1.1 shows some examples of the
main five arbovirus families.
The Togaviridae family is subdivided into two genera, the Alphavirus genus and
the Rubivirus genus, with the Alphavirus genus categorized fundamentally into
seven serogroups of which 50% can cause diseases in humans.1 Chikungunya virus
(CHIKV) (alphavirus genus, family Togaviridae) is one of the prevalent tropical
alphaviruses and is transmitted by the Aedes mosquitoe (Figure 1.1).4

Figure 1.1. Schematic representation of arbovirus subclasses taxonomy.

1.1.2

Origin, re-emergence and spread of the virus

The name chikungunya is a Makonde (one of the ethnic Eastern Africa languages)
word that means harsh joints pain, which are symptoms of pathogenesis of
chikungunya virus.5 The virus was first discovered in 1952-1953 during an
1
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outbreak in eastern Africa.5 Between the 1960s and 1970s, major outbreaks were
documented in Southeast Asia and India6 and in the past sixty years, many
intermittent outbreaks re-emerged in Africa and Asia.7, 8
There was no major re-emergence of chikungunya fever until the epidemic
outbreak in Kenya in 2004, which resulted in considerable mortality and morbidity
and infection spreading to neighboring areas.4 The spreading of the virus
throughout Europe and the Americas arose from the number of adaptive mutations
of the virus that allowed exploitation of a new vector (Aedes albopictus).9
After spreading in Africa and Asia, the virus continued to spread globally
throughout Asia, Europe and regions of the Americas.10 Moreover, some countries
in the Pacific have documented epidemics of chikungunya since 2013.11 In late
2014, more than 150 deaths and 750,000 suspected cases were reported in both the
north and south American continents, Latin America and Caribbean islands.11
United States of America and Mexico have also documented new cases. In October
2014, there were 4 domestically acquired chikungunya infection patients diagnosed
in Southern France.11 In 2018, around 14,000 cases of CHIKV were reported in
Sudan, with 95% in Kassala state.12
Between Jan-Dec 2019, 56 cases of the virus were diagnosed in Australia according
to statistics from the Australian National Communicable Diseases Surveillance
(NCDS) report.13 Zika and Dengue viruses are also arboviruses in the family
Flaviviridae and share the same vectors with chikungunya virus.14 All are
transmitted to the human through the bite of an infected Aedes aegypti or Aedes
albopictus mosquito. The spread of these viruses may also trigger the re-emergence
of chikungunya virus. During 2019, 1357 Dengue virus infection cases were
2
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diagnosed and at least 13 cases with Zika Virus infection were reported in Australia
during 2019 until the date of the report.13
1.1.3

Virus lifecycle

CHIKV is a small diameter (about 60–70 nm) positive strand RNA virus that
attaches to the host cell by endocytosis in vesicles coated with clathrin (Figure
1.2).15-17 Under the acidic conditions of the endosome, a cascade of conformational
changes of the viral envelope results in dissociation of the E2-E1 heterodimers to
assemble the E1 homotrimers that catalyse the fusion to host cell membrane.18 The
viral genome and the core are then delivered into the host cell. Translation of the
viral m-RNA produces two precursors of non-structural proteins (nsPs) that are
cleaved to non-structural proteins nsP1, nsP2, nsP3 and nsp4.19 These proteins form
a replication complex that serves as the template for the synthesis of 26S
subgenomic RNAs and genomic 49S (Figure 1.2).20
The expression of the polyprotein precursor (C–pE2–6K–E1) is encoded in
the positive strand of the 26S subgenomic RNA. Subsequently, serine protease in
the Golgi complex catalyses the formation of the capsid (C), while the pE2 and E1
glycoproteins are produced by further processing.21 The pE2 and E1 are assembled
in the Golgi and moved to the plasma membrane and further pE2 is processed into
E2 and E3.22 The assembly of the viral cell is initiated in the cytoplasm, where the
nucleocapsid is generated and contains 120 dimers of the C protein (Figure 1.2).23
The assembled virion is formed by the binding of the viral nucleocapsid to the viral
RNA and released from the host cell by budding (Figure 1.2).24
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Figure 1.2: Schematic diagram of alphavirus life cycle. Reproduced with permission
from reference 4.4

1.1.4 Chikungunya fever (CHIKF)
After an incubation period of about 2-4 days, symptoms start with the onset of high
fever and severe persistent joint pain that may last for weeks to years.24 Other
symptoms of CHIKF include headache, vomiting, rash, myalgia (muscle pain),
photophobia and maculopopular rash.4, 24, 25 Unlike other arbovirus infections, only
around 15% of the patients may encounter “silent infections”. The acute phase of
CHIKV infection may last from 1-10 days, while 30-40% of the cases might have
recurrent joint pain that can last for years in some cases although this is not likely
a result of chronic infection.26 After infection, CHIKV disseminates through the
blood stream, replicates in the fibroblasts of the skin, and can affect liver, muscles,
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joints, lymphoid tissues (lymph nodes and spleen) and brain. The target cells in
each organ are indicated in Table 1.1.24
Table 1.1: Target cells of CHIKV.
Brain

Joint

Affected

Epithelial

Fibroblasts

cells

and
Endothelial

Lymphoid
tissue
Stromal cells

Muscle

Liver

Satellite

Endothelial

Macrophages

cells

cells

Fibroblasts

cells

1.1.5 Possible drug targets
There are multiple druggable targets of the CHIKV that can be categorized into six
classes:
a) Structural proteins E1-E3: E1 and E2 CHIKV glycoproteins constitute the
icosahedra shell and are involved in the attachment and interaction with the host
cell.27, 28 The structural protein E3 prevents the earlier attachment of E1-E2
heterodimer with the cell membrane.29 Many studies revealed the importance
of 4 conserved amino acid residues in E1, namely Gly91, Val178, Ala226 and
His230 to the membrane fusion.30 Mutation of Gly91 or His230 is reported to
diminish the attachment of E1 to the host cell.30 Previous computational studies
in our laboratory revealed the presence of druggable pockets in these structural
proteins.31
b)

Receptors for CHIKV entry: Viral receptors available as drug targets

include prohibitin and glycosaminoglycan which both mediate the viral
endocytosis.32,33 In addition, heat shock protein 60 (Hsp60) function in the viral
cell fusion is not fully studied but could be another conceivable CHIKV
antiviral targets.32 Furthermore, clathrin was reported to catalyse the
5
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endocytosis

dependent

pH.34

Therefore,

inhibiting

clathrin-mediated

endocytosis might be an effective strategy to control viral entry and infection.
c)

Non-structural protein 1 (nsP1): Studies on nsp1 revealed the

multifunctional roles of this protein.35 It is involved in capping and methylation
of the newly formed viral genome as well as fusion with endosomes and
lysosomes at the membrane cytoplasmic surface.36 Moreover, it inhibits the
bone marrow stromal antigen 2 (BST-2), therefore enhancing the virus
attachment at the host cell membrane. BST-2 is induced by interferon (INFα)
and it is one of the defensive mechanisms of the host cell.37
d) Non-structural protein 2 (nsP2): The nonstructural protein nsP2 (Figure
1.3) is extensively studied as a possible drug target because of its
multifunctionality with various enzymatic activity.4, 10 It is a virulence factor
which represents a potential target for CHIKV inhibitors, due to its ability to
cause a “transcriptional shutoff” (block cellular gene transcription) and impair
the host cell defense mechanism.38
The C-terminus of nsp2 contains the protease activity of the viral cell,
specifically, cysteine carboxypeptidase activity (cleavage of protein substrates
from the C termini) that enables the replication of the viral cell.39 The mechanism
of cysteine protease action is initialized by deprotonation of the thiol group of the
cysteine residue by a basic amino acid most likely a histidine residue. Cysteines
Cys1233 and Cys1290 and the four histidine residues, His1222, His1228, His1229
and His1236 could be associated in the deprotonation mechanism.40
The nsp2 enzymatic activities within the N-terminus have been
demonstrated. The N-terminal residues catalyse the first RNA capping via their
6
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intrinsic RNA triphosphatase activity. Additionally, the N-terminus exhibits
nucleotide triphosphatase activity that supplies the RNA helicase with energy.41
e)

Non-structural protein 3 (nsP3): The X-ray structure of nsp3 consists of

four asymmetric subunits, each composed of six-stranded β-sheets and four αhelices (Figure 1.3).42 nsP3 was proposed to promote CHIKV replication by
interaction of the host heat shock protein 90 (HSP90).43 The protein consists of an
N-domain and C-domain; the N-domain is highly conserved while the C-domain
is not.44 The C-terminus function was investigated and has been implicated in RNA
synthesis.44 The N-terminus of nsP3 contains a macrodomain that modulates the
metabolism of ADP-ribose and regulates the function in the cell. The alpha virus
macrodomain has a positive charge at the pocket of the ADP-ribose, however, it
has a negative charge away from the active site (which might interact with the
RNA).42

a)

b)

Figure 1.3: a) CHIKV nsP2 crystal structure (PDB id: 3TRK). Reproduced with permission
from reference 4. b) The macrodomain (nsP3) of CHIKV (PDB id: 3GPG). Reproduced with
permission from reference 42.
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Non-structural protein 4 (nsP4): The exact functions of nsP4 remain

ambiguous. A recent study stated that the alphaviruses nsP4 might downregulate
the host cell unfolding protein response (UPR) by its RNA-dependent-RNA
polymerase activity.45 UPR is a defense mechanism of the host cell that inhibits the
viral replication and protein synthesis.46 Therefore, blocking the nsP4 will retain
the normal immunological function of the UPR and control the viral infection by
enhancing the innate immunity.

1.2 Development of chemotherapeutics against chikungunya virus
1.2.1

Vaccines

Different methods have been utilised to develop vaccines against CHIKV,
including the use of inactivated vaccines, live attenuated or live vector virus, virus
like particle vaccine, consensus-based DNA vaccine, recombinant subunit
vaccines, passive immunization and plant derived vaccines.47 Despite these
attempts, only one candidate vaccine is in phase II clinical trials in humans.48
1.2.2 Hits discovered by virtual screening
The exploitation of the X-ray structures of the CHIKV proteins in the virtual
screening of libraries is a promising approach to develop new lead compounds
against the chikungunya virus.7, 10, 49 Alphavirus nsP2 protein is considered an
interesting and attractive antiviral drug target due to its crucial rule in the
replication of the viral cell. In this context, our group discovered NCI_217697 (1.1,
Figure 1.4), NCI_61610 (1.2, Figure 1.3) and NCI_67436 (1.3, Figure 1.3) as nsP2
protease inhibitors identified by virtual screening of the NCI Diversity Set II
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database.10 Agarwal et. al. reported CID_5808891 (1.4, Figure 1.3) as in silico nsP2
protease inhibitor (Figure 1.4).50

Figure 1.4: Structure of CHIKV nsP2 inhibitors identified by in silico studies.

In addition to nsP2, other computational studies performed on CHIKV proteins
identified potential inhibitors for nsP3, nsP4 or/and the envelope glycoprotein
(Table 1.2).
Table 1.2: The structures of some hit compounds identified by in silico studies against
CHIKV proteins.

Compounds
number or
name

Structure

Target

NCI_345647

nsP342

NCI_37168

nsP342
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Baicalin

nsP351

JTK 109

nsP452

NCI_293778

envelope
glycoprotein,
nsP2, nsP331

1.2.3 Anti-viral drugs inhibiting CHIKV
The screening of known antiviral drugs against emerging viral infections is a
strategy applied mainly when there is no effective chemotherapeutic agent
available. Hence, in vitro whole cell phenotypic screening of a selection of known
drugs revealed examples with anti CHIKV activity (Figure 1.5).17, 53-55
The approved antimalarial drug, chloroquine (Figure 1.5, 1.10) showed antiviral
activity among different viruses including CHIKV,56 possibly due to interaction
with the endosomes eventually preventing viral fusion to the host cell.57 However,
it showed no significant activity in a small-scale double-blind placebo-controlled
randomized trial.58 Therefore, further studies are required to evaluate its
effectiveness against the CHIKV.
The anti-viral agent ribavirin, (Figure 1.5, 1.11) a triazole guanosine analogue,
slowed the CHIKV replication in cell culture (IC50 = 83.3 mg/mL), but complete
suppression of CHIKV particles was not observed (Figure 1.5, 1.11).59,17
10
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Sofosbuvir, (Figure 1.5, 1.12), is a uridine nucleoside prodrug approved for
treatment of HCV in combination with other antiviral drugs.60 Evaluation of the
antiviral activity of sofosbuvir against CHIKV infection unveiled the potency and
selectivity of sofosbuvir over ribavirin in human liver cells infected with CHIKV
(Figure 1.5, 1.12).60 It also showed in vivo prevention of CHIKV-induced paw
edema at a dose of 20 mg/kg/day and with decreased mortality in neonatal mice at
doses of 40-80 mg/kg/day.60 Arbidol, (Figure 1.5, 1.13), (IC50 = 12.2 mg/mL) is
an approved antiviral drug for treatment of acute respiratory tract infections that
showed a broad spectrum antiviral activity and inhibited arthropod-borne
flaviviruses and alphaviruses.61, 62 It inhibited CHIKV entry by targeting the E2
viral envelope protein, which is presumably involved in binding to host receptors.63

Figure 1.5: Some known drugs inhibiting CHIKV replication.

1.2.4

Genome-wide loss of function screen

A work by Karlas et. al. (2016) used a genome wide “loss of function screening”
to identify druggable CHIKV targets.64 Using a short interfering RNA genome
wide screen, they identified 156 proviral and 41 antiviral host factors controlling
the viral replication. The study revealed that 21 small molecule inhibitors have high
11
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in vitro antiviral activity along with low toxicity. The screening focused on six
proviral factors and pathways namely, i) fatty acid synthesis; ii) the vascular type
H+ ATPase (vATPase); iii) CDC-like kinase (CLK1); iv) fms related tyrosine
kinase 4 (FLT4 or VEGFR3); v) calmodulin signalling; vi) the k (lysine)
acetyltransferase 5. An example of some of these inhibitors that emerged are
represented in Figure 1.6 (1.14 - 1.19). Interestingly, three identified inhibitors
(TOFA 1.14 and pimozide 1.15, tivozanib 1.16) achieved prophylaxis against the
viral infection in an in vivo mouse model.64 Tivozanib 1.16, linifanib 1.18 and
sorafenib 1.19 (Figure 1.6) are clinically approved tyrosine kinase inhibitors that
elicited anti-CHIKV activity in this study.64

Figure 1.6: Selected CHIKV inhibitors from genome wide-loss of function screens. CHIKV
EC50 are in parenthesis.
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1.2.5

Other inhibitors of the CHIKV

The recent advances and growing knowledge about arboviruses expand our
understanding of the CHIKV life cycle, pathogenesis and infection. Intensive
research has led to the identification of new chemical scaffolds that might be
potential anti CHIKV agents. In 2012, purine-β-lactam 1.20 and 1.21 and purineamino propanol 1.22 (Figure 1.7) were screened against nine different viruses
including CHIKV. The amino propanol derivative 1.22 (EC50 = 11.51 μM) showed
relatively higher activity when compared to the purine-β-lactam. Therefore, the βlactam is not essential for activity.65

Figure 1.7: Purines as of CHIKV inhibitors.

In an effort to find new leads as CHIKV inhibitors, a random screening identified
the [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)ones as potential candidates.66 Iterative
optimization cycles led to the most potent compound (1.23, Figure 1.8) with EC50
= 3 µM and a selectivity index greater than 600. The 3-isopropyloxyphenyl
triazolopyrimidine derivative (1.23, Figure 1.8) may be the first step in the process
of development of a clinical drug candidate.66 Rhodanine is a thiazolidin-4-one
derivative presenting a promiscuous scaffold exhibiting broad antiviral activity
against HCV, HIV-1 and chikungunya.67 In a recent study, a series of rhodanine
derivatives was tested for their anti CHIKV activity by cytopathic effect CPE
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reduction assay. Among the tested compounds, the 2-methyl analogue (1.24, Figure
1.8) displayed excellent activity with submicromolar EC50. The docking study
showed good interaction points between the ligand and CHIKV nsp2 protease.67

Non-steroidal anti-inflammatory drugs (NSAID) have been used to alleviate the
symptoms of the CHIKF because of the lack of effective prevention or curing of
the viral infection. Strikingly, NSAID can not only be used as anti-inflammatories,
but also can be considered as antiviral agents.59 Individually or in combination with
ribavirin, mefenamic acid (anthranilic acid derivative) (1.25, Figure 1.8) inhibited
the viral replication.59 The estimated EC50 of the mefenamic acid alone was 13 µM,
however the combination of mefenamic acid and ribavirin showed 3 µM inhibition.
Ching et. al. (2015) investigated the synthesis and structure-activity relationship of
a class of thieno[3,2-b]pyrroles for their antiviral activities and identified
trisubstituted thieno[3,2-b]pyrrole 5-carboxamide (1.26, Figure 1.8) as a potent and
broad antiviral agent with limited cytotoxicity. It can effectively inhibit the
expression of capsid, E2, nsP1 and nsP3 of the CHIKV.68

Figure 1.8: Selected CHIKV inhibitors with different scaffolds.
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1.3 Thesis plan
1.3.1 Drug design and development cycle
Figure 1.9 shows the drug discovery cycles, where many of the current drug
discovery strategies are relied on. Finding leads, for a certain disease, is the first
milestone along the way to the introduction of new drug.69

Figure 1.9: Iterative cycle of drug design and lead identification and optimization.

Lead identification is usually obtained by optimization of hits.70, 71 A hit is defined
as an organic or inorganic molecule that maintains reproducible activity and
selectivity in a relevant bioassay. Hit identification could be achieved by random
screening of small molecules, including using high throughput screening and
fragment-based drug design techniques, in silico screening, repurposing of known
drugs and de novo synthesis.72 A lead could be defined as a hit with defined
structure activity relationship.69 The most challenging aspects in the lead
identification include, drug like physicochemical properties, pharmacokinetics
(absorption, distribution, metabolism and elimination) and toxicity.73, 74 Iterative
15
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cycles of synthesis and biological screening would be performed for the potential
lead molecules, followed by clinical trials of the promising compounds (Figure
1.9).69

1.3.2 Application to drug design cycle towards anti-CHIKV agents
Strategies to discover antiviral agents have been described previously, however our
limited knowledge about the virus impedes drug development and therefore the
availability of a clinical anti-CHIKV drug.17
In this dissertation, one aim was to apply the basic concepts of medicinal chemistry
such as hybridization (Chapter 2), simplification or bioisosterism (Chapter 3) of
known inhibitors and the use of structure-guided drug design (Chapter 4) as steps
in the discovery of unprecedented anti-CHIKV agents (Figure 1.9). The antiviral
project design was aimed to follow the general drug design cycles (Figure 1.9).
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regioselective synthesis of

thiazolo[3,2-a]pyrimidines as potential anti-

chikungunya agents. Density functional theory (DFT) calculations were performed
to investigate the observed preference for the Z isomer, using the widely applied
M06-2X functional with a Dunnings aug-cc-pVDZ basis set. Appendix material
pertaining to this chapter can be found in Appendix A (p. 211).
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2.1 Introduction
Arboviruses mainly use arthropod vectors for transmission between hosts and they
are considered a growing global health threat.1, 2 This arises from the increasing
number of international travellers, from 450 million in 1990 to nearly 1.4 billion in
2018, and consequently travel-related diseases incidence has increased
significantly.3

Chikungunya

virus

(CHIKV)

(alphavirus

genus,

family

Togaviridae) is one of the prevalent tropical alphaviruses that is transmitted by the
Aedes mosquitoes.4, 5 After an incubation period of 2-4 days, symptoms start with
the onset of high fever and severe persistent joint pain that may last for weeks to
years.6,

7

Other symptoms of chikungunya fever (CHIKF) include headache,

vomiting, rash, myalgia (muscle pain), photophobia and maculopopular rash.6, 8
Unlike other arbovirus infections, around 15% of the patients may encounter “silent
infections”.6
A variety of strategies have been applied to develop anti-CHIKV treatments,
including vaccines, and for small molecule inhibitors, random screening, computer
aided drug design, ligand-based drug design, high throughput screening and
Genome-Wide loss of function screens.9-17 Non-steroidal anti-inflammatory drugs
(NSAID) have been used to alleviate the symptoms of the CHIKF because of the
lack of effective prevention or curing of the viral infection.18 However, so far there
is no vaccine or approved medication to prevent or treat CHIKV infection.
The recent advances and growing knowledge about the arboviruses expand our
understanding of the CHIKV life cycle, pathogenesis and infection.1-6 Intensive
research in the past 10 years has led to the identification of new chemical scaffolds
that might be potential anti CHIKV agents. Rhodanin 2.1 is a thiazolidin-4-one
derivative, presenting a scaffold that exhibited broad antiviral activity against
22
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HCV, HIV-1 and chikungunya (2.1, Figure 2.1).19 A series of rhodanine derivatives
was tested for their anti-CHIKV activity by a cytopathic effect (CPE) reduction
assay (Figure 2.1). The 2-methyl analogue 2.2 emerged as the best compound and
displayed excellent activity with submicromolar EC50 (EC50 = 0.42 µM) against
CHIKV. A docking study also showed good interaction between the ligand and
CHIKV nsp2 protease.19

Figure 2.1: Examples of heterocyclic classes showing anti-CHIKV activity, including
thiazolidineone 2.1 and 2.2, pyrimidine 2.3 and pyrimidine fused rings 2.4 and 2.5-2.7.

Among the main heterocycles that form the basis of small molecule inhibitors of
CHIKV are the pyrimidine and fused pyrimidine rings, e.g. 2.3, 2.4 and 2.5-2.7
(Figure 2.1).15, 20, 21 Recent reports indicated that hybridization between uracilcoumarin–arenes 2.3 resulted in the discovery of a novel anti-CHIKV scaffold that
was found to impede CHIKV replication.20 In an effort to find new leads as CHIKV
inhibitors, a random screening identified the [1,2,3]triazolo[4,5-d]pyrimidin7(6H)ones as potential candidates.21 Iterative optimization cycles led to the most
potent compound 2.4 with EC50 = 3 µM and a selectivity index greater than 600
(Figure 2.1).21 In 2012, purine-β-lactams 2.5 and 2.6 and purine-amino propanol
23
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2.7 (Figure 2.1) conjugates were screened against nine different viruses including
CHIKV. The amino propanol derivative 2.7 (EC50 = 11.51-17.11 μM) showed
relatively higher activity when compared to the purine-β-lactam hybrids.
Therefore, the β-lactam was not essential for activity.15
Recently, hybridization of two or more bioactive fragments has emerged as a
concept for the exploration of novel multitarget acting inhibitors as well as novel
anti CHIKV agents (Figure 2.2).15, 20, 22, 23 Therefore, in our ongoing efforts to
discover new scaffolds for CHIKV infection, we investigated a molecular
hybridization approach with the fusion of the uracil and the rhodanine
pharmacophoric moieties (Figure 2.2).22

Figure 2.2: Design of the targeted Uracil-Rhodanine conjugates.

2.2 Results and discussion
The synthetic strategy started with the condensation of ethyl propionylacetate 2.9
and thiourea 2.10 to afford the known 6-ethyl-2-thiouracil 2.11 with 69% yield.24,
24
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Although the synthesis of the thiazolopyrimidine derivatives from the 6-ethyl-2-

thiouracil substrate has not previously been reported, this multi-component reaction
(MCR) was achieved using an analogous procedure26-29 by reacting 2.11 with the
aldehyde, chloroacetic acid, sodium acetate anhydrous, acetic anhydride and acetic
acid in one pot and at reflux for 4 h (Scheme 2.1).

Scheme 2.1: Reagents and conditions: i) NaOEt, C2H5OH, 6 h, reflux; ii) ClCH2COOH,
anhydrous CH3COONa, (CH3CO)2, CH3COOH, 4-chlorobenzaldehyde, reflux, 4 h.

These conditions consistently gave low yields and two configurational isomers (e.g
chlorobenzaldehyde 2.16 E:Z 16%:84%), the latter determined by analysis of the
1

H NMR spectrum (Figure 2.3) – attempts to separate the isomers by column

chromatography failed.
Optimization of the reaction involved varying the mode of addition, replacement
of the chloroacetic acid with bromoacetic acid, and lowering the reaction
temperature. This aimed to favour the formation of the kinetic regioisomer (Z)-A,
assumed to be the desired product, over the thermodynamic regioisomer (Z)-B
(scheme 2.2), and resulted in the crystallization of only one regioisomer from the
reaction mix (acetic acid) in each case. This may be due to lower regioselectivity
of the chloroacetic acid compared to bromoacetic acid.
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Figure 2.3: 1H NMR spectrum of the MCR product of the two regioisomers of 2.16 in a
ratio of 1:5.

Scheme 2.2: Reactions and conditions: i: BrCH2COOH, anhydrous CH3COONa,
(CH3CO)2, CH3COOH, 60 °C, 3 h; ii: Benzaldehyde, anhydrous CH3COONa, CH3COOH,
60 °C, 2 h. iii) BrCH2COOH, anhydrous CH3COONa, (CH3CO)2, CH3COOH, aldehyde,
60 °C, 4 h.

From the convergent reaction conditions, four possible isomers can be formed: the
Z or E configurations of structural isomers A or B – (Z)-A, (E)-A, (Z)-B and (E)-B
26
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(Figure 2.4). Analysis of the 1H NMR spectra showed a quartet at 2.48-2.57 ppm
assigned to methylene hydrogens of the ethyl substituent – these were assigned to
structural isomer A as a result of the adjacent carbonyl group and the sp2 nitrogen
atom (of the pyrimidine ring). The corresponding resonances of isomer B are
expected to resonate more downfield (~ 3 ppm) as a result of the additional
deshielding anisotropic effect of the adjacent carbonyl group of the thiazole ring.

Figure 2.4: The four possible isomers that can be produced from the MCR reaction.

The Z absolute configuration of this class of molecules was confirmed by X-ray
crystallographic analysis of derivative 2.20 (Figure 2.5). This illustrated the
planarity of the thiazolopyrimidine rings with the aryl group, which may be
attributed to two intramolecular hydrogen bonds. The Z-configuration is
presumably stabilized by the two intramolecular hydrogen bonds between the
arylidene H and the oxygen atom of the thiazole carbonyl group (HB1) and between
the sulfur atom and the aryl hydrogen (HB2). The distance of both hydrogen bonds
is 2.49 and 2.50 Å, for HB1 and HB2, respectively, and the angles are 102.81˚ and
132.94˚ for HB1 and HB2 respectively.
27
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Figure 2.5: a) ORTEP diagram of compound 2.20, b) Representation of stabilizing
hydrogen bonds of the regioisomer ZA.

To investigate the observed preference for the Z isomer, density functional theory
(DFT) calculations were performed using the widely applied M06-2X functional
with a Dunnings aug-cc-pVDZ basis set. Compound 2.14 (Ar = C6H6) was selected
for the theoretical study and all structures were optimised using acetic acid
solvation modelling (SMD). Analysis of the proposed mechanism indicated a
possible alcohol intermediate and dehydration step preceded the final Z/E isomer
formation, and to keep the model simple, the calculations focussed on these
molecules only, maintaining chirality where applicable (Figure 2.6).

Figure 2.6: Proposed mechanism for the synthesis of isomers Z and E, the alcohol
intermediate of interest (red) and the dehydration step (blue) are highlighted. Note the Z
isomer is the product of the reaction in this example.

Conformer analysis of the alcohol intermediate indicated a Gibbs free energy of
reaction (ΔrG0(298K)) range of +0.35 to -2.30 kcal.mol-1 with the Z arranged C1
being the lowest and the E arranged C2 the highest energy conformers respectively
28
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(Figure 2.7). Analysis of the optimised geometries gave no indication of hydrogen
bond stabilisation for the alcohol, despite attempts at manually inputing the
conformation. This indicated steric and geometric arrangement of the alcohol
intermediate is more significant for the energy term.

C1
-2.30(M06-2X)
-1.43 (M06-2X-D3-gCP)

C2
+0.35 (M06-2X)
+1.20 (M06-2X-D3-gCP)

C3
-1.30 (M06-2X)
-0.01 (M06-2X-D3-gCP)
Figure 2.7: Structures of three alcohol intermediate conformers (C1 – C3) investigated.
ΔrG0 (298 K) energies calculated relative to the starting materials, Compound 2.13 and
benzaldehyde, in kcal.mol-1. All methods employed the aug-cc-pVDZ basis set.

A stacked ring conformer (C3) was also observed with a favourable ΔrG0(298K) of
-1.30 kcal.mol-1. To better account for this interaction, Grimmes dispersion (D3)
and geometric counterpoise (gCP) corrections

30

were applied to the energy term,

and the stacked C3 was observed to increase by +1.29 kcal.mol-1, whereas C1/C2
increased by +0.87 and +0.85 kcal.mol-1 respectively. The similar increase to the
29
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energy term for C1/C2 suggested there are no differences in dispersion effects to
account for in these conformers. However, the greater energy change observed with
C3 was indicative the ring stacking is not a favourable intramolecular force. Based
on the subtle differences in energies of the conformers, C1 is the apparent favoured
alcohol intermediate conformer, which is arranged to dehydrate to the Z isomer.
The transition states of the proposed dehydration reactions were calculated and the
saddle point ΔrG0(298K) were found to be +32.58 and +30.05 kcal.mol-1 for the E
T1 and Z T2 arranged transition states respectively (Figure 2.7). With the D3-gCP
corrections ΔrG0(298K) were +33.51 and +30.90 kcal.mol-1 for T1 and T2
respectively. The similar increases in energy (+0.93 and +0.85 kcal.mol-1) indicated
negligible differences in dispersion force correction required when comparing T1
and T2. What was particularly interesting to note, in contrast to the alcohol
intermediate, is the preference of the water leaving hydrogen bound to the carbonyl.
Despite attempts in manually positioning the water to leave adjacent to the sulfur,
and in turn have H – S interaction, the transition state only converged to allow
hydrogen bonding of the water with the thiazole carbonyl. Subsequently, it was
proposed the principal factor dictating the favoured transition state is the
arrangement of the aryl group, as the water has apparent preference for leaving
trans to the sulfur, in favour of Z isomer formation. Subsequent calculation of the
product (E)-2.14 and (Z)-2.14 isomers indicated ΔrH0(298K) of -2.40 and -6.78
kcal.mol-1 respectively, which indicates the Z isomer to be thermodynamically
favoured, and D3-gCP corrections were in good agreement (Figure 2.8).
Comparison of the calculated (Z)-6 structure with the X-ray crystal structure of
compound 2.14 indicated similar bond distances of H.B 1 = 2.43 Å and H.B 2 =
2.50 Å for the proposed intramolecular hydrogen bonds (Figure 2.5).
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Figure 2.8: Energy profile for the formation of compound 2.14(Z) and 2.14(E),
calculated with DFT M06-2X/aug-cc-pVDZ. Divergent reaction pathways are colour
coded red for E formation and blue for Z formation. SR = stacked rings conformer.

Likewise, the bond angles were in good agreement for H.B 1 and H.B 2 calculated
at 101.34˚ and 127.70˚, compared with 102.81˚ and 132.94˚ from the crystal
structure, respectively. In conclusion, although the energy differences are small
between the investigated reaction pathways, there is a consistent preference for the
Z forming pathway at each step investigated and this result was reciprocated by D3gCP energy corrections (Figure 2.8).
The compounds were screened for their antiviral activities in a viral-cell based
assay against chikungunya virus (Indian Ocean strain 899) (Table 2.1). Based on
the biological results, compounds 2.14-2.28 showed different percentages of viral
replication inhibition at 20 μg/mL with (Z)-7-ethyl-2-((4'-methyl-[1,1'-biphenyl]4-yl)methylene)-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)-dione 2.23 showing the
best activity with 58% inhibition of CHIKV replication. Derivatives 2.14, 2.19 and
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2.28 showed 19, 28 and 34% inhibition of viral replication, whilst rest of the
compounds showed fair or no activity. However, thiazolodione 2.23 can be
considered as a potential lead compound in our future
iterative cycles of optimization. The compound emerged
as the most promising antiviral among the tested series
with EC50 = 42 µM, with IC50 > 250 μM against the breast
cancer cell line MCF-7 and the endothelial human sapiens cell line EA.hy926.
Compound 2.23 is endowed with p-methylbiphenyl tail functionality which might
interact favourably with the target. Our outlook will include optimization of
compound 2.23 with the prime aim to find safe and effective anti-CHIKV agents.

Table 2.1. The observed %inhibition of CHIKV activity of the novel compounds 2.142.26.

% inhibition at
EC50
20 μg/mL
(μΜ)
2.14
-C6H5
19
ND
2.15
4-FC6H4
ND
ND
2.16
4-ClC6H4
ND
ND
2.17
4-CH3C6H4
ND
ND
2.18
4-OCH3C6H4
4.3
ND
2.19
1-Naphthyl
29
ND
2.20
4-OAc-3-OCH3 C6H3
5.5
ND
2.21
3,4-(OCH2O)C6H3
ND
ND
2.22
4-C6H5-C6H4
5.0
ND
2.23
4(4-CH3C6H4)C6H4
58
42
2.24
2-Pyrrolo
ND
ND
2.25
2-Thieno
5
ND
2.26
2-Nitro-2-furo
10
ND
2.27
2-Pyridyl
13
ND
2.28
7-Indolyl
34
ND
ND: not determined; EC50: concentration of compound that inhibits virus-induced
cell death with 50%.
Compound
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2.3 Conclusions
In this chapter, we reported the convergent synthesis of a new series of 2-arylidene
thiazolo[3,2-a]pyrimidines. Using simple synthons, namely 6-ethylthiouracil,
bromoacetic acid and different aldehydes in a mixture of acetic acid\acetic
anhydride and catalytic amount of anhydrous sodium acetate, a novel series of (Z)7-ethyl-2-arylidine-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)-diones was achieved.
Optimization of the multi-component reaction conditions was achieved by
replacing chloroacetic acid with the more regioselective bromoacetic acid,
lowering reaction temperature and changing the mode of addition and we were able
to prepare one isomer at each case. X-ray crystal structure of compound 2.20 shows
that only one regioselective isomer formed with the Z configuration that is
potentially stabilized by two intramolecular hydrogen bonds. Antiviral activity
evaluation demonstrated the tailed thiazolodione 2.23 as a candidate for future
development.

2.4 Experimental section
2.4.1

Chemistry

General methods and material
All reagents and solvents were purified and dried by standard techniques. Melting
points were measured with a Stuart apparatus and were uncorrected. Reactions
were monitored by TLC analysis using silica gel GF/UV 254. NMR spectra were
recorded on Varian Gemini-300BB 500 MHz FT-NMR spectrometers (Varian Inc.,
Palo Alto, CA). 1H spectra were run at 500 MHz and 13C spectra were run at 126
MHz, in deuterated dimethylsulfoxide (DMSO-d6), (CD3)2CO and CDCl3.
Chemical shifts (δH) are reported relative to TMS as internal standard and coupling
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constant (J) values are reported in Hertz. The abbreviations used are as follows: s,
singlet; d, doublet; t, triplet; m, multiplet. Electrospray ionization (ESI single
quadrupole) mass spectra have their ion mass to charge values (m/z) stated with
their relative abundances as a percentage in parentheses. Peaks assigned to the
molecular ion are denoted as [M+H]+ or [M+Na]+. Column chromatography was
performed using silica gel 60 (0.063-0.200 mm). All reagents and solvents were
purified and dried by standard techniques.

6-Ethyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (2.11):
After preparing a sodium ethoxide solution by dissolving sodium (4.6 g, 0.1 mole)
in absolute ethanol (150 mL), the thiourea 2.10 (3.8 g, 0.05 mole) was added with
stirring till complete dissolution. The ethyl 3-oxopentanoate ester 2.9 (7.21 g, 0.05
mole) was then added and the reaction mixture was heated at reflux for 4 hours.
After cooling the reaction mixture, water was added dropwise till complete
dissolution of the formed white precipitate. Ice was added, and neutralization of the
alkaline solution was accomplished using HCl (5 M). The reaction flask left
overnight in the fridge and the formed white precipitate was filtered, washed
thoroughly 3 times with water and 2 timed with diethyl ether and dried to give 2.11
(5.38 g, 69%) as a white powder. In some cases, when glacial acetic acid was used
instead of HCl as neutralizing agent, 2.11 was obtained as pink powder. m.p: 230
°C; 1H NMR ((CD3)2SO2) δ: 1.07 (t, J = 7.5 Hz, 3H, CH3), 2.33 (q, J = 7.5 Hz, 2H,
CH2), 5.33 (s, 1H, pyridine-H), 12.30 (br s, 2H, 2 x -NH);

13

C NMR (CD3OD):

13.4, 27.8, 103.9, 162.0, 165.8, 179.4; MS (ESI): 157 (20%, M+H)+, 179 (100%,
M+Na)+.
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7-Ethyl-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)-dione (2.13):
A previously dried sodium acetate (82 mg, 1 mmol) was added to a suspension of
6-ethyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one 2.11 (156 mg, 1 mmol) and
bromoacetic acid (153 mg,1.1 mmol) in glacial acetic acid (2 mL) and acetic
anhydride (1 mL). The reaction flask was heated gently at no more than 60 °C for
3 h. The formed precipitate was filtered while hot and washed thoroughly with
water (3 x 10 mL) and diethyl ether (2 x 5 mL) and dried to afford 2.13 (79 mg,
40%) as a white solid. 1H NMR ((CD3)2CO) δ: 1.19 (t, J = 7.5 Hz, 3H, CH3), 2.49
(q, J = 7.5 Hz, 2H, CH2), 4.02 (s, 2H, CH2), 6.02 (s, 1H, pyridine-H); 13C NMR
((CD3)2CO): 11.5, 30.0, 32.4, 105.7, 147.3, 163.6, 169.0, 169.3; MS (ESI): 197
(25%, M+H)+, 219 (100%, M+Na)+; HRMS (ESI) calcd for C8H9N2O2S: 197.0381
found 197.0385.

General procedures for the synthesis of 2-aryl-7-ethyl-5H-thiazolo[3,2a]pyrimidine-3,5(2H)-dione (2.14-2.28):

Method A: A previously dried sodium acetate (164 mg, 2 mmol) sample was added
to a solution of 6-ethyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one 2.11 (156 mg, 1
mmol), corresponding aldehyde (1.1 mmol) and bromoacetic acid (153 mg, 1.1
mmol) in glacial acetic acid (2 mL) and acetic anhydride (1 mL). After gentle
heating at no more than 60 ºC, the reaction was monitored using TLC analysis till
consumption of the stating material or until conversion was observed to stall.
Heating was then discontinued, and the reaction mixture was filtered while hot and
the residue washed with water (3 × 10 mL), and diethyl ether (2 × 10 mL) then
dried to give the desired thiazolopyrimidine 2.14-2.28.
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Method B: A previously dried sodium acetate (82 mg, 1 mmol) was added to a
suspension of 7-ethyl-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)-dione (196 mg, 1
mmol) 2.13 in glacial acetic acid, and 1.1 mmol of the appropriate aldehyde was
added and the mixture was gently heated at less than 60 ºC. The reaction was
monitored by TLC and the workup was similar to method A.

(Z)-2-benzylidene-7-ethyl-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)-dione (2.14):
The compound was prepared according to method A (yield = 39%) and method B
(yield = 24% over 2 steps); m.p: 170 °C; 1H NMR (CDCl3) δ: 1.24 (t, J = 7.5 Hz,
3H, CH3), 2.54 (q, J = 7.5 Hz, 2H, CH2), 6.10 (s, 1H, pyridine-H), 7.50-7.54 (m,
3H, ArH), 7.58 (d, J = 7.5 Hz, 2H, ArH), 8.07 (s, 1H, arylidene H);

13

C NMR

(CDCl3): 11.7, 30.5, 108.9, 118.6, 129.6, 130.8, 131.4, 133.1, 137.4, 158.2, 158.9,
163.2, 168.4; MS (ESI): 285 (60%, M+H)+, 307 (100%, M+Na)+, 323 (70%,
M+K)+; HRMS (ESI) calcd for C15H12N2O2SNa: 307.0502, found: 307.0517.

(Z)-7-ethyl-2-(4-fluorobenzylidene)-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)dione (2.15): The compound was prepared according to method A (yield = 40%)
m.p: 210 °C; 1H NMR (CDCl3) δ: 1.23 (t, J = 7.5 Hz, 3H, CH3), 2.56 (q, J = 7.5
Hz, 2H, CH2), 6.11 (s, 1H, pyridine-H), 7.21 (t, J = 8.5 Hz, 2H, Ar-H), 7.56 (dd, J
= 8.5, 5.3 Hz, 2H, Ar-H), 8.01 (s, 1H, arylidene H);

13

C NMR (CDCl3) δ: 11.6,

30.3, 108.8, 116.8 (d, J2C−F 21 Hz), 118.1, 129.3, 132.8 (d, J3C−F 9 Hz), 135.9, 157.7,
158.7, 163.0, 163.0 (d, J1C−F 267 Hz), 168.3; MS (ESI): 303 (10%, M+H)+, 325
(65%, M+Na)+, 627 (100%, 2M+Na)+; HRMS (ESI) calcd for C15H12FN2O2S:
303.0618, found: 303.0604.
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(Z)-2-(4-chlorobenzylidene)-7-ethyl-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)dione (2.16): The compound was prepared according to method A (yield = 48%);
m.p: 184 °C; 1H NMR (CDCl3) δ: 1.23 (t, J = 7.5 Hz, 3H, CH3), 2.55 (q, J = 7.5
Hz, 2H, CH2), 6.12 (s, 1H, pyridine-H), 7.50 (m, 4H, ArH), 8.02 (s, 1H, arylidene
H); 13C NMR (CDCl3): 11.6, 30.4, 108.9, 119.1, 129.8, 131.4, 131.8, 135.7, 137.5,
157.6, 158.6, 162.9, 168.3; MS (ESI): 319 (20%, M+H)+, 341 (100%, M+Na)+, 357
(25%, M+K)+; HRMS (ESI) calcd for C15H11ClN2O2SNa: 319.0302 found:
319.0308.

(Z)-7-ethyl-2-(4-methylbenzylidene)-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)dione (2.17): The compound was prepared according to method A (yield = 37%)
m.p: 180 °C; 1H NMR (CDCl3) δ: 1.24 (t, J = 7.5 Hz, 3H, CH3), 2.42 (s, 3H, CH3),
2.56 (q, J = 7.5 Hz, 2H, CH2), 6.09 (s, 1H, pyridine-H), 7.31 (d, J = 8.0 Hz, 2H,
Ar-H), 7.46 (d, J = 8.0 Hz, 2H, Ar-H), 8.04 (s, 1H, arylidene H); 13C NMR (CDCl3)
δ: 11.6, 21.7, 30.4, 108.7, 117.1, 130.2, 130.2, 130.9, 137.5, 142.4, 158.2, 158.8,
163.2, 168.2; MS (ESI): 299 (7%, M+H)+, 321 (35%, M+Na)+, 619 (100%,
2M+Na)+; HRMS (ESI) calcd for C16H14N2O2SNa: 321.0688, found: 321.0674.

(Z)-7-ethyl-2-(4-methoxybenzylidene)-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)dione (2.18): The compound was prepared according to method A (yield = 44%)
m.p: 168 °C; 1H NMR (CDCl3) δ: 1.23 (t, J = 7.5 Hz, 3H, CH3), 2.56 (q, J = 7.5
Hz, 2H, CH2), 3.89 (s, 3H, OCH3), 6.05-6.10 (m, 3H, pyridine-H + OCH2O), 7.02
(d, J = 9.0 Hz, 2H, ArH), 7.53 (d, J = 9.0 Hz, 2H, ArH), 8.01 (s, 1H, arylidene H);
13

C NMR (CDCl3): 11.6, 30.3, 55.6, 108.5, 115.0, 115.1, 125.6, 132.9, 137.2,

158.3, 158.9, 162.2, 163.2, 168.2; MS (ESI): 315 (10%, M+H)+, 337 (25%,
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M+Na)+, 651 (100%, 2M+Na)+; HRMS (ESI) calcd for C16H14N2O3SNa: 337.0606
found: 337.0623.

(Z)-7-ethyl-2-(naphthalen-1-ylmethylene)-5H-thiazolo[3,2-a]pyrimidine3,5(2H)-dione (2.19): The compound was prepared according to method A (yield
= 70%) m.p: 175 °C; 1H NMR (CDCl3) δ: 1.24 (t, J = 7.5 Hz, 3H, CH3), 2.56 (q, J
= 7.5 Hz, 2H, CH2), 6.26 (s, 1H, pyridine-H), 7.57-7.67 (m, 3H, Ar-H), 7.73 (d, J
= 7.0 Hz, 1H, Ar-H), 7.92 (d, J = 8.0 Hz, 1H, Ar-H), 7.98 (d, J = 8.0 Hz, 1H, ArH), 8.14 (d, J = 8.5 Hz, 1H, Ar-H), 8.82 (s, 1H, arylidene H); 13C NMR (CDCl3) δ:
11.7, 30.5, 108.8, 121.6, 123.5, 125.4, 127.2 (2C), 127.9, 129.2, 130.3, 131.9,
132.1, 133.9, 134.4, 158.5, 159.0, 162.8, 168.4; MS (ESI): 335 (20%, M+H)+, 691
(100%, 2M+Na)+; HRMS (ESI) calcd for

C19H15N2O2S: 335.0849, found:

335.0854.

(Z)-4-((7-ethyl-3,5-dioxo-5H-thiazolo[3,2-a]pyrimidin-2(3H)-ylidene)methyl)2-methoxyphenyl acetate (2.20): The compound was prepared according to
method A (yield = 59%) m.p: 208 °C; 1H NMR (CDCl3) δ: 1.24 (t, J = 7.5 Hz, 3H,
CH3), 2.34 (s, 3H, COCH3), 2.56 (q, J = 7.5 Hz, 2H, CH2), 3.90 (s, 3H, OCH3),
6.10 (s, 1H, pyridine-H), 7.13 (s, 1H, Ar-H), 7.18 (s, 2H, Ar-H), 8.01 (s, 1H,
arylidene H);

13

C NMR (CDCl3) δ: 11.0, 20.0, 29.8, 55.4, 108.2, 113.4, 117.9,

123.1, 123.3, 131.2, 135.9, 141.5, 151.2, 157.2, 158.0, 162.3, 167.6, 167.9; MS
(ESI):

373 (15%, M+H)+, 767 (100%, 2M+Na)+;

C18H17N2O5S: 373.0862, found: 373.0858.
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(Z)-2-(benzo[d][1,3]dioxol-5-ylmethylene)-7-ethyl-5H-thiazolo[3,2a]pyrimidine-3,5(2H)-dione (2.21): The compound was prepared according to
method A (yield = 67%) m.p: 206 °C; 1H NMR (CDCl3) δ: 1.23 (t, J = 7.5 Hz, 3H,
CH3), 2.55 (q, J = 7.5 Hz, 2H, CH2), 6.07-6.10 (m, 3H, pyridine-H + OCH2O), 6.93
(d, J = 8.3 Hz, 1H, Ar-H), 7.02 (s, 1H, Ar-H), 7.12 (d, J = 8.3 Hz, 1H, Ar-H), 7.95
(s, 1H, arylidene H); 13C NMR (CDCl3) δ: 11.7, 30.5, 120.3, 108.7, 109.4, 109.5,
115.9, 127.4, 127.8, 137.3, 148.9, 150.6, 158.2, 158.9, 163.2, 168.3; MS (ESI): 351
(70%, M+Na)+, 679 (100%, 2M+Na)+; HRMS (ESI) calcd for C16H12N2O4SNa:
351.0405, found: 351.0415.

(Z)-2-([1,1'-biphenyl]-4-ylmethylene)-7-ethyl-5H-thiazolo[3,2-a]pyrimidine3,5(2H)-dione (2.22): The compound was prepared according to method A (yield
= 77%) m.p: 172 °C; 1H NMR (CDCl3) δ: 1.23 (t, J = 7.5 Hz, 3H, CH3), 2.55 (q, J
= 7.5 Hz, 2H, CH2), 6.08 (s, 1H, pyridine-H), 7.39-7.42 (m, 1H, ArH), 7.47 (t, J =
7.5 Hz, 2H, ArH), 7.62-7.64 (m, 4H, ArH), 7.74 (d, J = 8.0 Hz, 2H, ArH), 8.07 (s,
1H, arylidene H);

13

C NMR (CDCl3) δ: 11.7, 30.4, 108.8, 118.1, 127.2, 128.0,

128.5, 129.2, 131.4, 131.8, 136.9, 139.5, 144.0, 158.1, 158.8, 163.1, 168.3; MS
(ESI):

383 (70%, M+Na)+, 743 (100%, 2M+Na)+;

HRMS (ESI) calcd for

C21H16N2O2SNa: 383.0837, found: 383.0830.

(Z)-7-ethyl-2-((4'-methyl-[1,1'-biphenyl]-4-yl)methylene)-5H-thiazolo[3,2a]pyrimidine-3,5(2H)-dione (2.23): The compound was prepared according to
method A (yield = 69%) m.p: 218 °C; 1H NMR (CDCl3) δ: 1.24 (t, J = 7.5 Hz, 3H,
CH3), 2.56 (q, J = 7.5 Hz, 2H, CH2), 7.28 (d, J = 7.8 Hz, 2H, ArH), 7.54 (d, J = 7.8
Hz, 2H, ArH), 7.62 (d, J = 8.1 Hz, 2H, ArH), 7.73 (d, J = 8.1 Hz, 2H, ArH), 8.08
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(s, 1H, arylidene H); 13C NMR (CDCl3) δ: 11.7, 21.3, 30.5, 108.8, 117.9, 127.1,
127.8, 129.9, 131.5, 131.6, 136.6, 137.0, 138.6, 144.1, 158.2, 158.9, 163.2, 168.3;
MS (ESI): 375 (65%, M+H)+, 397 (75%, M+Na)+, 771 (100%, 2M+Na)+; HRMS
(ESI) calcd for C22H18N2O2SNa: 397.0996, found: 397.0987.

(Z)-2-((1H-pyrrol-2-yl)methylene)-7-ethyl-5H-thiazolo[3,2-a]pyrimidine3,5(2H)-dione (2.24):The compound was prepared according to method A (yield =
27%) m.p: 220 °C; 1H NMR (DMSO-d6) δ: 1.15 (t, J = 7.5 Hz, 3H, CH3), 2.48 (q,
J = 7.5 Hz, 2H, CH2), 6.05 (s, 1H, pyridine-H), 6.44 (s, 1H, ArH), 6.66 (s, 1H,
ArH), 7.32 (s, 1H, ArH), 7.89 (s, 1H, arylidene H), 11.86 (br s, 1H, NH); 13C NMR
(DMSO-d6) δ: 12.3, 30.1, 108.6, 110.8, 113.5, 116.1, 126.1, 126.8, 128.0, 159.0,
159.3, 163.5, 167.9; MS (ESI): 274 (10%, M+H)+, 296 (40%, M+Na)+, 569 (15%,
2M+Na)+; HRMS (ESI) calcd for C13H11N3O2SNa: 296.0484, found: 296.0470.

(Z)-7-ethyl-2-(thiophen-2-ylmethylene)-5H-thiazolo[3,2-a]pyrimidine3,5(2H)-dione (2.25): The compound was prepared according to method A (yield
= 43%) m.p: 216 °C; 1H NMR (CDCl3) δ: 1.23 (t, J = 7.5 Hz, 3H, CH3), 2.57 (q, J
= 7.5 Hz, 2H, CH2), 6.11 (s, 1H, pyridine-H), 7.24-7.26 (m, 1H, ArH), 7.51 (d, J =
3.0 Hz, 1H, ArH), 7.75 (d, J = 5.0 Hz, 1H, ArH), 8.01 (s, 1H, arylidene H); 13C
NMR (CDCl3) δ: 11.6, 30.4, 108.8, 116.3, 129.1, 129.6, 133.3, 134.7, 137.7, 157.8,
158.9, 162.9, 168.3; MS (ESI): 291 (15%, M+H)+, 313 (75%, M+Na)+, 603 (100%,
2M+Na)+; HRMS (ESI) calcd for C13H10N2O2S2Na: 313.0081, found: 313.0071.
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(Z)-7-ethyl-2-((5-nitrofuran-2-yl)methylene)-5H-thiazolo[3,2-a]pyrimidine3,5(2H)-dione (2.26): The compound was prepared according to method A (yield
= 46%) m.p: 202 °C; 1H NMR (DMSO-d6) δ: 1.14 (t, J = 7.5 Hz, 3H, CH3), 2.48
(q, J = 7.5 Hz, 2H, CH2), 6.14 (s, 1H, pyridine-H), 7.40 (d, J = 3.8 Hz, 1H, ArH),
7.84 (d, J = 3.8 Hz, 1H, Ar-H), 7.94 (s, 1H, arylidene H); 13C NMR (DMSO-d6) δ:
11.5, 29.3, 108.5, 114.7, 118.6, 120.4, 123.7, 151.1, 152.8, 157.8, 158.3, 162.1,
167.2; MS (ESI): 320 (5%, M+H)+, 661 (100%, 2M+Na)+; HRMS (ESI) calcd for
C13H10N3O5S: 320.0335, found: 320.0341.

(Z)-7-ethyl-2-(pyridin-2-ylmethylene)-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)dione (2.27): The compound was prepared according to method A (yield = 22%)
m.p: 225 °C; 1H NMR (CDCl3) δ: 1.24 (t, J = 7.5 Hz, 3H, CH3), 2.56 (q, J = 7.5
Hz, 2H, CH2), 6.08 (s, 1H, pyrimidine H), 7.32 (dd, J = 7.4, 4.7 Hz, 1H), 7.59 (d, J
= 7.7 Hz, 1H), 7.81 (dd, J = 7.4, 6.7 Hz, 1H), 7.98 (s, 1H, arylidene H), 8.78 (d, J
= 4.7 Hz, 1H); 13C NMR (CDCl3) δ: 11.6, 30.4, 108.5, 124.0, 124.3, 157.5, 132.0,
137.1, 149.2, 151.3, 159.1, 162.1, 163.5, 168.5; MS (ESI): 286 (5%, M+H)+, 308
(10%, M+Na)+; HRMS (ESI) calcd for C14H12N3O2S: 286.0649, found: 286.0650.

(Z)-2-((1H-indol-7-yl)methylene)-7-ethyl-5H-thiazolo[3,2-a]pyrimidine3,5(2H)-dione (2.28): The compound was prepared according to method A (yield
= 37%) m.p: 190 °C; 1H NMR (CDCl3) δ: 1.27 (t, J = 7.5 Hz, 3H, CH3), 2.57 (q, J
= 7.5 Hz, 2H, CH2), 6.08 (s, 1H, pyrimidine H), 6.64 (s, 1H, ArH), 7.18 (t, J = 7.5
Hz, 1H, ArH), 7.34 (d, J = 7.5 Hz, 1H, ArH), 7.46 (s, 1H, ArH), 7.72 (d, J = 7.5
Hz, 1H, ArH), 8.78 (s, 1H, arylidene H), 9.67 (br s, 1H, NH); 13C NMR (CDCl3) δ:
11.7, 30.4, 103.2, 108.4, 110.0, 117.2, 118.4, 119.9, 122.1, 125.0, 129.4, 133.4,
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135.5, 158.8, 159.2, 163.5, 168.4; MS (ESI): 324 (30%, M+H)+, 346 (100%,
M+Na)+; HRMS (ESI) calcd for C17H14N3O2S: 324.0799, found: 324.0807.

2.4.2

Anti-viral assay

CHIKV Indian Ocean strain 899 (Genbank FJ959103.1) was generously provided
by Prof. S. Günther (Bernhard Nocht Institute for Tropical Medicine, Hamburg,
Germany) (Panning M et al., Emerging Infectious Diseases 2008). BGM cells were
maintained in cell growth medium composed of minimum essential medium (MEM
Rega-3, Gibco, Belgium) supplemented with 10% Foetal Bovine Serum (FBS,
Integro, The Netherlands), 1% L-glutamine (Gibco), and 1% sodium bicarbonate
(Gibco). The antiviral assays were performed in virus growth medium which is the
respective cell growth medium supplemented with 2% (instead of 10%) FBS. Cell
cultures were maintained at 37 °C in an atmosphere of 5% CO2 and 95-99%
humidity. BGM cells were seeded in 96-well tissue culture plates (Becton
Dickinson, Aalst, Belgium) at a density of 2.5 x 104 cells/well in 100 μL assay
medium and were allowed to adhere overnight. Next, a compound dilution series
was prepared in the medium on top of the cells after which the cultures were
infected with 0.001 MOI of CHIKV 899 inoculum in 100 μL assay medium. On
day 5 post-infection (p.i.), the plates were processed using the MTS/PMS method
as described by the manufacturer (Promega, The Netherlands). The 50% effective
concentration (EC50), which is defined as the compound concentration that is
required to inhibit virus-induced cell death by 50%, was determined using
logarithmic interpolation. All assay wells were checked microscopically for minor
signs of virus induced CPE or possible alterations to the cell or monolayer
morphology caused by the compound.
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2.4.3 X-ray crystallographic data for compound 2.20
Crystal data. Compound 12. C18H16N2O5S, M= 372.40, T=150 K, Triclinic, P1 ,
Z=2, a= 7.8375 (3), b= 8.2458 (3), c= 14.5394 (7) Å, α = 87.176 (4)°, β = 74.562
(4)°, γ = 73.335 (4)° ,V= 867.31 (7) Å3, Dx= 1.426 g cm-3, Cu Kα radiation,
λ=1.54184 Å, 16946 reflections measured (θ = 6–74˚), merged to 3491 unique data,
R=0.034 [for 3396 data with I > 2σ(I)], Rw= 0.089 [all data], S = 1.00
Structure determination of compound 2.20. Images were measured on an Agilent
SuperNova diffractometer (Cu Kα radiation, mirror monochromator, λ=1.54184 Å)
and data extracted using the CrysAlis PRO package.1 Structure solution was by
direct methods (SIR92).2 The structure was refined using the CRYSTALS program
package.3 CDCC 1968317.

2.4.4

Computational methods

Structures were built intuitively in Avogadro and initially optimized with
Molecular Mechanics (Universal force field). These structures were used for
subsequent DFT calculations utilizing Gaussian16 with initial optimization at
B3LYP/def2SVP for minima structures and M06-2X/6-31G(d) for transition states.
All final structures and thermodynamics were calculated with M06-2X/aug-ccpVDZ and solvation in acetic acid modelled (SMD). Minima were confirmed by
analysis of the normal modes. The transition states were confirmed saddle points
by observation of one imaginary frequency with mode analysis indicating
molecular displacement corresponding to the transition of interest. All structures
energies were also corrected for dispersion (D3) and geometric counterpoise (gCP).
Thermodynamic changes in the Gibbs free energy of reaction ΔrG0 (298K) from the
starting materials, compound 2.13 and benzaldehyde, were calculated as per
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equation (E1), that is ΔrG0(298K) for the product of interest is equal to the sum of
electronic energy of the product – the sum of electronic energy for the starting
materials, with all values having the free energy correction applied.
∆𝑟 𝐺°(298 𝐾) = ∑(𝜀0 + 𝐺𝑐𝑜𝑟𝑟 )𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠 − ∑(𝜀0 + 𝐺𝑐𝑜𝑟𝑟 )𝑟𝑒𝑎𝑐𝑡𝑎𝑛𝑡𝑠
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and simplification concepts
towards anti-CHIKV

FOREWORD TO CHAPTER 3
This chapter is a full research manuscript prepared for submission to the RSC
Medicinal Chemistry. This chapter describes the synthesis of 1-aryl[1,2,4]triazolo[4,3-a]pyrimidines

and

2-anilinopyrimidines

as

potential

chikungunya virus inhibitors. It also describes the preparation and characterisation
of the key intermediates as well as the synthesis of target compounds. X-ray single
crystal studies of three intermediates and two target compounds were performed
and confirmed their structure. In silico pharmacokinetic and drug likeness
modelling of target compounds were conducted, followed by biological evaluation.
DFT calculations and analysis of ESP were performed and revealed new insights
into the viral-target binding site.
Supporting information for this chapter can be found in Appendix B (p. 228).

Contributions
Mohamed Fares

Compound design, performed the work and
analysis, input into experimental design and
prepared/edited the paper

Peter Canfield

Performed and analysed the computational studies

Anthony C. Willis

Performed and solved the X-ray structures

William Lewis
Muhammad A. Alsherbiny

Performed the cytotoxicity assay.

Johan Neyts

Performed the antiviral evaluation.

Dirk Jochmans
Philip A. Gale

Editing and proof-reading.

Paul A. Keller

Oversight of the project, editing and proof-reading.

46

Chapter 3

Application of the bioisosterism and simplification concepts

3.1 Introduction
Recent reports by the World Health Organization (WHO) on neglected tropical
diseases underline the pressing need to discover new lead compounds to treat
chikungunya virus (CHIKV) infection.1, 2 Strategies to discover antiviral agents
have been described previously,3, 4 however our limited knowledge about the virus
impedes drug development and therefore the availability of a clinical anti-CHIKV
drug.
There is no vaccine or an approved drug for CHIKV-infection prophylaxis or
treatment and current management is limited to supportive measures and includes
non-steroidal anti-inflammatory drugs (NSAID) and corticosteroids to alleviate the
symptoms of acute viremia.5 Strategies to discover anti-CHIKV agents include
vaccine development, the development of small molecule drug-like ligands
discovered through virtual screening, in vitro whole cell phenotypic screening, and
genome-wide loss of function screens.6-13 Advances in anti-CHIKV drug discovery
have been reviewed.3, 4, 14
Amongst synthetic compounds, the triazolo[4,5-d]pyrimidin-7(6H)ones have
emerged as promising and potent anti-CHIKV agents (Figure 3.1.)

11, 12, 15

as

exemplified by the optimised compound MADTP-372 (3.1) with a reported EC50
(CHIKV) in the 0.75 – 2.6 μM range.16 We note, however, that for 1 there is very
limited scope for structural elaboration of the fused bicyclic core and, therefore,
limited scope for improving the molecular design with the goal of an effective and
commercial drug.
By applying robust medicinal chemistry strategies including bioisosteric
substitution and simplification to 3.1 we devised two series of analogue scaffolds
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as shown in Figure 3.1. with the prime aim of demonstrating their anti-CHIKV
potential for future drug design and to provide insight into ligand-target interactions
critical for activity.
Series A was arrived at through bioisosteric substitution freeing up ring position 3
for additional substitutional elaboration (R2), and Series B through simplification
to the conformationally more flexible 2-anilino pyrimidones. In both series we
maintained the peripheral ethyl group adjacent to the ring nitrogen, the carbonyl
group and unsubstituted intervening position as suggested by earlier structure
activity studies.11

Figure 3.1: Application of medicinal chemistry concepts to current CHIKV inhibitor
MADTP-372 towards new potential anti-CHIKV agents. The assumed core, including the
explicit hydrogen, are highlighted green.

The selection of the simple acetyl and ethyl carboxylate groups for R2 (Figure 3.1.)
was principally to demonstrate the initial inclusion of scaffold functionality useful
for further derivatisation. Different aryl substituents were selected including the 3iso-propoxy of MADTP-372, the 3-acetyl group present in the parent compound
used in the same study11, the sulfonamide group considered an acetyl isostere with
increased H-bond acceptor potential, the 3-fluoro and 4-bromo moieties.
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3.2 Results and discussion
Syntheses of both series began with the construction of the thiouracil 3.4 achieved
by the simple expedient of heating thiourea 3.3 at reflux with the β-keto ester 3.2
in the presence of sodium ethoxide in 69% yield (Scheme 3.1).17 The synthesis of
the 2-anilinopyrimidine series 3.6-3.10 (Scheme 3.1) started with methylation of
3.4 with methyl iodide and sodium hydroxide as reported.18 The reaction between
3.5 and anilines was investigated using different conditions, including using a neat
reaction, using catalytic amounts of bases or acids. The best reaction conditions
were heating pivalic acid at reflux with S-methylthiouracil 3.5 and the
corresponding aniline (Scheme 3.1).19 Applying these reaction conditions afforded
the 2-anilinopyrimidine derivatives 3.6-3.9 in yields ranging from 22-82%.

Scheme 3.1: Reagents and conditions: i) NaOEt, C2H5OH, 6 h, reflux; ii) NaOH, EtOH,
CH3I, 3 h, 50 °C; iii) Corresponding aniline, pivalic acid, 130 °C.

Hydrazonoyl chlorides (highlighted in green in Scheme 3.2 are the main building
blocks in this synthesis of these triazolo[4,3-a]pyrimidine derivatives and can be
made via several routes from inexpensive and readily available precursors. Here we
synthesised 3.14-3.24 starting with chlorination of the active methylene group of
acetylacetone 3.10 and ethyl acetoacetate 3.11 using sulfuryl chloride as described
by Alihn in 187820 (Scheme 3.2). Conventional coupling of the α-chloroacetyl
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derivatives 3.12 and 3.13 (Scheme 3.2) with the readily prepared aryl diazonium
salts afforded compounds 3.14-3.24 (Scheme 3.2) in yields ranging from 32-79%.21

Scheme 3.2: Reagents and conditions: i) SO2Cl2, 0 °C; ii) CH3COONa/ 0 °C.

Analysis of the single crystal X-ray diffraction (Figure 3.2) of derivatives 3.15, 3.20
and 3.24 confirmed the presence of the (Z) configuration (Figures 3.2).

Figure 3.2: X-ray crystal structure of 3.15 (a), 3.20 (b) and 3.24 (c).
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The reactions of the thiouracil derivatives and hydrazonoyl halides have been
extensively studied (Scheme 3.3).22-24 Generally, the reaction proceeds via a 1,3addition if the reacting heterocyclic thiones are protic nucleophiles, or a 1,3-dipolar
cycloaddition pathway in the case that the heterocyclic thiones are dipolarophiles.22
A review of this reaction revealed an almost exclusive preference for product
isomer A (3.29-3.39) over B (3.42-3.52) (Scheme 3.3).22 This suggests a reaction
process through the cycloaddition of carbon-2 and nitrogen-3 (rather than nitrogen1) of the thiouracil analogues with the hydrazonoyl chloride derivative in presence
of base (Scheme 3.3).67 The reaction mechanism was postulated to start with Salkylation of the thiouracil derivative via a Japp-Klingmann reaction to afford the
thiohydrazontes 3.25. In the presence of base, the nucleophilicity of the terminal
hydrazone N increases and the compound undergoes Chapman-like rearrangement
to give the corresponding thiohydrazide 3.26. The latter thiohydrazide cyclized in
situ to afford A or B.22 The use of the triethylamine in this reaction which was
reported to be one of the best bases to use, resulted in low yields. Changing the base
to DIPEA provided good reaction outcomes with good yields in short reaction
times.
Analysis of 13C NMR spectra of compounds 3.29-3.39 (corresponds to isomer A)
or 3.42-3.52 (corresponds to isomer B) showed resonances at 172 – 173 ppm and
was assigned to the carbonyl of the pyrimidine ring which might indicate that
isomer B was preferentially obtained as reported.25 However, single crystal X-ray
diffraction (SCXRD) of two compounds confirmed the presence of the other isomer
(3.32 and 3.39, Fig. 2), required for the antiviral testing. X-ray analysis of
compounds 3.32 and 3.39 showed the planarity of the fused bicyclic and the
terminal aryl rings (Figure 3.3).
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Scheme 3.3: Reagents and conditions: i) DIPEA, dioxane, 100 °C

Figure 3.3: ORTEP depictions of compounds 3.23 and 3.39 at 70% probability.
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In a typical example, analysis of the 1H NMR spectrum of 3.29 revealed a triplet at
1.31 ppm and a quartet at 2.70 assigned to the CH3 and CH2 of the ethyl group,
respectively and a resonance at 2.81 ppm assigned to the methyl of the acetyl group.
The pyrimidine H was assigned to the singlet at δ 6.05 in the 1H NMR spectrum.
To the corresponding aryl hydrogens were assigned the triplet at 7.09 ppm, the
doublet of doublet at 7.50 ppm, and the multiplet at 8.08-8.12 ppm. The 13C NMR
spectrum of the fluorine containing compound 3.29 showed a typical splitting
pattern of the fluorine and carbon with coupling constants J1C−F

=

248 Hz, at

resonance 161.9 ppm, J2C−F = 28 Hz at resonance 108.1 ppm, J2C−F = 21 Hz at
resonance 114.5, J3C−F = 9 Hz, at resonance 103.8, J3C−F = 10 Hz at resonance 137.8
and J4C−F = 4 Hz at resonance 115.9 ppm.
Compounds

[1,2,4]triazolo[4,3-a]pyrimidin-7(1H)-ones

3.29-3.39

and

2-

anilinopyrimidin-4(3H)-one 3.6-3.9 were screened for their antiviral activities in a
viral-cell based assay against chikungunya virus (Indian Ocean strain 899) (Table
3.1). The most active compounds were further tested for their cytotoxic activity
against the normal cell line, EA.hy926, the endothelial human cell line, and two
human breast cancer cell lines, namely, MCF-7 and MDA-MB-231 (Table 3.1).
Compound,

3-acetyl-5-ethyl-1-(3-isopropoxyphenyl)-[1,2,4]triazolo[4,3-

a]pyrimidin-7(1H)-one 3.33, being the 3-acetyl analogue of the protype 3.1
emerged as having the most promising antiviral activity among the tested series
3.29-3.39 with EC50 = 38 μM, and IC50 > 300 μM against breast cancer cell lines,
MCF-7 and MDA-MB-231 and normal cell line EA.hy926 (Table 3.1). The 3acetylphenyl analogue 3.31 was approximately three times less active than 3.33
paralleling the activities of the 3-acetylphenyl analogue of 3.1.11 Of special interest
was the finding that the only active ethyl carboxylate compound, 3.34, as expected
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featured the high activity 3-iso-propoxyphenyl group and exhibiting low antiviral
activity, but also exhibited pronounced and consistent cytotoxicity across all cell
lines. The sulfonamide derivatives 3.35-3.38 showed no antiviral activity, even at
high concentrations (1% inhibition at 100 μg/mL for 3.36) (Table 3.1). Whilst all
of the conformationally more flexible Series B compounds 3.6-3.9 demonstrated
weak inhibition of viral replication, all exhibited an EC50 > 200 μM.

Table 3.1: In vitro antiviral and cytotoxic activities of compounds 3.29-3.39 and 3.6-3.9.

Ar

Anti-CHIKV activity

Cytotoxic activity
EC50 (µM)

%inhi-

at [ ]

EC50

MCF

MDAM

Eahy

bition

μg/m

(µM)

7a

B231a

926a

L
3.29

COCH3

3-F-C6H4

80

100

183

>300

250

>300

3.30

COOC2H5

3-F-C6H4

9

100

>200

NT

NT

NT

3.31

COCH3

3-(COCH3)-C6H4

100

100

136

>300

198

207

3.32

COOC2H5

3-(COCH3)-C6H4

0

20

>200

NT

NT

NT

3.33

COCH3

3-O-iPr-C6H4

69

20

38

>300

>300

>300

3.34

COOC2H5

3-O-iPr -C6H4

90

75

100

68

65

73

3.35

COCH3

3-SO2NH2-C6H4

0

100

>200

NT

NT

NT

3.36

COOC2H5

3-SO2NH2-C6H4

1

100

>200

NT

NT

NT

3.37

COCH3

4-SO2NH2-C6H4

2

20

>200

NT

NT

NT

3.38

COOC2H5

4-SO2NH2-C6H4

2

100

>200

NT

NT

NT

3.39

COCH3

4-Br-C6H4

54

75

186

128

81

147

3.6

-

-C6H5

6

75

>200

NT

NT

NT

3.7

-

3-F-C6H4

30

75

>200

NT

NT

NT

i

3.8

-

3-Pr O-C6H4

26

20

>200

NT

NT

NT

3.9

-

3-SO2NH2-C6H4

0

75

>200

NT

NT

NT

NT: not tested, a Mean from three replicates, (errors were in the range  5-10 % of the reported
values).
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Drug Likeness Scores (DLS) were calculated using MolSoft26 and are listed in
Table 3.2 Drug candidates typically show positive DLS values, while non-drug
candidates might elicit zero or negative DLS values. Whilst all tested compounds
complied with Lipinski guidelines, only 3.33, 3.34, 3.37, 3.39, 3.6-3.9 received
positive DLS ranging from 0.03 - 0.77, with the rest of the compounds showing
zero or negative DLS.

Table 3.2: Drug likeness calculations and Lipinski parameters of the compounds 3.293.39 and 3.6-3.9.
M.

log Pb

Wta

HB

HBDd

Ac

n

Rule

nrot

TPSA

%A

violatione

of 5

f

g

BSh

DLSi

3.29

300

1.8

4

0

0

pass

3

69.3

85.1

0.00

3.30

330

2.6

5

0

0

pass

5

78.5

81.9

-0.05

3.31

324

1.3

5

0

0

pass

4

86.4

79.2

-0.37

3.32

354

2.1

6

0

0

pass

6

95.6

76.0

-0.45

3.33

340

2.4

5

0

0

pass

5

78.5

81.9

0.29

3.34

370

3.2

6

0

0

pass

7

87.7

78.7

0.29

3.35

361

0.4

7

2

0

pass

4

129.4

64.4

-0.39

3.36

391

1.2

8

2

0

pass

6

138.7

61.1

-0.42

3.37

361

0.4

7

2

0

pass

4

129.4

64.4

0.07

3.38

391

1.2

8

2

0

pass

6

138.7

61.1

-0.10

3.39

360

2.4

4

0

0

pass

3

69.3

85.1

0.03

3.6

215

1.9

2

2

0

pass

3

57.8

89.1

0.69

3.7

233

2.2

2

2

0

pass

3

57.8

89.1

0.41

3.8

273

2.7

3

2

0

pass

5

67.0

85.9

0.77

3.9

294

0.7

5

4

0

pass

4

118.0

68.3

0.27

a

Molecular weight. b Lipophilicity. c Number of hydrogen bond acceptors. d Number of

hydrogen bond donors. e Number of violations. f Number of rotatable bonds. g Topological
polar surface area. h Percentage absorption. i Drug-likeness model score.

In order to infer the nature of the ligand – target interactions important for binding
and inhibition, a series of minimal pharmacophore models was developed using the
closely comparable bioactivity results of compounds 3.53 and 3.56 (Figure 3.4)
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along with 3.54 and 3.55 (pink-dashed box in Figure 3.4) for the 3-isopropoxyphenyl analogues.11 As we are unable to infer orientation of an asymmetric
pendant aryl group due to free rotation it was modelled as a phenyl moiety. A
methyl group on the bicyclic core is a suitable stand-in for substituents at that
location.
All compounds were modelled using Density-Functional Theory (DFT) using the
Gaussian16 package at the B3LYP-D3(BJ)/6-311G(2d,p) using implicit water
solvation to reflect in vivo conditions. The possible tautomerism in 3.54 – 3.56 was
examined with DFT calculated free energies indicating that for 3.54 and 3.55 only
the single tautomer shown in each case is present in solution. For 3.56, two of the
three possible tautomers, 3.56a and 3.56b, would be present at 3% and 97%
respectively.
The calculated Electrostatic Potential (ESP) was mapped onto two values of the
electron isodensity and is shown in Figure 3.4. The large valued isodensity clearly
resolves the atoms (middle row in Figure 3.4) whilst the lower value better reflects
how the molecules are seen by the chemical environment, i.e. the ligand target. The
closely similar molecular shapes of 3.53 – 3.56, the very similar polarities of the πsystems and the comparable EC50 values for 3.53 – 3.55

indicate that this

comparative approach is valid for inferring the important ligand – target
interactions. Both tautomers 3.56a-b feature reversed polarity in contrast to 3.53 –
3.55 arising from the N-H groups. Not surprisingly, such a situation correlates
with antiviral activity, but at levels higher than the bioassays could measure.
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Figure 3.4: Structures and DFT minimal pharmacophore models of the [1,2,4]triazolo[4,3a]pyrimidine (3.53), the azahypoxanthine (3.54), the hypoxanthine (3.55) and the
pyrimidone tautomers (3.56a-b) showing the electrostatic potential mapped onto two
different electron isodensities to convey both the resolved atoms (middle row) and the
diffuse molecular surface as seen by the chemical environment (bottom row). Potential Hbond interactions indicated by coloured arrows. The tautomers shown for 3.54 and 3.55
calculated by DFT to represent 100% of the species in vivo. For the pyrimidones 3.56, the
relative concentration of the two tautomers is shown.

Figure 3.5 is the consensus model, principally arrived at through comparisons of
steric and charge features of 3.53 – 3.55. The H-bond acceptor facility at position
8 and the oxygen substituent at position 5 would both be expected to be important.
Whilst no substituent can be tolerated at positions 2 and 6, there would seem to be
a nebulous region of H-bond acceptor potential proximal to position 3. Since 3.33
is of comparable activity to 3.1 yet features greater steric bulk at position 3, we
speculate that antivirals based on 3.54 and 3.55 interact with the target via a H2O
molecule H-bonded to the 5-membered ring imine nitrogen(s).
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Figure 3.5: (a) Consensus picture of the minimal pharmacophore with inferred important
H-bond interactions indicated. For compounds like 3.54 and 3.55 R2 could likely represent
an H-bonded H2O molecule. (b) The DFT Potential Energy Surfaces of 3.53 – 3.55 for the
phenyl torsions as defined by the bold blue bonds in (a).

Whilst the precise orientation of the aryl group is both unknown and cannot be
inferred from our analysis, the calculated Potential Energy Surfaces (PES) for 3.53
– 3.55 as shown in Figure 3.5 does indicate the energetic penalty (with concomitant
reduction in activity) for geometries deviating from the unconstrained equilibrium
torsions. These predictions only apply to 2,6-unsubstituted phenyl groups.

3.3 Conclusions
Inspired by the reported anti-CHIKV activity of MADTP-372 (3.1), two series of
compounds, the triazolopyrimidines 3.29-3.39 and anilinopyrimidines 3.6-3.9,
were designed, synthesised and bioassayed for anti-CHIKV activity and
cytotoxicities. Whilst the series 3.6-3.9, proved to only exhibit weak anti-CHIKV
activity, 3.33, the 3-acetyl analogue of 3.1 exhibited comparable anti-CHIKV
activity and low cytotoxicity to 3.1. The advantage of 3.33 over 3.1 is that the ability
of the 3 position to accommodate substituents, these being accessed from easy to
prepare hydrazonoyl chlorides, provides new and promising scope for improved
drug design utilising this inexpensive scaffold. Comparisons of the geometries and
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Electrostatic Potential-mapped surfaces of minimal pharmacophore models 3.53 –
3.56 of anti-CHIKV agents has allowed for a consensus model for effective target
binding. These results place future research into anti-CHIKV agents in better
standing.

3.4 Experimental section
3.4.1

Chemistry

General methods and material
All reagents and solvents were purified and dried by standard techniques. Melting
points were measured and were uncorrected. Reactions were monitored by TLC
analysis using silica gel GF/UV 254. NMR spectra were recorded on Varian
Gemini-300BB 500 MHz FT-NMR spectrometers (Varian Inc., Palo Alto, CA). 1H
spectra were run at 500 MHz and 13C spectra were run at 126 MHz, in deuterated
dimethylsulfoxide (DMSO-d6), (CD3)2CO and CDCl3. Chemical shifts (δH) are
reported relative to TMS as internal standard and coupling constant (J) values are
reported in Hertz. The abbreviations used are as follows: s, singlet; d, doublet; t,
triplet; m, multiplet. Electrospray ionization (ESI single quadrupole) mass spectra
have their ion mass to charge values (m/z) stated with their relative abundances as
a percentage in parentheses. Peaks assigned to the molecular ion are denoted as
[M+H] or [M+Na]. Column chromatography was performed using silica gel 60
(0.063-0.200 mm). Compounds 3.6-3.9 and 3.29-3.39 were ≥95% pure. The purity
was determined by HPLC analysis using a Shimadzu CLASS-VP LC10 analytical
HPLC system equipped with a Photo Diode Array Detector and autosampler (100%
H2O/0.1% TFA → 100% CH3CN/0.1% TFA over 30 min.
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6-Ethyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one (3.4):17
After preparing a sodium ethoxide solution by dissolving sodium (4.6 g, 0.1 mole)
in absolute ethanol (150 mL), the thiourea (3.8 g, 0.05 mole) was added with
stirring with complete dissolution. The ethyl 3-oxopentanoate ester 2 (7.21 g, 0.05
mole) was then added and the reaction mixture was heated at reflux for 4 hours.
After cooling the reaction mixture, water was added dropwise untill complete
dissolution of the formed white precipitate. Ice was added, and neutralization of the
alkaline solution was accomplished using HCl (5 M). The reaction flask was left
overnight at 4 °C and the resulting white precipitate was filtered, washed with water
(3 x 50 mL) and diethyl ether (2 x 30 mL) and dried to give 3 (5.38 g, 69%) as a
white powder. m.p 230 °C; 1H NMR (DMSO, δ): 1.07 (t, J = 7.5 Hz, 3H, CH3),
2.33 (q, J = 7.5 Hz, 2H, CH2), 5.33 (s, 1H, pyrimidine-H), 12.30 (br s, 2H, 2 x NH); 13C NMR (CD3OD, δ): 13.4, 27.8, 103.9, 162.0, 165.8, 179.4; MS (ESI+): 157
(20%, M+H)+, 179 (100%, M+Na)+.

6-Ethyl-2-(methylthio)pyrimidin-4(3H)-one (3.5): A mixture of 6-ethyl-2thioxo-2,3-dihydropyrimidin-4(1H)-one 3 (156 mg, 1 mmol), sodium hydroxide
(44 mg, 1.1 mmol) in water (1 mL) and ethanol (3 mL) were stirred for 30 min.
Methyl iodide (142 mg, 1 mmol) was added dropwise to the slurry and the reaction
mixture was gently heated at 50 °C with stirring for 3 h. The reaction mixture was
allowed to cool to r.t and the resulting white solid was filtered out, washed with
water (3 x 30 mL) and dried to give 4 (128 mg, 75%) as a white powder; 1H NMR
(CDCl3, δ): 1.24 (t, J = 7.5 Hz, 3H, CH3), 2.56 (q, J = 7.5 Hz, 2H, CH2), 2.60 (s,
3H, SCH3), 6.09 (s, 1H, pyrimidine-H), 9.32 (br. s, 1H, -NH); 13C NMR (CDCl3,
δ): 12.0, 13.2, 30.8, 106.7, 161.1, 165.9, 170.7; MS (ESI+): 171 (35%, M+H)+, 193
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(100%, M+Na)+.
General procedure A for the preparation of 6-ethyl-2-(anilino)pyrimidin4(3H)-ones (3.6-3.9):19 A mixture of 6-ethyl-2-(methylthio)pyrimidin-4(3H)-one
3.5 (170 mg, 1 mmol) and the corresponding aniline (1.2 mmol) in pivalic acid (9
volumes) was heated at 130 °C with stirring. Heating was maintained until the
starting materials were fully consumed or until no further conversion was observed
(as monitored by TLC analysis). The slurry was allowed to cool to 60-70 °C and
hexanes (18 volumes) was added slowly with stirring and was further cooled to r.t.
The resulting solid was filtered, washed with hexanes and dried.

6-Ethyl-2-(phenylamino)pyrimidin-4(3H)-one

(3.6):

The

compound

was

prepared according to general method A (yield = 79%) as a white powder, m.p:
178-180 °C; HPLC purity 96.3%. 1H NMR (CDCl3, δ): 1.27 (t, J = 7.0 Hz, 3H,
CH3), 2.55 (q, J = 7.0 Hz, 2H, CH2), 5.81 (s, 1H, pyrimidine-H), 7.05-7.13 (m, 1H,
ArH), 7.36 (t, J = 8.0 Hz, 2H, ArH), 7.75 (d, J = 7.0 Hz, 2H, ArH), 9.50 (br. s, 1H,
-NH), 11.62 (br. s, 1H, -NH); 13C NMR (CDCl3, δ): 14.5, 31.4, 101.1, 120.2, 123.4,
129.1, 138.9, 151.7, 165.5, 173.9; MS (ESI+) m/z 216 (65%, M+H) +, MS (ESI-)
m/z 214 (100%, M-H)-; HRMS (ESI+) calcd for C12H14N3O: 216.1142 (M+H)+,
found: 216.1137.

6-Ethyl-2-((3-fluorophenyl)amino)pyrimidin-4(3H)-one (3.7): The compound
was prepared according to general method A (yield = 82%) as a buff powder, m.p:
198-200 °C; HPLC purity 98.1%. 1H NMR (CDCl3, δ): 1.26 (t, J = 7.0 Hz, 3H,
CH3), 2.56 (q, J = 7.0 Hz, 2H, CH2), 5.83 (s, 1H, pyrimidine-H), 6.76-6.80 (m, 1H,
ArH), 7.20-7.31 (m, 2H, ArH), 7.81 (d, J = 10.0 Hz, 1H, ArH), 9.45 (br. s, 1H, 61
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NH), 11.44 (br. s, 1H, -NH); 13C NMR (CDCl3, δ): 12.2, 31.2, 101.4, 107.1 (d, J2C−F
= 26

Hz), 109.7 (d, J2C−F = 21 Hz), 114.9, 129.9 (d, J3C−F = 10 Hz), 140.2 (d, J3C−F =

11 Hz), 151.0, 162.1 (d, J1C−F = 248 Hz), 165.1, 173.9; MS (ESI+) m/z 234 (40%,
M+H), MS (ESI-) m/z 232 (100%, M-H)-; HRMS (ESI-) calcd for C12H11FN3O:
232.0886 (M-H)-, found: 232.0879.

6-Ethyl-2-((3-isopropoxyphenyl)amino)pyrimidin-4(3H)-one

(3.8):

The

compound was prepared according to general method A (yield = 24%) as a green
powder, m.p: 100-102 °C; HPLC purity 95.2%. 1H NMR (CDCl3, δ): 1.27 (t, J =
7.0 Hz, 3H, CH2CH3), 1.38 (d, J = 5.0 Hz, 6H, 2CH3), 2.55 (q, J = 7.0 Hz, 2H,
CH2CH3), 4.45-4.59 (m, 1H, CH), 5.82 (s, 1H, pyrimidine-H), 6.63 (d, J = 7.0 Hz,
1H, ArH), 7.12 (d, J = 8.0 Hz, 1H, ArH), 7.22 (dd, J = 7.0, 8.0 Hz, 1H, ArH), 7.60
(s, 1H, ArH), 9.43 (br. s, 1H, -NH), 11.47 (br. s, 1H, -NH); 13C NMR (CDCl3, δ):
12.2, 22.1, 31.2, 70.0, 101.0, 107.4, 111.2, 112.0, 129.6, 139.8, 151.4, 158.5, 165.2,
173.5; MS (ESI+) m/z 274 (50%, M+H)+, MS (ESI-) m/z 272 (60%, M-H)-; HRMS
(ESI-) calcd for C15H18N3O2: 272.1401 (M-H)-, found: 272.1399.

3-((4-Ethyl-6-oxo-1,6-dihydropyrimidin-2-yl)amino)benzenesulfonamide
(3.9): The compound was prepared according to general method A (yield = 22%)
as a buff powder, m.p: 203-205 °C; HPLC purity 95.6%. 1H NMR (DMSO, δ): 1.17
(t, J = 8.0 Hz, 3H, CH2CH3), 2.44 (q, J = 8.0 Hz, 2H, CH2CH3), 5.78 (s, 1H,
pyrimidine-H), 7.33 (br. s, 2H, -SO2NH2), 7.42-7.49 (m, 2H, ArH), 7.83 (d, J = 7.0
Hz, 1H, ArH), 8.26 (s, 1H, ArH), 9.18 (br. s, 1H, -NH), 11.79 (br. s, 1H, -NH); 13C
NMR (DMSO, δ): 12.6, 30.5, 101.2, 116.6, 119.5, 122.4, 129.7, 140.2, 145.1,
153.7, 164.9, 171.0; MS (ESI-) m/z 293 (60%, M-H)-, 587 (100%, 2M-H)-; HRMS
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(ESI-) calcd for C12H13N4O3S: 293.0711 (M-H)-, found: 293.0708.

General procedure B for preparation of hydrazonyl chlorides (3.14-3.24):27
The diazonium salt was prepared by slowly adding a cold sodium nitrite solution
(0.7 g, 10 mmol) in deionized water (5 mL) to a cold solution of the appropriate
arylamine (10 mmol) dissolved in hydrochloric acid (6 M, 6 mL). In a second
beaker, sodium acetate trihydrate (4.1 g, 30 mmol) was added to a stirred solution
of 3-chloro-2,4-pentanedione 3.12 (1.34 g, 10 mmol) or ethyl 2-chloro-3oxobutanoate 3.13 (1.64 g, 10 mmol) in ethanol (100 mL) and the slurry was stirred
for 15 min. The diazonium salt was added dropwise to the second beaker and the
reaction was stirred for 2 h at 0-5 °C, then left for 8 h in a refrigerator (4 °C). The
resulting solid was collected by filtration, washed thoroughly with water and dried.
The crude product was crystallized from ethanol to give the corresponding
hydrazonoyl chlorides 3.14-3.24.

(Z)-N-(3-Fluorophenyl)-2-oxopropanehydrazonoyl

chloride

(3.14):

The

compound was prepared according to method B (yield = 63%) as yellow crystals,
m.p: 155-157 °C. 1H NMR (CDCl3, δ): 2.58 (s, 3H, CH3), 6.77 (td, J = 2.0, 8.5 Hz,
1H, ArH), 6.95 (dd, J = 1.0, 8.0 Hz, 1H, ArH), 7.02 (dt, J = 2.0, 10.0 Hz, 1H, ArH),
7.29-7.33 (m, 1H, ArH), 8.48 (br. s, 1H, NH); 13C NMR (CDCl3, δ): 25.4, 101.9 (d,
J2C−F = 28 Hz), 110.1 (d, J4C−F = 5 Hz), 110.2 (d, J2C−F = 14 Hz), 126.1, 130.9 (d, J3C−F
=9

Hz), 143.0 (d, J3C−F = 10 Hz), 162.8 (d, J1C−F = 246 Hz), 188.3; MS (ESI-) m/z 213

(100%, M-H)-, 249 (10%, M+Cl)-; HRMS (ESI+) calcd for C9H8ClFN2ONa:
237.0218 (M+Na)+, found: 237.0207.
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Ethyl (Z)-2-chloro-2-(2-(3-fluorophenyl)hydrazineylidene)acetate (3.15): The
compound was prepared according to method B (yield = 78%) as yellow crystals,
m.p: 110-112 °C. 1H NMR (CDCl3, δ): 1.44 (t, J = 7.5 Hz, 3H, CH3), 4.43 (q, J =
7.5 Hz, 2H, CH2), 6.76 (td, J = 2.0, 8.0 Hz, 1H, ArH), 6.97 (d, J = 8.0 Hz, 1H, ArH),
7.06 (d, J = 10.0 Hz, 1H, ArH), 7.28-7.33 (m, 1H, ArH), 8.38 (br. s, 1H, NH); 13C
NMR (CDCl3, δ): 14.2, 63.0, 102.0 (d, J2C−F = 26 Hz), 109.7 (d, J2C−F = 23 Hz), 110.0
(d, J4C−F = 2 Hz), 117.1, 130.7 (d, J3C−F = 9 Hz), 143.0 (d, J3C−F = 10 Hz), 159.5, 162.8
(d, J1C−F = 246 Hz); MS (ESI-) m/z 243 (50%, M-H)-, 279 (15%, M+Cl)-; HRMS
(ESI-) calcd for C10H9ClFN2O2: 243.0344 (M-H)-, found: 243.0337.

(Z)-N-(3-Acetylphenyl)-2-oxopropanehydrazonoyl

chloride

(3.16):

The

compound was prepared according to method B (yield = 50%) as a white powder,
m.p: 160 -162 °C. 1H NMR ((CD3)2CO, δ): 2.56 (s, 3H, CH3), 2.59 (s, 3H, CH3),
7.49 (t, J = 7.5 Hz, 1H, ArH), 7.68-7.72 (m, 2H, ArH), 8.02 (s, 1H, ArH), 10.01
(br. s, 1H, NH); 13C NMR ((CD3)2CO, δ): 24.6, 25.9, 114.1, 118.8, 122.7, 124.9,
129.8, 138.5, 143.0, 187.4, 196.7; MS (ESI-) m/z 237 (100%, M-H)-, 273 (20%,
M+Cl)-; HRMS (ESI-) calcd for C11H10ClFN2O2: 237.0431 (M-H)-, found:
237.0431.

Ethyl (Z)-2-(2-(3-acetylphenyl)hydrazineylidene)-2-chloroacetate (3.17): The
compound was prepared according to method B (yield = 61%) as yellow crystals,
m.p: 142-144 °C. 1H NMR ((CD3)2CO, δ): 1.36 (t, J = 7.0 Hz, 3H, -CH2CH3), 2.58
(s, 3H, COCH3), 4.43 (q, J = 7.0 Hz, 2H, -CH2CH3), 7.49 (t, J = 7.5 Hz, 1H, ArH),
7.62-7.66 (m, 2H, ArH), 7.97 (s, 1H, ArH), 9.91 (br. s, 1H, NH);

13

C NMR

((CD3)2CO, δ): 13.6, 25.9, 62.2, 113.9, 115.7, 118.7, 122.5, 129.7, 138.4, 143.2,
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159.2, 196.7; MS (ESI-) m/z 267 (100%, M-H)-, 303 (20%, M+Cl)-; HRMS (ESI-)
calcd for C12H12ClN2O3: 267.0528 (M-H)-, found: 267.0536.

(Z)-N-(3-Isopropoxyphenyl)-2-oxopropanehydrazonoyl chloride (3.18): The
compound was prepared according to method B (yield = 47%) as red crystals, m.p:
80-82 °C. 1H NMR (CDCl3, δ): 1.37 (d, J = 6.0 Hz, 6H, 2CH3), 2.57 (s, 3H, CH3),
4.56-4.60 (m, 1H, CH), 6.62 (dd, J = 2.0, 8.0 Hz, 1H, ArH), 6.76 (dd, J = 1.0, 8.0
Hz, 1H, ArH), 6.82 (dd, J = 2.0, 2.0 Hz, 1H, ArH), 7.20-7.26 (m, 1H, ArH), 8.43
(br. s, 1H, NH); 13C NMR (CDCl3, δ): 22.1, 25.3, 70.1, 102.6, 106.9, 110.6, 125.1,
130.5, 142.6, 159.2, 188.4; MS (ESI-) m/z 253 (15%, M-H)-; HRMS (ESI-) calcd
for C12H14ClN2O2: 253.0749 (M-H)-, found: 253.0744.

Ethyl (Z)-2-chloro-2-(2-(3-isopropoxyphenyl)hydrazineylidene)acetate (3.19):
The compound was prepared according to method B (yield = 51%) as brown
needles, m.p: 67-69 °C. 1H NMR (CDCl3, δ): 1.34 (d, J = 7.0 Hz, 6H, 2CH3, C10),
1.39 (t, J = 7.0 Hz, 3H, -CH2CH3), 4.37 (q, J = 7.0 Hz, 2H, -CH2CH3), 4.54-4.59
(m, 1H, CH), 6.57 (dd, J = 2.0, 8.0 Hz, 1H, ArH), 6.73 (d, J = 8.0 Hz, 1H, ArH),
6.82 (t, 2.0 Hz, 1H, ArH), 7.20 (dd, J = 8.0, 8.0 Hz, 1H, ArH), 8.31 (br. s, 1H, NH);
13

C NMR (CDCl3, δ): 14.4, 22.2, 62.9, 70.1, 102.5, 107.0, 110.5, 116.0, 130.4,

143.0, 159.2, 159.8; MS (ESI+) m/z 591 (70%, 2M+Na)+; MS (ESI-) m/z 283 (5%,
M-H)-.

(Z)-2-Oxo-N-(3-sulfamoylphenyl)propanehydrazonoyl chloride (3.20): The
compound was prepared according to method B (yield = 65%) as a yellow powder,
m.p: 223-225 °C. 1H NMR (DMSO, δ): 2.49 (s, 3H, CH3), 7.39 (br. s, 2H, NH2),
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7.44 (d, J = 7.0 Hz, 1H, ArH), 7.51 (t, J = 7.5 Hz, 2H, ArH), 7.61 (dd, J = 2.0, 7.5
Hz, 1H, ArH), 7.89 (dd, J = 2.0 Hz, 2H, ArH), 10.90 (br. s, 1H, NH);

13

C NMR

(DMSO, δ): 25.9, 112.3, 118.2, 120.0, 124.7, 130.5, 143.4, 145.8, 188.4; MS (ESI)
m/z 274 (100%, M-H)-; HRMS (ESI-) calcd for C9H9ClN3O3S: 274.0050 (M-H)-,
found: 274.0053.

Ethyl (Z)-2-chloro-2-(2-(3-sulfamoylphenyl)hydrazineylidene)acetate (3.21):
The compound was prepared according to method B (yield = 72%) as an orange
powder, m.p: 213-215 °C. 1H NMR (DMSO, δ): 1.30 (t, J = 7.0 Hz, 3H, CH3), 4.30
(q, J = 7.0 Hz, 2H, CH2), 7.38 (br. s, 2H, NH2), 7.44 (d, J = 7.0 Hz, 1H, ArH), 7.497.54 (m, 2H, ArH), 7.84 (s, 1H, ArH), 10.80 (br. s, 1H, NH); 13C NMR (DMSO,
δ): 14.6, 62.9, 112.0, 115.6, 118.0, 119.8, 130.5, 143.6, 145.7, 159.6; MS (ESI-) m/z
304 (100%, M-H)-, 340 (30%, M+Cl)-; HRMS (ESI-) calcd for C10H11ClN3O4S:
304.0160 (M-H)-, found: 304.0159.

(Z)-2-Oxo-N-(4-sulfamoylphenyl)propanehydrazonoyl chloride (3.22): The
compound was prepared according to method B (yield = 68%) as a buff powder,
m.p: 190-192 °C. 1H NMR (DMSO, δ): 2.52 (s, 3H, CH3), 7.24 (br. s, 2H, NH2),
7.56 (d, J = 9.0 Hz, 2H, ArH), 7.78 (d, J = 9.0 Hz, 2H, ArH), 10.93 (br. s, 1H, NH);
13

C NMR (DMSO, δ): 25.5, 114.5, 124.6, 127.3, 137.7, 145.2, 188.1; MS (ESI-)

m/z 274 (100%, M-H)-, 310 (15%, M+Cl)-; HRMS (ESI-) calcd for C9H9ClN3O3S:
274.0059 (M-H)-, found: 274.0053.

Ethyl (Z)-2-chloro-2-(2-(4-sulfamoylphenyl)hydrazineylidene)acetate (3.23):
The compound was prepared according to method B (yield = 75%) as an orange
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powder, m.p: 178-180 °C. 1H NMR ((CD3)2CO, δ): 1.37 (t, J = 7.0 Hz, 3H, CH3),
4.38 (q, J = 7.0 Hz, 2H, CH2), 6.57 (br. s, 2H, NH2), 7.51 (d, J = 8.0 Hz, 2H, ArH),
7.87 (d, J = 8.0 Hz, 2H, ArH), 10.03 (br. s, 1H, NH);

13

C NMR ((CD3)2CO, δ):

13.8, 62.0, 114.0, 117.1, 127.6, 137.8, 145.9, 159.5; MS (ESI-) m/z 304 (100%, MH)-; HRMS (ESI+) calcd for C10H1135ClN3O4S: 306.0315 (M+H)+, found: 306.0316.

(Z)-N-(4-Bromophenyl)-2-oxopropanehydrazonoyl chloride (3.24):28 The
compound was prepared according to method B (yield = 81%) as a yellow needles,
m.p: 154-156 °C. 1H NMR (CDCl3, δ): 2.57 (s, 3H, CH3), 7.12 (d, J = 8.5 Hz, 2H,
ArH), 7.47 (d, J = 8.5 Hz, 2H, ArH), 8.42 (br. s, 1H, NH); 13C NMR (CDCl3, δ):
25.3, 115.9, 116.0, 126.0, 132, 140.5, 188.2; MS (ESI-) m/z 273 (100%, M-H, 79Br).

General procedure C for preparation of target compounds (3.29-3.39)
To a mixture of 6-ethyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one 3.4 (156 mg, 1
mmol) and the corresponding hydrazonoyl chloride 3.14-3.24 (1 mmol) in dioxane
(15.0 mL), DIPEA (174 μL, 1 mmol) was added. The reaction mixture was heated
at reflux until the starting materials were fully consumed or until no further
conversion was observed (monitored by TLC analysis). The solvent was removed
under vacuum and the residue was triturated with methanol and the resulting
precipitate filtered, taken up in EtOAc and washed with water (2 x 30 mL), brine
(30 mL), dried (MgSO4), filtered and concentrated then subjected to flash
chromatography (methanol/dichloromethane, 1:10) to give 3.29-3.39.

3-Acetyl-7-ethyl-1-(3-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyrimidin-5(1H)one (3.29): The compound was prepared according to method C (yield = 35%) as
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a buff powder, m.p: 122-124 °C; HPLC purity 95.3%. 1H NMR (CDCl3, δ): 1.31 (t,
J = 7.5 Hz, 3H, CH3), 2.70 (q, J = 7.5 Hz, 2H, CH2), 2.81 (s, 3H, COCH3), 6.05 (s,
1H, ArH), 7.09 (app t, J = 8.0 Hz, 1H, ArH), 7.50 (dd, J = 8.0, 14.5 Hz, 1H, ArH),
8.08-8.12 (m, 2H, ArH); 13C NMR (CDCl3, δ): 12.7, 30.0, 31.4, 101.2, 108.1 (d,
J2C−F = 28 Hz), 114.5 (d, J2C−F = 21 Hz), 115.9 (d, J4C−F = 4 Hz), 130.8 (d, J3C−F = 9
Hz), 137.8 (d, J3C−F = 10 Hz), 141.6, 147.8, 155.9, 161.9 (d, J1C−F = 248 Hz), 172.2,
186.6; MS (ESI+) m/z 301 (80%, M+H)+, 623 (100%, 2M+Na)+; HRMS (ESI+)
calcd for C15H14FN4O2: 301.1101 (M+H)+, found: 301.1095.

Ethyl

7-ethyl-1-(3-fluorophenyl)-5-oxo-1,5-dihydro-[1,2,4]triazolo[4,3-

a]pyrimidine-3-carboxylate (3.30): The compound was prepared according to
general method C (yield = 42%) as a buff powder, m.p: 92-94 °C; HPLC purity
98.7%. 1H NMR (CDCl3, δ): 1.31 (t, J = 7.5 Hz, 3H, CH3), 1.46 (t, J = 7.0 Hz, 3H,
CH3), 2.69 (q, J = 7.5 Hz, 2H, CH2), 4.58 (q, J = 7.0 Hz, 2H, CH2), 6.05 (s, 1H,
ArH), 7.07 (td, J = 1.5, 8.0 Hz, 1H, ArH), 7.49 (dd, J = 8.0, 14.5 Hz, 1H, ArH),
8.06-8.11 (m, 2H, ArH); 13C NMR (CDCl3, δ): 12.8, 14.0, 31.5, 64.2, 100.7, 108.0
(d, J2C−F = 28 Hz), 114.4 (d, J2C−F = 21 Hz), 115.7 (d, J2C−F = 3 Hz), 130.8 (d, J3C−F =
9 Hz), 135.8, 137.7 (d, J3C−F = 11 Hz), 147.2, 155.6, 156.7, 161.8 (d, J2C−F = 247 Hz),
172.6; MS (ESI+) m/z 331 (55%, M+H)+, 683 (100%, 2M+Na)+; HRMS (ESI+)
calcd for C16H16FN4O3: 331.1218 (M+H)+, found: 331.1206.

3-Acetyl-1-(3-acetylphenyl)-7-ethyl-[1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-one
(3.31): The compound was prepared according to general method C (yield = 19%)
as an orange powder, m.p: 118-120 °C; HPLC purity 97.5%. 1H NMR (CDCl3, δ):
1.32 (t, J = 7.5 Hz, 3H, CH3), 2.68-2.71 (m, 5H, CH3 + CH2), 2.83 (s, 3H, COCH3),
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6.07 (s, 1H, ArH), 7.66 (app t, J = 8.0 Hz, 1H, ArH), 7.97 (d, J = 8.0 Hz, 1H, ArH),
8.47 (d, J = 8.0 Hz, 1H, ArH), 8.90 (s, 1H, ArH); 13C NMR (CDCl3, δ): 12.6, 27.0,
30.0, 31.3, 101.2, 120.3, 124.7, 127.3, 129.9, 136.9, 138.1, 141.5, 147.8, 155.8,
172.1, 186.6, 197.1; MS (ESI+) m/z 325 (20%, M+H)+, 671 (100%, 2M+Na)+;
HRMS (ESI+) calcd for C17H17N4O3: 325.1293 (M+H)+, found: 325.1301.

Ethyl

1-(3-acetylphenyl)-7-ethyl-5-oxo-1,5-dihydro-[1,2,4]triazolo[4,3-

a]pyrimidine-3-carboxylate (3.32): The compound was prepared according to
general method C (yield = 43%) as a white powder, m.p: 120-122 °C; HPLC purity
99.5%. 1H NMR (CDCl3, δ): 1.32 (t, J = 7.5 Hz, 3H, CH3), 1.48 (t, J = 7.5 Hz, 3H,
CH3), 2.68-2.71 (m, 5H, CH3 + CH2), 4.59 (q, J = 7.0 Hz, 2H, CH2), 6.03 (s, 1H,
ArH), 7.64 (app t, J = 8.0 Hz, 1H, ArH), 7.97 (d, J = 8.0 Hz, 1H, ArH), 8.46 (d, J
= 8.0 Hz, 1H, ArH), 8.90 (s, 1H, ArH); 13C NMR (CDCl3, δ): 12.7, 14.1, 26.9, 31.5,
64.2, 100.7, 120.4, 124.6, 127.1, 129.9, 136.1, 137.2, 138.3, 147.4, 155.6, 156.7,
172.5, 197.0; MS (ESI+) m/z 355 (20%, M+H)+, 377 (90%, M+Na)+; HRMS (ESI+)
calcd for C18H19N4O4: 355.1422 (M+H)+, found: 355.1406.

3-Acetyl-7-ethyl-1-(3-isopropoxyphenyl)-[1,2,4]triazolo[4,3-a]pyrimidin5(1H)-one (3.33): The compound was prepared according to general method C
(yield = 27%) as a buff powder, m.p: 88-90 °C; HPLC purity 96.5%. 1H NMR
(CDCl3, δ): 1.30 (t, J = 7.5 Hz, 3H, CH3), 1.40 (d, J = 5.5 Hz, 6H, 2 x CH3), 2.68
(q, J = 7.5 Hz, 2H, CH2), 2.80 (s, 1H, 3H, CH3), 4.62-4.64 (m, 1H, CH), 6.04 (s,
1H, ArH), 6.91 (d, J = 7.5 Hz, 1H, ArH), 7.40 (app t, J = 7.5 Hz, 1H, ArH), 7.737.79 (m, 1H, ArH), 7.84 (s, 1H, ArH); 13C NMR (CDCl3, δ): 12.7, 22.1, 30.0, 31.4,
70.6, 100.8, 108.3, 112.7, 115.7, 130.3, 137.6, 141.3, 148.0, 156.1, 158.7, 172.2,
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186.7; MS (ESI+) m/z 341 (60%, M+H)+, 703 (100%, 2M+Na)+; HRMS (ESI+)
calcd for C18H21N4O3: 341.1611 (M+H)+, found: 341.1614.

Ethyl

7-ethyl-1-(3-isopropoxyphenyl)-5-oxo-1,5-dihydro-[1,2,4]triazolo[4,3-

a]pyrimidine-3-carboxylate (3.34): The compound was prepared according to
general method C (yield = 35%) as a buff powder, m.p: 95-97 °C; HPLC purity
98.3%. 1H NMR (CDCl3, δ): 1.30 (t, J = 7.5 Hz, 3H, CH3), 1.38 (d, J = 6.0 Hz, 6H,
2CH3), 1.46 (t, J = 7.0 Hz, 3H, CH3), 2.67 (q, J = 7.5 Hz, 2H, CH2), 4.57 (q, J = 7.0
Hz, 2H, CH2), 4.60-4.65 (m, 1H, CH), 6.00 (s, 1H, ArH), 6.89 (d, J = 8.0 Hz, 1H,
ArH), 7.39 (dd, J = 8.0, 8.5 Hz, 1H, ArH), 7.74 (d, J = 8.5 Hz, 1H, ArH), 7.82 (s,
1H, ArH); 13C NMR (CDCl3, δ): 12.8, 14.1, 22.2, 31.6, 64.1, 70.5, 100.3, 108.0,
112.7, 115.8, 130.3, 135.7, 137.7, 147.4, 155.9, 157.0, 158.7, 172.7; MS (ESI+) m/z
371 (80%, M+H)+, 763 (100%, 2M+Na)+; HRMS (ESI+) calcd for C19H23N4O3:
371.1720 (M+H)+, found: 371.1719.

3-(3-Acetyl-7-ethyl-5-oxo-[1,2,4]triazolo[4,3-a]pyrimidin-1(5H)yl)benzenesulfonamide (3.35): The compound was prepared according to general
method C (yield = 39%) as a buff powder, m.p: 180-182 °C; HPLC purity 96.5 %.
1

H NMR ((CD3)2CO), δ: 1.30 (t, J = 7.5 Hz, 3H, CH3), 2.68 (q, J = 7.5 Hz, 2H,

CH2), 2.77 (s, 1H, 3H, CH3), 6.00 (s, 1H, ArH), 6.85 (br. s, 2H, NH2), 7.82 (dd, J
= 8.0, 8.5 Hz, 1H, ArH), 7.94 (d, J = 8.0 Hz, 1H, ArH), 8.61 (d, J = 8.5 Hz, 1H,
ArH), 8.79 (s, 1H, ArH); 13C NMR ((CD3)2CO), δ: 12.2, 29.8, 31.0, 100.1, 118.1,
123.5, 124.7, 130.3, 137.5, 142.1, 145.8, 148.5, 155.9, 172.0, 188.0; MS (ESI+) m/z
362 (10%, M+H)+, 384 (15%, M+Na)+; HRMS (ESI+) calcd for C15H16N5O4S:
362.0917 (M+H)+, found: 362.0923.
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7-ethyl-5-oxo-1-(3-sulfamoylphenyl)-1,5-dihydro-[1,2,4]triazolo[4,3-

a]pyrimidine-3-carboxylate (3.36): The compound was prepared according to
general method C (yield = 55%) as a pale yellow powder, m.p: 176-178 °C; HPLC
purity 98.7%. 1H NMR (DMSO, δ): 1.24 (t, J = 7.5 Hz, 3H, CH3), 1.35 (t, J = 7.0
Hz, 3H, CH3), 2.62 (q, J = 7.5 Hz, 2H, CH2), 4.48 (q, J = 7.0 Hz, 2H, CH2), 6.02
(s, 1H, ArH), 7.59 (br. s, 2H, NH2), 7.81-7.86 (m, 2H, ArH), 8.42 (d, J = 8.0 Hz,
1H, ArH), 8.57 (s, 1H, ArH); 13C NMR (DMSO, δ): 12.9, 14.2, 31.0, 64.0, 100.0,
118.1, 123.8, 124.8, 130.8, 135.8, 137.0, 145.8, 148.2, 155.5, 157.0, 172.0; MS
(ESI+) m/z 414 (35%, M+H)+, 805 (100%, 2M+Na)+; HRMS (ESI+) calcd for
C16H17N5O5S: 414.0858 (M+Na)+, found: 414.0848.

4-(3-Acetyl-7-ethyl-5-oxo-[1,2,4]triazolo[4,3-a]pyrimidin-1(5H)yl)benzenesulfonamide (3.37): The compound was prepared according to general
method C (yield = 51%) as a buff powder, m.p: 162-164 °C; HPLC purity 96.3%.
1

H NMR (DMSO, δ): 1.25 (t, J = 7.5 Hz, 3H, CH3), 2.65 (q, J = 7.5 Hz, 2H, CH2),

2.72 (s, 1H, 3H, CH3), 6.07 (s, 1H, ArH), 7.49 (br. s, 2H, NH2), 8.05 (d, J = 8.5 Hz,
2H, ArH), 8.37 (d, J = 8.5 Hz, 2H, ArH); 13C NMR (DMSO, δ): 13.0, 30.6, 30.9,
100.5, 121.1, 127.6, 139.1, 141.9, 142.9, 148.4, 155.9, 171.8, 188.6; MS (ESI+) m/z
384 (10%, M+Na)+, 745 (15%, 2M+Na)+; HRMS (ESI+) calcd for C15H16N5O4S:
362.0912 (M+H)+, found: 362.0923.

Ethyl

7-ethyl-5-oxo-1-(4-sulfamoylphenyl)-1,5-dihydro-[1,2,4]triazolo[4,3-

a]pyrimidine-3-carboxylate (3.38): The compound was prepared according to
general method C (yield = 61%) as a pale yellow powder, m.p: 180-182 °C; HPLC
purity 96.7%. 1H NMR ((CD3)2CO), δ: 1.32 (t, J = 7.5 Hz, 3H, CH3), 1.45 (t, J =
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7.0 Hz, 3H, CH3), 2.71 (q, J = 7.5 Hz, 2H, CH2), 4.56 (q, J = 7.0 Hz, 2H, CH2),
6.00 (s, 1H, ArH), 6.72 (br. s, 2H, NH2), 8.13 (d, J = 8.5 Hz, 2H, ArH), 8.51 (d, J
= 8.5 Hz, 2H, ArH); 13C NMR ((CD3)2CO), δ: 12.1, 13.3, 30.9, 63.5, 99.8, 120.4,
127.4, 136.2, 139.5, 142.6, 148.0, 155.1, 156.7, 172.0; MS (ESI+) m/z 392 (5%,
M+H)+, MS (ESI-) m/z 390 (100%, M–H)-; HRMS (ESI+) calcd for C16H18N5O5S:
392.1032 (M+H)+, found: 392.1029.

3-Acetyl-1-(4-bromophenyl)-7-ethyl-[1,2,4]triazolo[4,3-a]pyrimidin-5(1H)one (3.39): The compound was prepared according to general method C (yield =
32%) as a buff powder, m.p: 155-157 °C; HPLC purity 95.4%. 1H NMR (CDCl3,
δ): 1.30 (t, J = 7.5 Hz, 3H, CH3), 2.68 (q, J = 7.5 Hz, 2H, CH2), 2.81 (s, 3H,
COCH3), 6.05 (s, 1H, ArH), 7.66 (d, J = 9.0 Hz, 2H, ArH), 8.17 (d, J = 9.0 Hz, 2H,
ArH);

13

C NMR (CDCl3, δ): 12.6, 29.9, 31.3, 100.9, 121.3, 122.0, 132.4, 135.6,

141.5, 147.6, 155.8, 172.1, 186.5; MS (ESI+) m/z 361 (10%, M+H,
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Br)+, 363

(10%, M+H, 81Br)+; HRMS (ESI+) calcd for C15H1479BrN4O2: 361.0301 (M+H)+,
found: 361.0300.
3.4.2
-

Biological evaluation

Antiviral assay: 29

CHIKV Indian Ocean strain 899 (Genbank FJ959103.1) was generously provided
by Prof. S. Günther (Bernhard Nocht Institute for Tropical Medicine, Hamburg,
Germany) (Panning M et al., Emerging Infectious Diseases 2008). BGM cells were
maintained in cell growth medium composed of minimum essential medium (MEM
Rega-3, Gibco, Belgium) supplemented with 10% Foetal Bovine Serum (FBS,
Integro, The Netherlands), 1% L-glutamine (Gibco), and 1% sodium bicarbonate
(Gibco). The antiviral assays were performed in virus growth medium which is the
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respective cell growth medium supplemented with 2% (instead of 10%) FBS. Cell
cultures were maintained at 37 °C in an atmosphere of 5% CO2 and 95-99%
humidity. BGM cells were seeded in 96-well tissue culture plates (Becton
Dickinson, Aalst, Belgium) at a density of 2.5 x 104 cells/well in 100 μL assay
medium and were allowed to adhere overnight. Next, a compound dilution series
was prepared in the medium on top of the cells after which the cultures were
infected with 0.001 MOI of CHIKV 899 inoculum in 100 μL assay medium. On
day 5 post-infection (p.i.), the plates were processed using the MTS/PMS method
as described by the manufacturer (Promega, The Netherlands). The 50% effective
concentration (EC50), which is defined as the compound concentration that is
required to inhibit virus-induced cell death by 50%, was determined using
logarithmic interpolation. All assay wells were checked microscopically for minor
signs of virus induced CPE or possible alterations to the cell or monolayer
morphology caused by the compound.
-

Cell viability assay:

Exactly 100 µL of cells were cultured in 96 well-plates at a seeding density of 105
cells/mL. After 24 h, the cells were treated with the samples (dissolved in DMSO)
and incubated for 72 h. Doxorubicin at 1 µM concentration was used as a positive
control with 0.1% DMSO as a negative control for each plate. At the end of
incubation period the culture media were aspirated followed by the addition of
100 µL of 0.1 mg/mL Alamar blue solution (resazurin, stock solution (1 mg/mL in
a freshly prepared PBS), followed by 1:10 dilution with FBS free media) was added
to each well. Absorbance at 570 nm and 600 nm was measured using a BMG
LABTech FLUOstar OPTIMA plate reader (Mount Eliza, Victoria, Australia). The
drugs were tested in triplicate with a negative control was taken as 100% cell
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viability. Nonlinear regression and IC50 calculations were performed with
GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA).
3.4.3

Computational studies

All geometries and energies were calculated using the Gaussian16 package at the
B3LYP-D3(BJ)/6-311++G(2d,p) level including implicit solvation (polarisable
continuum model, solvent excluded surface and solvent-solute dispersion
interaction included) using the standard parameters for water. Normal mode
frequency analysis was performed on all ground state structures to confirm the
nature of the energy stationary point and estimate free energies.
For tautomer distributions, the molar free energies (ΔG) of each tautomer (relative
to that of the lowest) was calculated and isomer distributions derived using the
Boltzmann factor:

−Δ𝐺
𝑝𝑖
= ⅇ 𝑅T
𝑝0

where R is the molar gas constant, T the temperature (37° C = 310.15 K). The
results are shown in Table S1.
Electron density and Electrostatic Potential (ESP) cube files were calculated using
the Gaussian cubegen utility. ESP mapped onto electron isodensities were
generated using the GausView 6.0.16 application (Table 3.3).
Potential Energy Surfaces for the N-Ar torsion for 3.53, 3.54 and 3.55 were
calculated at the B3LYP-D3(BJ)/6-311G(2d,p) (Table 3.3) level including implicit
solvation (continuum model, solvent excluded surface and solvent-solute
dispersion interaction included) using the standard parameters for water. The
torsional angle defined by the blue heavy bonds (9,1,a,b) shown below and scanned
in 1° increments:
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Table 3.3: B3LYP-D3(BJ)/6-311++G(2d,p)-(water solvation) calculated free
energies and relative concentrations at 37° C for tautomers of the minimal
pharmacophores 3.54, 3.54b, 3.55, 3.55a, 3.56a-c.
Tautomer

G / Ha

ΔG / kJ mol-

3.54

-773.743900

[0]

Relative
conc.
[1]

3.54b

-773.728761

40

2.0  10-7

3.55

-757.711628

[0]

[1]

3.55b

-757.695321

43

6.1  10-8

3.56a

-665.434824

9

3.2  10-2

3.56b

-665.438199

[0]

[1]

3.56c

-665.431651

17

1.3  10-3

1
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3.4.4 X-ray crystallography
-

Single solid X-ray crystallographic data of 3.15
Crystal data. Compound 3.15. C10H10ClFN2O2, M = 244.65, T =153 K,
Orthorhombic, Z = 4, a = 4.590 (1), b = 9.619 (2), c = 25.879 (4) Å, V = 1142.6
(4) Å3, Dx = 1.422 Mg m-3, synchrotron radiation, λ = 0.710919 Å, 4577
reflections measured (θ = 1.6–29.1˚), merged to 2330 unique data, R= 0.040
[for 2089 data with I > 2σ(I)], R [F2 > 2σ (F2)]= 0.043 [all data], S = 0.99
Structure determination of compound 3.15. Data was collected using Dectris
Eiger 16M diffractometer with radiation source: MX1 Beamline Australian
Synchrotron.30 Structure solution was by direct methods (SIR92).31 The
structure was refined using the CRYSTALS program package.32

-

Single solid X-ray crystallographic data of 3.20
Crystal data. Compound 3.20. C10H10ClFN2O2, M = 275.72, T = 153 K,
Orthorhombic, Z = 8, a = 15.154 (1), b = 8.056 (10), c = 19.144 (4) Å, V = 2337
(3) Å3, Dx = 1.567 Mg m-3, synchrotron radiation, λ = 0.710919 Å, 26664
reflections measured (θ = 2.1–29.2˚), merged to 2408 unique data, R = 0.111
[for 1625 data with I > 2σ(I)], R[F2 > 2σ (F2)] = 0.060 [all data], S = 0.90.

-

Structure determination of compound 3.20. Data was collected using Dectris
Eiger 16M diffractometer with radiation source: MX1 Beamline Australian
Synchrotron.30 Structure solution was by direct methods (SIR92).31 The
structure was refined using the CRYSTALS program package.32
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Single solid X-ray crystallographic data of 3.24
Crystal data. Compound 3.24. C9H8BrClN2O, M = 275.53, T = 153 K,
Orthorhombic, Z = 4, a = 8.821 (6), b = 25.123 (15), c = 4.560 (4) Å, V = 1010.5
(13) Å3, Dx = 1.811 Mg m-3, synchrotron radiation, λ = 0.710919Å, 12004
reflections measured (θ = 1.6–29.0˚), merged to 2334 unique data, R= 0.093
[for 2022 data with I > 2σ(I)], R [F2 > 2σ (F2)] = 0.046 [all data], S = 1.01.
Structure determination of compound 3.24. Data was collected using Dectris
Eiger 16M diffractometer with radiation source: MX1 Beamline Australian
Synchrotron.30 Structure solution was by direct methods (SIR92).31 The
structure was refined using the CRYSTALS program package.32

-

Single solid X-ray crystallographic data of 3.23
Crystal data. For compound 3.23 C18H18N4O4 (M =354.36 g/mol): monoclinic,
space group P21/n (no. 14), a = 16.2162(9) Å, b = 5.5670(3) Å, c =
19.1376(13) Å, β = 96.256(6)°, V = 1717.37(19) Å3, Z = 4, T = 100(2) K,
μ(CuKα) = 0.824 mm-1, Dcalc = 1.371 g/cm3, 11249 reflections measured
(7.564° ≤ 2Θ ≤ 145.012°), 3326 unique (Rint = 0.0503, Rsigma = 0.0396) which
were used in all calculations. The final R1 was 0.0575 (I > 2σ(I)) and wR2 was
0.1665 (all data).
Structure determination of compound 3.23: Data was collected using
SuperNova, Dual, Cu at home/near, Atlas diffractometer. Using Olex2 33, the
structure was solved with the olex2.solve34 structure solution program using
Charge Flipping and refined with the ShelX35 refinement package using Least
Squares Minimization.
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-

Single solid X-ray crystallographic data of 3.39
Crystal data. Compound 3.39. C15H13BrN4O2, M = 361.20, T = 153 K,
Monoclinic, Z = 4, a = 4.668 (1), b = 21.780 (2), c = 14.348 (2) Å, β = 93.379
(6)°, V = 1456.2 (5) Å3, Dx = 1.647 Mg m-3, synchrotron radiation, λ = 0.710919
Å, 19044 reflections measured (θ = 1.7–29.2˚), merged to 2876 unique data, R
= 0.053 [for 2544 data with I > 2σ(I)], R [F2 > 2σ (F2)] = 0.031 [all data], S =
0.99.
Structure determination of compound 3.39. Data was collected using Dectris
Eiger 16M diffractometer with radiation source: MX1 Beamline Australian
Synchrotron.30 Structure solution was by direct methods (SIR92).31 The
structure was refined using the CRYSTALS program package.32
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Chapter 4:
Structure-guided drug design
targeting CHIKV

FOREWORD TO CHAPTER 4
This chapter describes application of structure-guided design approaches in the
development of new anti-CHIKV agent. Herein, the biological evaluation of the
active hits discovered by in silico screening is described. This chapter reports three
potential CHIKV inhibitors discovered from the antiviral screening. It also
describes the synthesis of a small library of the naphthamide derivative. However,
more studies need to be performed, including biological testing of the naphthamide
library at lower concentration and also development of the quinoline and the
spirobi[cyclopenta[b]naphthalene]dione scaffolds. NMR data of the synthesized
compounds from this chapter can be found in Appendix C (p. 257).
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4.1

Introduction

Chikungunya virus (CHIKV) is an arbovirus that is transmitted mainly by female
Aedes aegypti or Aedes albopictus mosquito and is accompanied with abrupt
onset of fever and debilitating acute and chronic joints pain in humans.1 In 1952
symptoms of the CHIKV infection were reported for the first time after an outbreak
in eastern Africa.2 Many intermittent outbreaks re-emerged in Africa and Asia in
the past sixty years.

3-5

There was no major re-emergence of chikungunya fever

until the epidemic outbreak in Kenya in 2004.

1

This epidemic CHIKV fever

resulted in considerable mortality and morbidity and unfortunately, the infection
spread to neighbouring areas. 6
The wider spreading of the virus throughout Europe and Americas was due to
number of adaptive mutations of the virus that allowed for exploitation a new vector
(Aedes albopictus).7 In 2013, CHIKV infection has been reported on the Caribbean
island of Saint Martin and spread to another 22 countries in Caribbean and America
in less than a year. In 2018, around 14,000 cases of CHIKV were reported in Sudan,
with 95% in Kassala state.9,

10

More than 55 countries have reported the CHIKV

infection so far and the virus was classified by US National Institute of Allergy and
Infectious Diseases (NIAID) as a category C priority pathogen; this category
includes reemerging pathogens that could be used for mass dissemination.1
So, far, there is no vaccine or an approved drug to treat, cure or prevent the CHIKV
infection. Current management of the CHIKV infection includes non-steroidal antiinflammatory drugs (NSAID) to alleviate the symptoms of CHIKV and
corticosteroids as anti-inflammatory in chronic CHIKV infection.11 Efforts have
been made to discover clinical anti-CHIKV agents by many research groups. This
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includes vaccine development, virtual screening, in vitro whole cell phenotypic
screening and genome-wide loss of function screens.6, 12-18 Recent advances in
CHIKV drug discovery have been recently reviewed.1, 19, 20

In 2010, crystal structure of the virus genome was fully elucidated offering an
important step for anti-CHIKV in-silico drug discovery.1 A computational study in
our research group has led to identification of potential CHIKV inhibitors,6, 12, 21
using in silico tools to elucidate possible interactions of small molecule inhibitors
with the viral protein. Molecular docking, virtual screening, molecular dynamic
(MD) simulation and binding free energy calculations were computational
strategies used to identify novel CHIKV inhibitors from the NCI Diversity Set II
database (1541 compounds). The study investigated nsP2 proteases and the nsP3
macrodomain, in addition to the envelope glycoprotein complexes responsible for
virus entry and attachment as targets for potential inhibitors.21
Table 4.1 presents the outcomes of the above study showing the compounds
and their binding activity. Analysis of the docking experiments showed the
different interactions between the ligands and the viral targets.21 Two promiscuous
compounds were reported interacting with all the tested viral components, namely,
the benzimidazole derivative, NCI_61610 and the quinoxaline derivative,
NCI_293778 (1.9).21 Among the investigated compounds, NCI_25457 1.30,
NCI_37553 1.27, and NCI_127133 1.28, showed good interaction with two of the
three target proteins and glycoproteins (Table 4.1).21
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Table 4.1: Results of the selected compounds of focused dockings on the nsP2, nsP3 and
the glycoprotein envelope.

Target

BA*
Kcal/mol

nsP2

-9.2

nsP2

-10.6

nsP3

-11.1

E glyp

-12.2

nsP2

-15.5

345647

nsP3

-10.9

37168

nsP3

-10.0

nsP2

-9.6

E glyp

-11.7

NCI #

217697

61610

67436

Chemical Structure

37553
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nsP3

(-9.8) –
(-10.4)
-9.4

E glyp

-13.2

nsP2

-8.8

nsP3

-8.3

E glyp

-11.1

nsP2

-9.0

nsP3

-10.8

nsP3

-10.6

nsP2

293778

127133

156219

25457

670283

*BA: Binding Affinity

4.2 Results and discussion
In this dissertation, the eleven compounds (Table 4.1) which were discovered by
docking-based virtual screening and molecular dynamic simulation were selected
for biological investigation for their anti CHIKV activity. The selected ligands
were requested from Developmental Therapeutics Program Databases and Search
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Tools, National Cancer Institute, USA and were tested in Rega Institute, KU
Leuven, Belgium for their anti-CHIKV activity.
Three compounds, out of the tested eleven compounds, showed antiviral activities,
the quinoline derivative 4.1 (EC50 = 6.8 µg/mL and EC90 = 12.0 µg/mL) and the
naphthalene derivatives 4.5 (EC50 = 0.8 µg/mL) and 4.11 (11.5 µg/mL) (Figure
4.1). We chose compound 4.5 for the next cycle of optimization because of
availability of the starting materials and ease of synthesis.

Figure 4.1: Structure of the active potential leads.

To further gain insights into the structure activity relationship of NCI_37168 (4.5),
possible modifications were postulated including changing the aniline substitution
and spacer between the amide group nitrogen and aryl side chain and also
investigate the effect of the presence of naphthalene hydroxyl group (Figure 4.2).
Firstly, the effect of the presence of hydroxyl moiety in the parent molecule 4.5
was investigated 4.14.
Then, aniline substitution with different groups was suggested to explore the
structure activity relationship (4.15-4.17), while adding a spacer (1 carbon)
between the amino group and the aryl side chain was supposed to increase the
flexibility that can possibly add more points of interaction with the receptor (4.19
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and 4.20).

Figure 4.2: Possible modification of NCI_37168 (4.5).

Compounds 4.18 and 4.19 were prepared by the standard amide bond formation
using CDI in THF (yields 45 and 50%, respectively).22 It is worthy to note that the
CDI coupling procedure failed to prepare 3-hydroxy-N-aryl-2-naphthamides
compounds 4.5 and 4.14-4.17 presumably due to formation of the ester side
product. The required compounds 4.14-4.17 were prepared using PCl3 promoted
coupling of 2-naphthoic acid 4.12 or 3-hydroxy-2-naphthoic acid 4.13,
corresponding anilines and catalytic amounts of PCl3 (40 mol%) in xylene and
heating at reflux gave yields 14-32% (Scheme 4.1).22
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Scheme 4.1: Reagents and conditions i) 40 mol% PCl3, xylene, 2 h, reflux ii) CDI, THF,
18 h, rt.

The synthesized compounds were investigated for their biological activity against
CHIKV and showed considerable toxic effect to the Vero cells, which impedes
detection of their antiviral activity (Table 4.2). Although some compounds showed
antiviral activity such as 4.5, 4.15 and 4.16, however toxicity of these compounds
might impede further development of the naphthalene scaffold 4.5. Antiviral
testing of these inhibitors at lower concentration could be done to investigate their
antiviral activity, while lowering their toxic effect. It is worthy to note that another
study could investigate the development of the quinoline scaffold 4.1 and exploring
the potential antiviral activity of this scaffold.

88

Chapter 4

Structure-guided drug design

Table 4.2: In vitro antiviral and cytotoxic activities of compounds 4.14-4.20.

Cpd
number
4.14

R1

R2

n

CHIKV
at Toxicity
[20] µg/mL
IC50 µg/mL
3
NT

H

3-NO2

0

4.15

OH

H

0

25

NT

4.5

OH

3-NO2

0

49

1.74

4.16

OH

4-NO2

0

27

<0.4

4.17

OH

4-F

0

13

NT

4.18

OH

H

1

0

NT

4.19

OH

4-F

1

0

NT

NT: not tested

4.3 Conclusions
A virtual screening search using NCI Diversity Set II database (1541 compounds)
was performed against three CHIKV targets, namely nsP2, nsP3 and the envelope
glycoprotein. Eleven hits were identified and tested for their anti-CHIKV activity
in a cell-based assay and three hits, with naphthalene and quinoline scaffolds,
showed promising anti-CHIKV. A facile and applicable synthesis of a small library
4.14-4.19 of the naphthamide hit 4.5 and their characterization were reported.
Antiviral testing of these inhibitors at lower concentration will be done to
investigate their antiviral activity, while lowering their toxic effect.
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4.4 Experimental section
4.4.1

Chemistry

General
Electronspray ionisation mass spectra (ESI-MS) were recorded on a Shimadzu
LCMS 2010 EV spectrometer and are reported as ion mass to charge ratio (m/z)
with their abundance as a percentage. Solvents used were analytical reagent grade.
Reactions were monitored by TLC analysis using silica gel GF/UV 254. NMR
spectra were recorded on Bruker Avance III HD 500 or 400 MHz NMR
spectrometers with spectra run at 400 and 500 MHz and 13C spectra at 100 and 125
MHz, in deuterated chloroform or dimethylsulfoxide (DMSO-d6). Chemical shifts
(δH) are reported relative to TMS as an internal standard and coupling constant (J)
values are reported in Hertz. Abbreviations used are: s, singlet; d, doublet; t, triplet;
m, multiplet. All reagents and solvents were purified and dried by standard
techniques.

General method A:
A solution of 2-naphthoic acid 4.12 (182 mg, 1.06 mmol) or 3-hydroxy-2-naphthoic
acid 4.13 (200 mg, 1.06 mmol) in xylene (6 mL) and the corresponding aniline
(1.17 mmol) was heated at reflux. PCl3 (40.0 µL, 0.424 mmol) was added slowly
and heat was maintained till HCl evolution had ceased (ca. 1 h). The reaction
mixture was cooled down and water was added to decompose excess PCl3. The
resulting precipitate was filtered, washed with petroleum spirit (2 x 10 mL) and
recrystallized from THF and water (3:1, 20 mL) with a few drops of methanol.
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General method B:
A solution of 3-hydroxy-2-naphthoic acid 4.13 (109 mg, 0.58 mmol), CDI (197 mg,
1.22 mmol), in THF (4 mL) was stirred at r.t. overnight. The reaction mixture was
cooled to 0 °C and the corresponding benzylamine (1.16 mmol) in THF (4 mL) was
added dropwise. The reaction was stirred at room temperature for 18 h,
concentrated in vacuo and subjected to flash chromatography (MeOH 5%/ DCM
95%) to give compounds 4.19 and 4.20.

N-(3-Nitrophenyl)-2-naphthamide (4.14)22
Using general procedure A, 4.12 and 3-nitroaniline (98.4 mg, 0.697 mmol),
compound 4.14 (140 mg, 45%) was isolated as a white solid; m.p: 162-164 °C. 1H
NMR (500 MHz, DMSO) δ: 7.71-7.64 (m, 3H, ArH), 8.13-7.98 (m, 5H, ArH), 8.27
(dd, 1H, J = 8.2, 1.2 Hz, ArH), 8.65 (s, 1H, ArH), 8.86 (s, 1H, ArH), 10.89 (s, 1H,
NH);

13

C NMR (126 MHz, DMSO) δ: 114.8, 118.6, 124.8, 126.7, 127.5, 128.2,

128.6, 128.7, 128.8, 129.5, 130.6, 132.0, 132.5, 135.0, 141.0, 148.4, 166.6; ESIMS m/z 315 (53%, [M+Na]+), 291 (100%, [M-H]-).

3-Hydroxy-N-phenyl-2-naphthamide (4.15) 23
Using general procedure A, 4.13 and aniline (106 µL, 1.17 mmol), compound 4.15
(91 mg, 32%) was isolated as a red crystals; m.p: 244-246 °C. 1H NMR (500 MHz,
DMSO) δ: 7.23-7.19 (m, 1H, ArH), 7.39 (s, 1H, ArH), 7.47-7.41 (m, 3H, ArH),
7.59-7.56 (m, 1H, ArH), 7.83-7.81 (m, 3H, ArH), 7.99 (d, 1H, J = 8.1 Hz, ArH),
8.56 (s, 1H, ArH), 10.65 (s, 1H, NH), 11.40 (s, 1H, OH);

13

C NMR (126 MHz,

DMSO) δ: 111.0, 121.0, 122.3, 124.3, 124.6, 126.3, 127.4, 128.6, 129.2, 129.3,
130.9, 136.2, 138.9, 154.2, 166.1; ESI-MS m/z 286 (100%, [M+Na]+), 262 (100%,
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[M-H]-).
3-Hydroxy-N-(3-nitrophenyl)-2-naphthamide (4.5) 23
Using general procedure A, 4.13 and 3-nitroaniline (162 mg, 1.17 mmol),
compound 4.16 (46 mg, 14%) was isolated as a yellow solid; m.p: 248-250 °C. 1H
NMR (500 MHz, DMSO) δ: 7.35 (s, 1H, ArH), 7.39-7.36 (m, 1H, ArH), 7.53 (app
t, 1H, J = 7.5 Hz, ArH), 7.69 (app t, 1H, J = 8.2 Hz, ArH), 7.78 (d, 1H, J = 8.3 Hz,
ArH), 7.95 (d, 1H, J = 8.2 Hz, ArH), 8.00 (dd, 1H, J = 8.2, 2.1 Hz, ArH), 8.12 (d,
1H, J = 8.8 Hz, ArH), 8.45 (s, 1H, ArH), 8.84 (s, 1H, ArH), 10.94 (s, 1H, NH),
11.09 (s, 1H, OH);

13

C NMR (126 MHz, DMSO) δ: 111.0, 114.8, 118.9, 123.0,

124.3, 126.3, 126.7, 127.3, 128.7, 129.2, 130.7, 131.0, 136.2, 140.3, 148.5, 153.8,
166.6; ESI-MS m/z 331 (100%, [M+Na]+), 307 (100%, [M-H]-).

3-Hydroxy-N-(4-nitrophenyl)-2-naphthamide (4.16) 23
Using general procedure A, 4.13 and 4-nitroaniline (162 mg, 1.17 mmol),
compound 4.17 (47 mg, 15%) was isolated as a green solid; m.p: 262-264 °C. 1H
NMR (500 MHz, DMSO) δ: 7.44-7.40 (m, 2H, ArH), 7.57 (app t, 1H, J = 7.5 Hz,
ArH), 7.83 (d, 1H, J = 8.3 Hz, ArH), 8.00 (d, 1H, J = 8.4 Hz, ArH), 8.10 (d, 2H, J
= 9.1 Hz, ArH), 8.35 (d, 2H, J = 9.1 Hz, ArH), 8.46 (s,1H, ArH), 11.21-11.08 (m,
2H, OH/NH); 13C NMR (126 MHz, DMSO) δ: 110.9, 120.3, 123.6, 124.3, 125.5,
126.3, 127.4, 128.7, 129.2, 131.2, 136.2, 143.1, 145.4, 153.4, 166.4; ESI-MS m/z
307 (100%, [M-H]-).

3-Hydroxy-N-(4-fluorophenyl)-2-naphthamide (4.17) 24
Using general procedure A, 4.13 and 4-fluoroaniline (110 µL, 1.17 mmol),
compound 4.18 (52 mg, 17%) was isolated as a pale green solid; m.p: 266-286 °C.
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H NMR (500 MHz, DMSO) δ: 7.24 (app t, 2H, J = 8.5 Hz, ArH), 7.38-7.34 (m,

2H, ArH), 7.52 (app t, 1H, J = 7.3 Hz, ArH), 7.80-7.77 (m, 3H, ArH), 7.93 (d, 1H,
J = 7.9 Hz, ArH), 8.50 (s, 1H, ArH), 10.64 (s, 1H, NH), 11.30 (s, 1H, OH);

13

C

NMR (126 MHz, DMSO) δ: 111.0, 115.9 (d, 2JCF = 22 Hz), 122.2, 122.9 (d, 3JCF =
7.9 Hz), 124.2, 126.8, 127.3, 128.6, 129.2, 130.8, 135.3, 136.3, 154.3, 159.0 (d,
1

JCF = 241 Hz), 166.2; ESI-MS m/z 304 (100%, [M+Na]+), 280 (100%, [M-H]-).

N-Benzyl-3-hydroxy-2-naphthamide (4.18) 23
Using general procedure B and benzyl aniline (124 mg, 1.16 mmol), compound
4.19 (72 mg, 45%) was isolated as white crystals; m.p: 168-170 °C. 1H NMR (500
MHz, DMSO): 4.59 (d, 2H, J = 5.8 Hz, CH2), 7.29-7.26 (m, 2H, ArH), 7.41-7.34
(m, 5H, ArH), 7.51 (ddd, 1H, J = 8.2, 6.8, 1.2 Hz, ArH), 7.75 (d, 1H, J = 8.2 Hz,
ArH), 7.86 (d, 1H, J = 8.1 Hz, ArH), 8.56 (s,1H, ArH), 9.53 (1H, J = 5.7 Hz, NH),
11.98 (s, 1H, OH);

13

C NMR (126 MHz, DMSO) δ: 43.1, 111.2, 119.1, 124.2,

126.3, 127.1, 127.4, 127.9, 128.7, 128.9, 129.2, 130.1, 136.5, 139.4, 155.8, 168.4;
ESI-MS m/z 300 (100%, [M+Na]+), 276 (100%, [M-H]-).

N-4-Fluorobenzyl-3-hydroxy-2-naphthamide (4.19) 23
Using general procedure B and benzyl aniline (145 mg, 1.16 mmol) compound 4.20
(86 mg, 50%) was isolated as white powder; m.p: 188-190 °C. 1H NMR (500 MHz,
DMSO): 4.68 (d, 2H, J = 5.2 Hz, CH2), 6.81 (s, 1H, ArH), 7.08 (t, J = 8.0 Hz, 2H,
ArH), 7.29-7.50 (m, 5H, ArH), 7.67-7.72 (m, 2H, ArH), 7.94 (1H, J = 5.7 Hz, NH),
11.65 (s, 1H, OH); 13C NMR (126 MHz, CDCl3) δ: 43.3, 110.0, 112.5, 115.8 (d,
2

JCF = 22 Hz), 116.8, 124.0, 126.3, 126.7, 128.5, 128.6, 129.7 (d, 3JCF = 8 Hz),

133.2, 137.2, 156.7, 161.8 (d, 1JCF = 241 Hz), 169.7; ESI-MS m/z 318 (100%,
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[M+Na]+), 294 (100%, [M-H]-). HRMS (ESI-) calcd for C18H13FNO2: 294.0927
(M-H)-, found: 294.0930.

4.4.2 Anti-viral assay
CHIKV Indian Ocean strain 899 (Genbank FJ959103.1) was generously provided
by Prof. S. Günther (Bernhard Nocht Institute for Tropical Medicine, Hamburg,
Germany) (Panning M et al., Emerging Infectious Diseases 2008). BGM cells were
maintained in cell growth medium composed of minimum essential medium (MEM
Rega-3, Gibco, Belgium) supplemented with 10% Foetal Bovine Serum (FBS,
Integro, The Netherlands), 1% L-glutamine (Gibco), and 1% sodium bicarbonate
(Gibco). The antiviral assays were performed in virus growth medium which is the
respective cell growth medium supplemented with 2% (instead of 10%) FBS. Cell
cultures were maintained at 37 °C in an atmosphere of 5% CO2 and 95-99%
humidity. BGM cells were seeded in 96-well tissue culture plates (Becton
Dickinson, Aalst, Belgium) at a density of 2.5 x 104 cells/well in 100 μL assay
medium and were allowed to adhere overnight. Next, a compound dilution series
was prepared in the medium on top of the cells after which the cultures were
infected with 0.001 MOI of CHIKV 899 inoculum in 100 μL assay medium. On
day 5 post-infection (p.i.), the plates were processed using the MTS/PMS method
as described by the manufacturer (Promega, The Netherlands). The 50% effective
concentration (EC50), which is defined as the compound concentration that is
required to inhibit virus-induced cell death by 50%, was determined using
logarithmic interpolation. All assay wells were checked microscopically for minor
signs of virus induced CPE or possible alterations to the cell or monolayer
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morphology caused by the compound.
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FOREWORD TO CHAPTER 5
This chapter is a full research manuscript is accepted to Angewandte Chemie, 2020
(doi: 10.1002/anie.202006392 and 10.1002/ange.202006392, impact factor
12.257). This manuscript describes the development stimuli-responsive
cycloaurated ‘OFF-ON’ switchable fluorescent anion transporters. Herein, we
report the synthesis and characterization of five anion transporters based on 1,3bis(benzimidazol-2-yl)pyrimidine scaffold. We also developed four putative anion
transporters that are switched-on in the presence of GSH, which is found in a higher
concentration in cancer cells. It also describes full transport and binding properties
of the free receptors and extensive reduction kinetic studies of the switchable
cycloaurated complexes under different conditions, including in DMSO, external
addition in liposomes and in GSH-encapsulated liposomes.
Supporting information for this chapter can be found in Appendix D (p. 264).

Contributions
Mohamed Fares

Performed the synthesis, the anion transport studies
and analysis, binding studies and reduction kinetics.
Input into experimental design, analysed the data
and prepared/edited the paper.

Xin Wu

Compound design.

Ethan Howe

Design of transport and reduction kinetics studies
experiments

97

William Lewis

Performed and solved the X-ray structures

Paul A. Keller

Editing and proof-reading.

Philip A. Gale

Oversight of the project, editing and proof-reading.

Switchable anion transporters Chapter 5

5.1

Introduction

Biomimetic stimuli-responsive systems activated under particular physical,
chemical or biological conditions have recently gained increasing attention and
represent a promising therapeutic approach due to their selective and controllable
action.1-4 These smart systems can be switched on under specific conditions,
including in the presence of certain proteins, redox states or chemical signals (such
as changes in pH).5 In the field of anion recognition, pH-responsive, redoxswitchable and photophysical controllable anion receptors have been developed.510

These switchable anion receptors have been recognised for diverse applications

including ion sensing, catalysis and can be used as potential drug candidates in
medicinal chemistry.11-13
Transmembrane ion transport is a fundamental biological process and is involved
in diverse physiological functions including, neuroexcitation, muscle contraction,
cell migration and proliferation, and maintaining cellular pH, membrane potential
and cellular secretions.14 Channelopathies are a group of diseases characterised by
impaired ion channel function, including cystic fibrosis, epilepsy and cancer.15-17
Anionophores are small molecules that are capable of transporting anions and they
demonstrated cytotoxic effects against stem cancer cells by facilitating the transport
of chloride and bicarbonate anions so changing the cellular pH, causing cellular
differentiation and death.13, 18-20
A recent mechanistic study of cancer death showed that the induction of apoptosis
and inhibition of autophagy by particular anion transporters are due to the cellular
osmotic stress which is caused by increasing cellular ion concentration.21 This
promotes the generation of reactive oxygen species (ROS) and activates a caspase98
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dependent apoptosis. Two of the tested transporters induced cellular osmotic stress,
by increasing the intracellular Ca+2 concentration and lysosomal pH (as a result of
a decrease in the lysosomal chloride ion concentration), leading eventually to
autophagy disruption.21
Glutathione (GSH), is a tripeptide and forms with glutathione disulfide (GSSG) a
redox complex that keeps the cellular oxidative properties under normal
physiological conditions.22 Many diseases such as diabetes, neurodegenerative
disorders and cancer are implicated with high levels of GSH. Redox state
environment in cancer cells is greatly dictated by the NADPH (NADPH, NADP+)
and GSH (GSH, GSSG) redox systems.23, 24 In normal cells, GSH intracellular
concentration was reported to be 10 mM, while the extracellular concentration was
ranged from 2 to 20 µM.25 However, previous reports stated that there was a fourfold increase in GSH concentration in cancer cells, compared to normal cells and
even higher in multi-resistant tumour cells.26,

27

These findings inspired the

development of stimuli-responsive systems targeting high GSH levels and these
systems have been widely used in contemporary drug delivery approaches.

28-32

Recently, Akhtar et al. developed water soluble GSH-responsive anion transporters
with potential activity to treat cystic fibrosis.33 However, GSH content in cystic
fibrosis cells is lower than normal cells presumably due to the abnormal
extracellular GSH transport ability of CFTR proteins, limiting the application of
these molecules as potential treatment.33, 34
Inspired by the high affinity of thiols, such as GSH, for gold and prompted by the
reported efficient anion transport activity of 1,3-bis(benzimidazol-2-yl)benzenes,
we designed and synthesized new switchable cycloaurated anion transporters based
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on the structurally related 1,3-bis(benzimidazol-2-yl)pyrimidine (BisBzImPy)
(Figure 5.1).

Figure 5.1: Schematic representation showing the design of switchable anion transporters.

Blocking groups, such as chloride or N-heterocyclic carbene (NHC) were used to
afford the switchable complexes (Figure 5.2).32,

35-37

These complexes were

designed to be reduced by GHS as a stimulus to liberate the fluorescent anion
transporters that can bind to chloride and facilitate transmembrane transport (Figure
5.2).

Figure 5.2: Reported GSH mediated activation and putative transporters 5.1-5.538

5.2
5.2.1

Results and discussion
Chemistry

Unsubstituted BisBzImPy 5.1 was synthesized by condensation of o100

Chapter 5

Switchable anion transporters

phenylenediamine with dipicolinic acid in phosphoric acid at 200 °C for 6 h
(Scheme 5.1).39, 40 Dinitro BisBzImPy derivative 5.5 was prepared by nitration of
5.1 and showed low solubility in most solvents.40

Scheme 5.1: Reagents and conditions: i) H3PO4, 200 °C, 6 h; ii) H2SO4/HNO3 3 h.

Attempts to synthesize ditrifluoromethyl BisBzImPy derivative 5.2 using the same
procedure failed may be due to the deactivating effect of the trifluoromethyl,
bistrifluoromethyl and difluoro groups that would make the amino groups in the
arylidene diamines less nucleophilic.

Scheme 5.2: Reagents and conditions: i) NaS2O5, EtOH, RT; ii) DMF, 120 °C, 4 h.
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BisBzImPy derivatives 5.2-5.4 were obtained in 42-54% yields by adopting an
alternative

procedure

using

sodium

metabisulfite

and

2,6-

pyridinedicarboxaldehyde (Scheme 5.2).41 The structure of 5.2 was confirmed by
X-ray diffraction analysis (Figure 5.3) which showed that transporter 5.2 formed a
1:1 complex with DMSO via two hydrogen bonds with nitrogen atoms of
benzimidazole (NH- - -O distances of 1.991 Å and 2.018 Å and NH- - -O bond
angles of 169.21° and 170.77°.

Figure 5.3: X-ray structure of anion transporter 5.2. DMSO complex.

Gold chloride derivatives 5.13 and 5.14 were readily prepared by heating at reflux
BisBzImPy derivatives 5.2 and 5.3, respectively, with KAuCl4 and anhydrous
sodium acetate in methanol for 3 h (Scheme 5.3).38 The structure of 5.14 was
determined by single X-ray crystallography (Figure 5.4) and showed a heptacyclic
flat planar gold chloride complex. The bond lengths between Au(III) and nitrogen
atoms of benzimidazole and pyridine rings were 1.98-1.99 Å. The angle between
the nitrogen atom of pyridine, Au(III) and nitrogen atoms of benzimidazole
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(N^Au^N) were 79.24° and 80.23°, while the angle between chloride, AuIII, and
nitrogen atoms of benzimidazole were (Cl^Au^N) 100.02° and 100.45°.

Scheme 5.3: Reagents and conditions: i) KAuCl4, MeOH, NaOAc, reflux; ii) AgOTf,
CH3CN, reflux, 12 h in dark.

Figure 5.4: X-ray structure of complex 5.14.

Reaction of 5.13 and 5.14 with NHC 5.15, silver triflate in acetonitrile in the
absence of light gave complexes 5.16 and 5.17 in 13% and 12% yields, respectively
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(Scheme 5.3).38
The X-ray crystal structure of the Au(III) complex 5.16 and 5.17 (Figures 5.5 and
5.6) revealed that the NHC plane is almost perpendicular to the BizBzImPy plane
with a torsion angle of 73.79° and 81.23° and for complexes 5.16 and 5.17,
respectively (Figures 5.5 and 5.6). The bond length between Au(III) and nitrogen
atoms of benzimidazole and pyridine rings were 2.007-2.015 Å for complex 5.16
and 1.988-2.009 Å for complex 5.17, slightly longer than in complex 5.14.

Figure 5.5: X-ray structure of anion complex 5.16.
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Figure 5.6: X-ray structure of anion transporter 5.17.

5.2.2 Binding in solution
To gain a better understanding of the anionophoric properties of the compounds,
NMR chloride binding studies were performed in DMSO-d6/0.5%H2O and CD3CN
with TBACl. Data were fitted globally to the 1:1 or 2:1 (host: guest) for transporters
5.1-5.4, while transporter 5.5 was omitted from this study due to it is low solubility
(Table 5.1, Figures 5.7, Figures D1-D8).
In DMSO, anionophores 5.1-5.4 were fitted to the 1:1 binding model giving Ka
ranging from 63 to 132 M-1. Transporters 5.1, 5.3 and 5.4 were fitted also to 2:1
model giving greater K21 values than K11. These findings show that transporters 5.1,
5.3 and 5.4 might adopt different binding modes in DMSO. NMR anion binding
titration studies in CD3CN showed that anion transporters 5.1 and 5.2 adopt the 1:1
binding mode and interestingly transporters 5.3 and 5.4 prefer the 2:1 sandwich
mode (Table 5.1) (Figures 5.7).
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Table 5.1: Binding properties of compounds 5.1–5.4.

DMSO

5.1

5.2

5.3

5.4

1:1 (Ka)

92

77

132

63

covfit [a]

1.1 x 10-2

2.3 x 10-4

2.0 x 10-3

3.0 x 10-4

2:1 (Ka)

K₁₁: 40;

-

K₁₁: 40;

K₁₁: 75;

K₂₁: 2.6 x 10

K₂₁: 89

K₂₁: 2.5 x 102

CD3CN

β21[b]

1.0 x 105

-

1.0 x 104

6.7 x 103

covfit

4.0 x 10-3

-

1.5 x 10-3

2.0 x 10-4

1:1 (Ka)

4.6 x 103

1.2 x 104

-

-

-

-

K₁₁ and K₂₁:

K₁₁: 0.69;

2.0 x 103

K₂₁: 8.2 x

covfit

[a]

2:1 (Ka)

-4

9.4 x 10

2.5 x 10

-

-

-4

106
β21[b]

-

-

4.4 X 106

5.5 X 106

covfit

-

-

2.9 x 10-4

5.2 x 10-3

[a] The covariance of the fit (covfit) is calculated by dividing the covariance of the residual (experimental
data − calculated data) with the covariance of the experimental data. [b] The association constant (β21)
for the 2:1 host:guest complex calculated by multiplying K11 and K21. nd: not determined.

Figure 5.7: Stack plot of 1H NMR spectroscopic titration of receptor 5.2 (1 mM) with
TBACl in CD3CN at 298 K.
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5.2.3 Binding in solid state
A single crystal of anionophore 5.2 with chloride ion was obtained for X-ray
crystallographic diffraction by vapor diffusion of Et2O into a CH3CN solution of
transporter 5.2 and two equivalents of TEACl (Figure 5.8). Interestingly, Cl- is
sandwiched between two molecules of compound 5.2, where it forms two hydrogen
bonds with imidazole NHs, with NH… Cl- distances of 2.41 and 2.63 Å, and one
hydrogen bond with a water molecule with an OH…Cl- distance of 2.29 Å (Figure
5.8).

Figure 5.8: Crystal structure of 5.2 with chloride complex.

This water molecule connects the chloride anion and the second transporter
molecule by acting as a hydrogen bond donor and an acceptor. It forms five
hydrogen bonds including two with imidazole NHs of the bottom compound 5.2,
one with imidazole NH of the top compound 5.2, one with the pyridine N and the
one mentioned earlier with chloride, with distances ranging from 2.29 to 3.54 Å.
The sandwich complex is further stabilized by another water molecule, which forms
hydrogen bonds with both molecules of 5.2 (Figure 5.8).
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5.2.4

Transport studies

Transporters 5.1-5.5 were investigated for their chloride transport property via
Cl/NO3 exchange assay using a chloride ion selective electrode (ISE) (Figure 5.9,
Table 5.2). Briefly, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
unilamellar liposomes were prepared with diameter 200 nm and loaded with 489
mM KCl, buffered to pH = 7.2 and suspended in 489 mM KNO3 solution which is
buffered to pH = 7.2. The chloride efflux which is considered as indication of Cl/NO3- exchange process, was monitored using chloride ion selective electrode upon
addition of DMSO solution of transporters 5.1-5.5 to the prepared liposomes.42 At
the same concentration, compounds 5.1-5.5 showed better transport properties
when transporter loading volume increased from 10 μL to 40 μL, presumably due
to better deliverability in a higher volume of DMSO. Chloride efflux at different
concentrations of tested compounds (expressed as mol% with respect to lipid
concentration (rtl)) was measured to obtain Hill plots and to calculate EC50 (defined
as the concentration required to achieve 50% the chloride efflux at 270 s) and Hill
coefficient (n). Hill coefficient indicates the stoichiometry of the formed complex
during the anion transport across the lipid bilayer, while EC50 is used as a measure
of anion transporter potency.
Compounds 5.1 and 5.5 were excluded from Hill plot analysis due to low potency
of compound 5.1 and solubility limitation of transporter 5.5. Among tested
anionophores 5.2-5.4, transporter 5.2 was the most active with EC50 = 0.42 mol%,
followed by transporters 5.3 and 5.4 (EC50 = 0.49 and 0.58 mol% (rtl), respectively)
(Figure 5.9a and 5.9d, Table 5.2). Cationophore coupling assay, using valinomycin
(Vln) or monensin (Mon) was used to investigate the mechanism of anion transport
of the novel transporters.
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Table 5.2: Transport properties of compounds 5.1–5.5.

cLog P [a]
KCl (EC50, mol%)

[b]

1

2

4.0

4.4

3

4

5.0
-1

4.0
-2

6.1 x 10-2

1.0 x 10

n[c]

2.2

1.3

0.7

1.2

0.9

KGlu (EC50, mol%) [d]

2.3

2.3 x 10-2

3.5 x 10-3

4.4 x 10-2

3.8 x 10-2

n[c]

1.4

1.2

1.2

1.0

1.0

nd

0.42

0.49

0.58

nd

nd

1.4

0.9

1.4

nd

Cl/NO3 (EC50, mol%)
n[c]

2.3 x 10

3.8
-1

4.8

[e]

9.4 x 10

5

[a] clog P values calculated using VCCLab. [b] EC50 from the KCl assay measuring H+/Cl− symport. [c]
Hill coefficient as an indicator of the stoichiometry the complex mediating transport. [d] EC50 from the
KGlu assay measuring Cl− uniport. [e] EC50 from the Cl/NO3 exchange assay. Nd: not determined.

Figure 5.9: a-c) Schematic representation of ISE-based assays used to investigate the
mechanism of anion transport of receptors 5.1-5.5. a) Cl-/NO3- antiport, b) and c)
cationophore coupled-KCl, valinomycin and monensin to measure the Cl- uniport and
M+/Cl+ transport, respectively. d) Chloride efflux achieved by transporters 5.1-5.5 (1.0
mol%, rtl) for transporters 5.1-5.4 and 0.8 mol% (rtl) for transporter 5.5 from unilamellar
POPC vesicles containing 489 mM KCl buffered to pH 7.2 with 5 mM potassium
phosphate salts, suspended in 489 mM KNO3 buffered to pH 7.2 with 5 mM phosphate
salts. e) Chloride efflux achieved by transporter 5.2 at 1.0 mol% (rtl) in the absence or
presence of cationophores (monensin or valinomycin) monitored over a period of 5 min.
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Such assays are used to determine the activities of Cl- uniport (coupling with
valinomycin) and H+/Cl- symport (coupling with monension) (Figure 5.9b-c and
5.9e).42 Compounds 5.1-5.5 were capable of both Cl- uniport and H+/Cl- symport
(Figure 5.9e).
BisBzImPy derivatives 5.1-5.5 were investigated for their potential anion transport
properties using 8-hydroxypyrene-1,3,6-trisulfonic acid (HPTS) assay (Table 5.2
and Figure 5.10).42 The HPTS-KCl assays measures the activity of anion
transporters in facilitating H+/Cl- cotransport leading to the dissipation of pH
gradients. The unsubstituted BisBzImPy 5.1 emerged as the lowest activity
transporter in HPTS-KCl (HCl symport, Figure 5.10a) assay with an EC50 = 4.8
mol%

(Table

5.2).

Grafting

electron

withdrawing

groups

such

as

bistrifluoromethyl, tetratrifluoromethyl, tetrafluoro or dinitro in the phenyl of
benzimidazole rings (5.2-5.5) increased the ability to facilitate H+/Cl- symport, with
EC50 values of these compounds ranging from (2.3 x 10-1) - (6.1 x 10-2) mol%, rtl,
(Figure 5.10e, Table 5.2). The activity decreased in the order of 5.5> 5.3> 5.2> 5.4.
To further investigate the intrinsic ability of transporters 5.1-5.5 to transport only
chloride ion, the same assay was employed at 1 mol% transporter (mol% relative
to lipid concentration, rtl) and using the protonophore carbonyl cyanide mchlorophenyl hydrazone (CCCP) as an efficient proton transporter (Figure 5.10b).
If H+ transport is the rate determining step of HCl symport, CCCP will improve
transport and accelerate the pH dissipation (Figure 5.10f, Figures D14-D18,
appendix D).42Anionophores 5.1-5.5 transport properties demonstrated no CCCP
dependence indicating effective H+ transport by these compounds.
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Figure 5.10: a-d) Schematic representation of the HPTS-based assays used in the current
study (a) H+/Cl- symport or OH-/Cl- antiport b) the presence of cccp (protonophore) to
asses Cl- uniport c) the presence of valinomycin to measure the proton flux d) the effect
of fatty acid presence as a fuel on the transport. (e) H+/Cl- symport or OH-/Cl- antiport
facilitated by compounds 5.1-5.5 (1.0 mol% (rtl)) from unilamellar POPC vesicles loaded
with 100 mM KCl buffered to pH 7.0 with 10 mM HEPES buffer and 1 mM HPTS internal
sensor. f) Using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM), buffered
to pH 7.0 with HEPES (10 mM), different conditions were applied to determine the effect
of addition of the protonphore cccp at 0.5 mol% (as a measure of Cl- uniport), oleic acid at
1 mol% (as a source of fatty acid) and BSA-treated lipid (to test if the transport is fatty acid
dependent) on the rate of chloride transport of receptor 5.2 (1 mol%).

We next examined the abilities of transporters 5.1-5.5 to transport only H+ using
the H+ transport assay by replacing potassium chloride with potassium gluconate
(KGlu) (Figure 5.10c) and using valinomycin to facilitate K+ transport and dissipate
the membrane potential generated by H+ transport.42 Gluconate is a relatively large
hydrophilic anion that can be considered lipid bilayer impermeable42. Apart from
the unsubstituted BisBzImPy 5.1 (EC50 = 2.3 mol%), tested compounds 5.2-5.5
showed a remarkable protonophoric affinity with EC50 spanning from (4.4 x 10-2)
– (3.5 x 10-3) mol%, rtl, (Table 5.2). These values are lower than the EC50 for H+/Clsymport, indicating faster H+ transport than Cl- transport.
The activity of transporters 5.2-5.5 as protonophores decreased in the order of 5.3>
5.2> 5.5> 5.4 (Table 5.2). To further investigate the potential interaction between
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fatty acids and the tested anion transporters 5.1-5.5, oleic acid (1 mol%) or BSA
treated liposomes (to remove fatty acids) were used (Figure 5.10f). It was reported
that some transporters could transport H+ indirectly by facilitating the
transmembrane flip-flop of deprotonated fatty acids.42, 43 The transport activity in
KCl and KGlu assays were not affected by addition or removal of fatty acids, which
indicate that H+ transport by 5.1-5.5 is fatty acid-independent and presumably
occurs via deprotonation of the NH groups. A liposomal leakage experiment
performed using self-quenching calcein confirm the absence of non-specific
membrane leakage.43

5.2.5 Anion and cation selectivity
A selectivity assay has demonstrated preferential transport of more lipophilic
anions including Br-, I-, NO3-, and ClO4- over Cl- for all anionphores 5.1-5.5
(Figures D29-D33, appendix D). Identical transport rates were found when the K+
in the HPTS assay was replaced with Na+ (Figures D34 and D35, appendix D)
consistent with the lack of metal ion transport.
0.6

Fluorescence ratio
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0.2

0.0
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Cl-
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BrI-

-0.4
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NO3-
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ClO4-
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0
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Figure 5.11: Observed fluorescence ratio response due to HCl influx in the presence of
compounds 5.2 (1 mol%) into vesicles loaded with KCl (100 mM) and suspended in KCl,
KBr, KI, KNO3 and KClO4 (100 mM). All external and internal solutions were buffered to
pH 7 with HEPES (10 mM).
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Reduction kinetic studies

We exploited the fluorescence and anion transport properties of transporters 5.2
and 5.3 and examined the corresponding gold complexes 5.13, 5.14, 5.16 and 5.17
(complexes 5.13 and 5.16 for transporter 5.2, while complexes 5.14 and 5.17 for
transporter 5.3) against the effect of the physiological reducing agent GSH 5.18 and
the non-physiological reducing agents DTT 5.19 and TCEP 5.20 (Figure 5.12).

Figure 5.12: Chemical structure of tested compounds and the three reducing agents used
in the current study.

Time-dependent reduction kinetics of these complexes were examined under
different conditions, including external addition of the reducing agent in organic
solvent (DMSO) and in liposomes (Figure 5.13-5.16). Also, encapsulation of GSH
in liposomes was performed to mimic the cellular physiological conditions (Figure
5.17). UV-Vis and fluorescence spectroscopies were used to detect the change in
the absorbance or fluorescence intensity upon reduction of complexes with GSH
5.18, DTT 5.19 and TCEP 5.20. GSH was tested at molar ratio 6:1, while TCEP
and DTT were used at molar ratio 3:1, with respect to tested compound.
In DMSO, complexes 5.13, 5.14, 5.16 and 5.17 showed higher affinity to thiols
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(GSH 5.18 and DTT 5.19) over TCEP. As indicated from fluorescence and UV-Vis
spectra, the reaction between complexes 5.13, 5.14, 5.16 and 5.17 and the reducing
agent is fast, and it took only few seconds to 20 minutes to reach a plateau in both
absorbance and fluorescence studies (Figures 5.13 and 5.14).
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Figure 5.13: Reduction by thiols; namely GSH (reduced glutathione) and DTT
(dithiothreitol), and TCEP (tris(2-carboxyethyl)phosphine hydrochloride) of complexes
5.13 and 5.16 in organic solvent (DMSO) monitored by a) fluorescence and b) UV-Vis
spectroscopies. Fluorescence readings are averages of three replicates and UV-Vis
readings are averages of two replicates, always with standard deviations less than 10%.
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Figure 5.14: Reduction by thiols; namely GSH (reduced glutathione) and DTT
(dithiothreitol), and TCEP (tris(2-carboxyethyl)phosphine hydrochloride) of complexes
5.14 and 5.17 in organic solvent (DMSO) monitored by a) fluorescence and b) UV-Vis
spectroscopies. Fluorescence readings are averages of three replicates and UV-Vis
readings are averages of two replicates, always with standard deviations less than 10%.

Moving to the liposome model, with external addition of the reducing agent,
affinities of the gold-NHC complexes 5.16 and 5.17 to the tested reducing agents
were much higher than their corresponding gold chloride complexes 5.13 and 5.14,
respectively (Figures 5.15 and 5.16). DTT emerged as the most powerful reducing
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agent in liposomes. NHC-gold complexes 5.16 and 5.17 responded rapidly to DTT
with prompt increase in the UV-Vis absorption spectra and reach a plateau after 12 minutes. Complex 5.14 showed a stronger response to DTT than complex 5.13
with a gradual increase in absorbance and reached a plateau in 30 minutes, while
the reduction of complex 5.13 took 3 h to reach a plateau.
Monitoring the reduction kinetics of compounds 5.13 and 5.16 by fluorescence
spectroscopy showed similar pattern as seen in the UV-Vis studies. Surprisingly,
complexes 5.14 and 5.17 reduction kinetics could not be chased by fluorescence
spectroscopy as the fluorescence intensity of the parent anion transporter 5.3 was
diminished in the liposome model. GSH and TCEP showed a comparable reduction
activity towards Au(III) chloride complexes 5.13 and 5.14 and it took less than 3 h
for a complete reduction and a stable fluorescence or absorbance reading (Figures
5.15 and 5.16).
GSH achieved fast reduction of NHC gold complexes 5.16 and 5.17 and reach a
plateau in 5 minutes as illustrated by UV-Vis spectroscopy. However, compound
5.16 showed a gradual increase in fluorescence in response to GSH and took 60
minutes to reach the highest fluorescence intensity. This may be attributed to
encapsulation of the formed free transporter in the membrane bilayer. TCEP
demonstrated the lowest reduction affinity to complexes 5.16 and 5.17 and it took
more than 3 h for complex 5.16 and 1 h for complex 5.17 to reach a plateau (Figures
5.15 and 5.16).
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Figure 5.15: Reduction by thiols; namely GSH (reduced glutathione) and DTT
(dithiothreitol), and TCEP (tris(2-carboxyethyl)phosphine hydrochloride) of complexes
5.13 and 5.16 in liposomes monitored by a) fluorescence and b) UV-Vis spectroscopies.
Fluorescence readings are averages of three replicates and UV-Vis readings are averages
of two replicates, always with standard deviations less than 10%.
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Figure 5.16: Reduction by thiols; namely GSH (reduced glutathione) and DTT
(dithiothreitol), and TCEP (tris(2-carboxyethyl)phosphine hydrochloride) of complexes
5.14 and 5.17 in liposomes monitored by UV-Vis spectroscopy. UV-Vis readings are
averages of two replicates, always with standard deviations less than 10%.

In order to mimic the physiological conditions, the reduction kinetics of complexes
5.13, 5.14, 5.16 and 5.17 in GSH-encapsulated liposomes were investigated
(Figures 5.17 and 5.18). In a similar pattern to the liposome model, complexes 5.16
and 5.17 showed a fast reaction with GSH and reach a plateau in 10 minutes as
illustrated from UV-Vis spectra, while complexes 5.13 and showed weaker
responses than complexes 5.16 and 5.17.
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Figure 5.17: Reduction of 5.13 and 5.16 in GSH encapsulated liposomes. Fluorescence readings
are averages of three replicates, always with standard deviations less than 10%.
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Figure 5.18: Reduction of complexes 5.13, 5.14, 5.16 and 5.17 in GSH encapsulated
liposomes. UV-Vis readings are averages of two replicates, always with standard
deviations less than 10%.

Generally, fluorescence and absorbance intensities of complexes 5.13, 5.14, 5.16
and 5.17 changed over time upon addition of the reducing agents under all
conditions, but with different rates.
5.2.7 Switchable time-dependant transport studies
Time-dependent transport studies of complexes 5.13, 5.14, 5.16 and 5.17 were
performed in HPTS-KCl liposome (HCl symport, Figure 5.19) against the threereducing agents at 1 mol% (rtl) of receptors 5.2-5.3 and complexes 5.13, 5.14, 5.16
and 5.17. Complexes 5.13 and 5.16 (without addition of the reducing agent) showed
low anion transport activities at 1 mol% (Figures 5.20 and 5.21, Figures D50-D57
appendix D).
Interestingly, complexes 5.14 and 5.17 showed 35% and 36% efflux respectively
at 1 mol% (rtl) (Figures 5.20 and 5.21), indicating that Au (III)-mediated chloride
transport across phospholipid membranes.44
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As evidenced by kinetic studies, DTT is the most potent reducing agent among all
tested complexes 5.13, 5.14, 5.16 and 5.17, followed by GSH and TCEP showed
the slowest reduction rate.

Figure 5.19: KCl-KOH liposomal model used to assess the switchable-time dependent
studies. POPC vesicles were loaded with KCl (100 mM), buffered to pH 7.0 with HEPES
(10 mM). The test compound was added at 0 s and detergent was added at 200 s.

Complex 5.13 showed the same chloride efflux as the parent anion transporter 5.2
after mixing with the reducing agents for 3 h (Figure 5.20a). Incubation of complex
5.14 with GSH and TCEP for 30 minutes demonstrated a similar chloride efflux
rate to that of the parent anion transporter 5.3, however, incubation with DTT for
30 minutes led to a faster chloride efflux than the parent compound 5.3 (Figure 20b,
Figures D52 and D53, appendix D). This is presumably due to anion transport
activity of complex 5.14 itself. Also, reacting complex 5.14 with all reducing agents
for 3 hours gave a higher chloride efflux than anion transporter 5.3 at 1 mol%.
Incubation of complex 5.16 with DTT or GSH for 5 minutes showed 100% and
~90% chloride efflux, respectively, in comparison with the parent transporter 5.2,
while incubation for 20 minutes reach 100% for both reductants (Figure 5.21a).
Incubation of DTT, GSH or TCEP with complex 5.17 showed higher chloride
efflux (with GSH and DTT) and similar chloride efflux (with TCEP) in comparison
to the parent transporter 5.3 (Figure 5.21b).

120

Chapter 5

Switchable anion transporters

a)

Fluorescence ratio

1.0

0.8

0.6

[5.2] and [5.13] = 1 mol%
DMSO
GSH
5.2
5.2 + GSH
5.13
5.13 + GSH 30 m
5.13 + GSH 3 h

0.4

0.2

0.0
0

50

100

150

200

250

300

Time / s
b)

Fluorescence ratio

1.0

0.8

0.6

[5.3] and [5.14] = 1 mol%
DMSO
GSH
5.3
5.3 + GSH
5.14
5.14 + GSH 30 m
5.14 + GSH 3 h

0.4

0.2

0.0
0

50

100

150

200

250

300

Time / s
Figure 5.20. Observed fluorescence ratio response due to H+/Cl- symport or Cl-/OHantiport upon reduction of complexes a) 5.13 and b) 5.14 (1 μM) by GSH (6 μΜ) using
KCl-KOH assay from POPC vesicles loaded with KCl (100 mM), buffered to pH 7.0 with
HEPES (10 mM) at different time intervals. The test complexes 5.13 and 5.14 (1 mol%)
and KOH were added firstly, then GSH was added at 0 s. DMSO, GSH (3 mol%), parent
anion transporters 5.2 and 5.3 and complex 5.13 and 5.14 (without addition of DTT) were
used as controls. Detergent was added at 200 s. Ionophore concentrations are shown as
ionophore to lipid molar ratios. Error bars represent SD from at least three repeats.
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Figure 5.21. Observed fluorescence ratio response due to H+/Cl- symport or Cl-/OHantiport upon reduction of complexes a) 5.16 and b) 5.17 (1 μM) by GSH (6 μΜ) using
KCl-KOH assay from POPC vesicles loaded with KCl (100 mM), buffered to pH 7.0 with
HEPES (10 mM) at different time intervals. The test complexes 5.16 and 5.17 (1 mol%)
and KOH were added firstly, then GSH was added at 0 s. DMSO, GSH (3 mol%), parent
anion transporters 5.2 and 5.3 and complex 5.16 and 5.17 (without addition of DTT) were
used as controls. Detergent was added at 200 s. Ionophore concentrations are shown as
ionophore to lipid molar ratios. Error bars represent SD from at least three repeats.
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5.3 Conclusions
We present herein stimuli-responsive gold complexes as efficient switchable anion
transporters that can be reduced to release active anion transporters by a set of
reducing agents, including the physiologically predominant GSH. Five BisBzImPy
anion transporters 5.1-5.5 have been synthesized and they have been shown to bind
Cl- with moderate affinity in DMSO-d6/0.5%H2O and CD3CN and facilitate the
transport of H+, Cl- and NO3- in liposomal models. Switchable cycloaurated
complexes 5.13, 5.14, 5.16 and 5.17 were constructed from the two most potent
anion transporters 5.2 and 5.3. The switch-off complexes 5.13, 5.14, 5.16 and 5.17
demonstrated higher affinity to DTT, followed by GSH, while TCEP emerged as
the weakest reducing agent. Finally transport studies showed that these switchable
anion transporters 5.13, 5.14, 5.16 and 5.17 are highly efficient and can be switched
on by all tested reducing agents with different rates. DTT emerged as the most
potent reducing agent followed by GSH and TCEP. A remarkably rapid reduction
of Au(III) centre was found for complex 5.17 upon treatment with GSH leading to
complete release of the active anion transporter within 5 min.

5.4 Experimental Section
5.4.1

Chemistry

General methods and material
All reagents and solvents were purified and dried by standard techniques. Reactions
were monitored by TLC analysis using silica gel GF/UV 254. NMR spectra were
recorded on Bruker 400 MHz FT-NMR spectrometer and Varian Gemini-300BB
300 MHz FT-NMR spectrometers (Varian Inc., Palo Alto, CA). 1H spectra were
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run at 300 and 400 MHz and 13C spectra were run at 75 and 101 MHz, in the stated
solvent. Chemical shifts (δH) are reported relative to TMS as internal standard and
coupling constant (J) values are reported in Hertz. The abbreviations used are as
follows: s, singlet; d, doublet; t, triplet; m, multiplet. Electrospray ionization (ESI
single quadrupole) mass spectra have their ion mass to charge values (m/z) stated
with their relative abundances as a percentage in parentheses. Peaks assigned to the
molecular ion are denoted as [M+H]+ or [M+Na]+. Column chromatography was
performed using silica gel 60 (0.063-0.200 mm). Low resolution mass spectra
(LRMS) and high-resolution mass spectra (HRMS) were recorded using
positive/negative ion electrospray ionization (ESI) and atmospheric pressure
photoionization (APPI) on Bruker amaZon SL mass spectrometer and Bruker
Solarix 2xR 7T Fourier transform ion cyclotron resonance mass spectrometer
(FTICR). UV-Vis kinetic studies were performed on an Agilent Cary 4000 UV-Vis
absorption spectrometer equipped with a magnetic stirrer and a temperature
controller. Synthesis of 2,6-bis(1H-benzo[d]imidazol-2-yl)pyridine 5.1, 2,6-bis(5nitro-1H-benzo[d]imidazol-2-yl)pyridine 5.5 and Ag N-hetercyclic carbene (NHC)
derivatives 5.15 were attempted according to literature.40, 45, 46

2,6-Bis(1H-benzo[d]imidazol-2-yl)pyridine

(5.1):

39,

40

Dipicolinic

acid

(pyridine-2,6-dicarboxylic acid) (1.67 g, 10 mmol) and o-phenylenediamine (2.38,
22 mmol) were suspended in orthophosphoric acid (30 mL) at 200 °C for 6 h. After
cooling, the reaction melt was poured in 500 mL of cold water and vigorous stirring
was applied. The blue-green precipitate was filtered out and then stirred with hot
10% aqueous sodium carbonate for 10 min. The formed solid was collected by
filtration and crystalized from methanol to give 5.1 (1.35 g, 43%); as a white
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powder 1H NMR (400 MHz, DMSO, d6) δ: 7.23-7.36 (m, 4H, ArH), 7.77 (dd, J =
8.0, 24.0 Hz, 4H, Ar-H), 8.18 (t, J = 8.0 Hz, 1H, Ar-H), 8.36 (d, J = 8.0 Hz, 2H,
Ar-H), 13.10 (br s, 2H, 2 x -NH); 13C NMR (101 MHz, DMSO, d6) δ: 112.3, 120.2,
121.8, 122.7, 124.2, 134.9, 139.7, 144.6, 148.3, 151.0. HRMS (ESI+) calcd for
C19H13N5Na (M+Na)+: m/z 334.1063, found 334.1061.

General procedure A of synthesis of anion transporters 5.2-5.4 41
Step 1. To a suspension of pyridine-2,6-dicarbaldehyde (270 mg, 2 mmol) in
ethanol (7 mL), was slowly added a solution of sodium metabisulfite (213 mg, 1.1
mmol) in water (1 mL). The mixture was stirred vigorously at room temperature
and ethanol (10 mL) was added. The reaction flask was left overnight at 0 °C and
the resulting pink precipitate was filtered and dried to give the aldehyde adduct
(611 mg, 89%) as a pink powder. The aldehyde adduct was used without further
purification.

Step 2.
A mixture of aldehyde adducts (342 mg, 1 mmol) and the appropriate phenylene
diamine (2 mmol) in dry DMF (1 mL) was heated at 120 °C for 4 h. The mixture
was cooled overnight and poured on brine solution and left to stir overnight. The
resulting solid filtered, washed with water (3 x 10 mL), dried and recrystallized
from ethanol to give anion transporter 2-4.

2,6-Bis(5(6)-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridine (5.2): Using
general procedure A and 4-(trifluoromethyl)benzene-1,2-diamine (352 mg, 2
mmol), anion transporter 5.2 (482 mg, 54%) was obtained as a white solid; m.p:
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285-287 °C. 1H NMR (400 MHz, CD3CN) δ: 7.39 (dd, J = 1.0, 9.0 Hz, 2H, Ar-H),
7.54 (d, J = 8.0 Hz, 2H, Ar-H), 7.72 (t, J = 8.0 Hz, 1H, Ar-H), 7.77-7.83 (m, 2H,
ArH), 8.02 (d, J = 8.0 Hz, 2H, Ar-H);

13

C NMR (101 MHz, CD3CN) δ: 118.1,

120.6, 121.9, 123.1, 124.6, 125.0 (d, J2C−F = 31 Hz), 127.3, 130.0, 139.5, 147.9,
153.2. HRMS (ESI+) calcd for C21H11F6N5Na (M+Na)+: m/z 470.0811, found
470.0809.

2,6-Bis(4,6(3,5)-bis(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridine (5.3):
Using general procedure A and 4-(trifluoromethyl)benzene-1,2-diamine (488 mg,
2 mmol), anion transporter 5.3 (495 mg, 42%) was obtained as a white solid; m.p:
290-291 °C. 1H NMR (300 Hz, CD3CN) δ: 7.78-7.90 (m, 2H, ArH), 8.13 (t, J = 8.0
Hz, 1H, Ar-H), 8.18-8.25 (m, 2H, ArH), 8.40 (d, J = 8.0 Hz, 2H, Ar-H); 13C NMR
(126 Hz, (CD3)2CO) δ: 113.6, 113.8, 116.2, 117.8, 120.9, 121.2, 121.5, 122.5,
123.7, 123.8, 124.0, 124.1, 124.4, 124.6, 125.3, 126.8, 132.7, 135.6, 139.3, 143.1,
145.6, 147.3, 154.2, 154.5; 19F (471 Hz, (CD3)2CO) δ: -61.63. HRMS (ESI+) calcd
for C23H9F12N5Na (M+Na)+: m/z 606.0559, found 606.0559.

2,6-Bis(5,6-difluoro-1H-benzo[d]imidazol-2-yl)pyridine (5.4)
Using general procedure A and 4-(trifluoromethyl)benzene-1,2-diamine (288 mg,
2 mmol), anion transporter 5.4 (390 mg, 51%) was obtained as a violet solid; m.p:
> 300 °C. 1H NMR (300 Hz, DMSO, d6) δ: 7.75-7.85 (m, 4H, ArH), 8.18 (t, J = 7.0
Hz, 1H, Ar-H), 8.30 (d, J = 7.0 Hz, 2H, Ar-H);

13

C NMR (75 Hz, DMSO, d6):

122.0, 139.9, 146.2, 147.7, 149.4, 152.8. HRMS (ESI+) calcd for C19H10F4N5
(M+H)+: m/z 384.0867, found 384.0864.
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2,6-Bis(6-nitro-1H-benzo[d]imidazol-2-yl)pyridine (5.5): 45
Compound 5.1 (311 mg, 1 mmol) was dissolved in concentrated H2SO4 (1 mL) and
was cooled in an ice-water mixture. A mixture of 1:1 HNO3/H2SO4 (0.25 mL) was
added dropwise and the reaction suspension was stirred for 3 h, poured into ice
water (10 mL) and neutralized with 20% NaOH. The resulting solid was filtered
and washed with water (2 x 10 mL) to give 5.5 (310 mg, 77%) as pale-yellow
powder. 1H NMR (500 Hz, pyridine, d5) δ: 7.70-7.85 (m, 4H, Ar-H), 8.06 (t, 1H, J
= 7.5 Hz , Ar-H), 8.27 (dd, 2H, J = 2.0, 9.0 Hz , Ar-H), 8.65 (d, 2H, J = 7.5 Hz ,
Ar-H); 13C NMR (126 Hz, pyridine, d5) δ: 118.8, 122.9, 134.9, 135.7, 138.9, 139.1,
144.0, 148.1, 149.2, 155.2; HRMS (ESI+) calcd for C19H12N7O4 (M+H)+: m/z
402.0945, found 402.0951.

General procedure B for synthesis of complexes 5.13 and 5.1438
Dry methanol (25 mL) was added a mixture of anion receptor 5.2 (224 mg, 0.50
mmol) or anion receptor 5.3 (292 mg, 0.50 mmol), dried sodium acetate (325 mg,
3.97 mmol) and KAuCl4 (284 mg, 0.75 mmol) and was heated at reflux for 3 h. The
resulting solid was filtered and washed with methanol (2 x 10 mL) and diethyl ether
(3 x 10 mL) and dried to give complex 5.13 (352 mg, 67%) and 5.14 (455 mg, 56%)
as yellow powders.

Characterisation of complex 5.13: Using general procedure B and anion receptor
5.2, complex 5.13 (352 mg, 67%) was obtained as a yellow solid; m.p: > 300 °C.
1

H NMR (500 Hz, DMSO, d6) δ: 7.56 (td, J = 2.0, 7.0 Hz, 1H, Ar-H), 7.70 (dd, J =

2.0, 9.0 Hz, 1H, Ar-H), 7.95-7.98 (m, 1H, Ar-H), 8.14 (s, 1H, Ar-H), 8.23 (t, J =
8.0 Hz, 1H, Ar-H), 8.33-8.40 (m, 3H, Ar-H), 8.61-8.66 (m, 1H, Ar-H); 13C NMR
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(126 Hz, DMSO, d6) δ: 111.1, 114.8, 118.7, 119.5, 122.2, 123.4, 123.5, 124.0,
142.2, 126.1, 140.0, 142.4, 142.8, 145.3, 146.7, 146.8, 147.6, 160.4, 160.8; 19F (471
Hz, DMSO) δ: -59.62, -59.26. HRMS (APPI) calcd for C21H9AuClF6N5 (M)+: m/z
677.0111, found 677.0107.

Characterisation of complex 5.14: Using general procedure B and anion receptor
5.3, complex 5.14 (455 mg, 56%) was obtained as a yellow solid; m.p: > 300 °C.
1

H NMR (500 Hz, (CD3)2CO) δ: 7.75 (s, 2H, Ar-H), 8.41 (d, J = 5.0 Hz, 2H, Ar-

H), 8.58 (s, 2H, Ar-H), 8.73 (t, J = 8.0 Hz, 1H, Ar-H);

13

C NMR (126 Hz,

(CD3)2CO) δ: 115.3 (d, J1C−F = 200 Hz), 120.8, 122.1 (d, J2C−F = 16 Hz), 122.9, 124.4
(d, J3C−F = 8 Hz), 125.1, 125.7 (d, J1C−F = 200 Hz), 125.9 (d, J2C−F = 33 Hz),127.3,
141.1, 141.7, 147.0, 147.8, 161.8.

19

F (471 Hz, (CD3)2CO) δ: -61.92. HRMS

(APCI) calcd for C23H7AuClF12N5 (M)+: m/z 812.9859, found 812.9898.

General procedure C of complexes 8 and 938
Previously dried silver triflate (46 mg, 0.18 mmol) was added to a suspension of
(1-methyl-3-pentyl-1,3-dihydro-2H-imidazol-2-ylidene)silver(I) bromide (60 mg,
0.18 mmol) 5.15 and complex 5.13 (100 mg, 0.15 mmol) or complex 5.14 (120 mg,
0.15 mmol) in acetonitrile (15 mL). After holding the reaction mixture in the dark
at reflux for 12 h, it was cooled, filtered and purified by cycles of crystallization of
diethyl ether diffusion in an acetonitrile solution of the product.

Characterisation of complex 5.16
Using general procedure C, complex 5.16 (18 mg, 13%); was obtained as a yellow
solid; m.p: > 237-239 °C. 1H NMR (300 MHz, CD3CN) δ: 0.51 (t, J = 7.0 Hz, 3H,
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CH3), 0.98-1.05 (m, 2H, CH2), 1.13-1.18 (m, 2H, CH2), 1.71-1.80 (m, 2H, CH2),
4.05 (s, 3H, CH3), 4.36-4.41 (m, 2H, CH2), 6.12-6.15 (m, 2H, Ar-H), 7.53-7.62 (m,
2H, Ar-H), 7.93-8.03 (m, 2H, Ar-H), 8.22 (s, 1H, Ar-H), 8.39 (d, J = 8.0 Hz, 2H,
Ar-H), 8.64 (t, J = 8.0 Hz, 1H, Ar-H); 13C NMR (101 MHz, CD3CN) δ: 12.6, 21.6,
27.8, 30.1, 38.4, 51.6, 108.8, 112.5, 112.7, 119.1, 122.4, 122.9, 125.5, 126.9, 138.3,
141.2, 142.3, 147.2, 147.2, 147.5, 161.6; HRMS (APPI) calcd for C30H25AuF6N7+
(M - OTf)+: m/z 794.1736, found 794.1737.

Characterisation of complex 5.17
Using general procedure C, complex 5.17 (20 mg, 12%); was obtained as a yellow
solid; m.p: > 231-233 °C. 1H NMR (300 Hz, (CD3)2CO) δ: 0.39 (t, J = 7.0 Hz, 3H,
CH3), 0.85-1.03 (m, 2H, CH2), 1.04-1.11 (m, 2H, CH2), 1.72-1.79 (m, 2H, CH2),
4.26 (s, 3H, CH3), 4.63 (t, J = 7.0 Hz, 2H, CH3), 6.45 (s, 2H, Ar-H), 7.77 (s, 1H,
Ar-H), 7.88 (s, 1H, Ar-H), 8.37 (d, J = 2.0 Hz, 2H, Ar-H), 8.42 (d, J = 2.0 Hz, 2H,
Ar-H), 8.51 (d, J = 8.0 Hz, 2H, Ar-H), 8.75 (t, J = 8.0 Hz, 1H, Ar-H); 13C NMR (75
MHz, (CD3)2CO) δ: 12.6, 21.7, 27.9, 30.4, 38.5, 51.8, 113.0, 116.8, 119.8, 119.9,
120.5, 122.1, 122.8 (q, 2JC,F = 34 Hz), 124.2, 124.5 (q, 1JC,F = 209 Hz), 127.6, 131.9,
139.8, 141.5, 147.4, 147.6, 163.9; HRMS (APPI) calcd for C32H23AuF12N7+ (M OTf)+: m/z 930.1484, found 930.1486.

5.4.2

X-ray crystallography

X-ray of transporter (5.2)
Single crystals of transporter 5.2 (C23H17N5OF6S) were obtained by slow diffusion
of DMSO solution of 5.2. A suitable crystal was selected and in Paratone on a
micromount on a SuperNova, Dual, Cu at home/near, Atlas diffractometer. The
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crystal was kept at 100 K during data collection. Using Olex247, the structure was
solved with the ShelXS48 structure solution program using Direct Methods and
refined with the ShelXL49 refinement package using Least Squares minimization.
Crystal Data for C23H17N5OF6S (M =525.47 g/mol): orthorhombic, space
group Pmc21 (no. 26), a = 6.841(2) Å, b = 17.047(3) Å, c = 19.783(4) Å, V =
2307.1(10) Å3, Z = 4, T = 100(2) K, μ(Cu Kα) = 1.943 mm-1, Dcalc = 1.513 g/cm3,
3102 reflections measured (8.94° ≤ 2Θ ≤ 147.086°), 3102 unique (Rsigma = 0.0551)
which were used in all calculations. The final R1 was 0.1265 (I > 2σ(I)) and wR2
was 0.3804 (all data).

X-ray of complex (5.14)
Single crystals of complex 5.14 (C26H13AuClF12N5O) were obtained by slow
diffusion of acetone solution of 5.14. A suitable crystal was selected and in Paratone
on a micromount on a SuperNova, Dual, Cu at home/near, Atlas diffractometer.
The crystal was kept at 100 K during data collection. Using Olex247, the structure
was solved with the ShelXS48 structure solution program using Direct Methods and
refined with the ShelXL49 refinement package using Least Squares minimization.
Crystal Data for C26H13AuClF12N5O (M =871.83 g/mol): orthorhombic, space
group P212121 (no. 19), a = 4.9760(2) Å, b = 18.4846(6) Å, c = 29.9692(9) Å, V =
2756.57(16) Å3, Z = 4, T = 100(2) K, μ(CuKα) = 11.990 mm-1, Dcalc =
2.101 g/cm3, 10634 reflections measured (9.57° ≤ 2Θ ≤ 146.43°), 5220 unique (Rint
= 0.0665, Rsigma = 0.0718) which were used in all calculations. The final R1 was
0.0895 (I > 2σ(I)) and wR2 was 0.2353 (all data).
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X-ray of transporter 5.16
Single crystals of transporter 5.16 (C33H28AuF9N8O3S) were crystalized by a
mixture of acetonitrile and diethyl ether solution of 5.16. A suitable crystal was
selected and in Paratone on a micromount on a SuperNova, Dual, Cu at home/near,
Atlas diffractometer. The crystal was kept at 100 K during data collection. Using
Olex247, the structure was solved with the ShelXS48 structure solution program
using Direct Methods and refined with the ShelXL49 refinement package using
Least Squares minimization.
Crystal Data for C33H28AuF9N8O3S (M =984.66 g/mol): monoclinic, space
group P21/n (no. 14), a = 15.51220(20) Å, b = 16.2596(2) Å, c = 28.5690(3) Å, β =
95.2011(11)°, V = 7176.06(16) Å3, Z = 8, T = 100(2) K, μ(Cu Kα) = 9.101 mm-1,
Dcalc = 1.823 g/cm3, 12657 reflections measured (7.894° ≤ 2Θ ≤ 133.198°), 12657
unique (Rint = ?, Rsigma = 0.0511) which were used in all calculations. The final R1
was 0.0380 (I > 2σ(I)) and wR2 was 0.0907 (all data).

X-ray of complex 5.17
Single crystals of complex 5.17 were obtained by slow diffusion vapour diffusion
of Et2O into an acetone solution of 5.17. A suitable crystal was selected and in
Paratone on a micromount on a SuperNova, Dual, Cu at home/near, Atlas
diffractometer. The crystal was kept at 100 K during data collection. Using Olex247,
the structure was solved with the ShelXS48 structure solution program using Direct
Methods and refined with the ShelXL49 refinement package using Least Squares
minimization.
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Crystal Data for C36H29N7O4F15SAu (M =1137.69 g/mol): triclinic, space
group P-1 (no. 2), a = 11.2877(3) Å, b = 14.0974(3) Å, c = 14.9642(4) Å, α =
109.821(2)°, β = 107.118(2)°, γ = 102.3303(19)°, V = 2006.66(9) Å3, Z = 2, T =
100(2) K, μ(CuKα) = 8.474 mm-1, Dcalc = 1.883 g/cm3, 14400 reflections
measured (6.848° ≤ 2Θ ≤ 145.304°), 7742 unique (Rint = 0.0278, Rsigma = 0.0382)
which were used in all calculations. The final R1 was 0.0337 (I > 2σ(I)) and wR2
was 0.0859 (all data).

X-ray of 5.2.TEACl complex
Single crystals of transporter 5.2 and chloride ion were obtained by slow diffusion
vapour diffusion of Et2O into acetonitrile solution of 5.2 and two equivalents of
TEACl. A suitable crystal was selected and in Paratone on a micromount on a
SuperNova, Dual, Cu at home/near, Atlas diffractometer. The crystal was kept at
100 K during data collection. Using Olex247, the structure was solved with the
ShelXS48 structure solution program using Direct Methods and refined with the
ShelXL49 refinement package using Least Squares minimization.

Crystal Data for C50H48ClF12N11O3 (M =1114.44 g/mol): triclinic, space
group P-1 (no. 2), a = 11.3690(16) Å, b = 11.800(2) Å, c = 19.141(3) Å, α =
100.941(16)°, β = 90.546(14)°, γ = 104.405(14)°, V = 2437.5(7) Å3, Z = 2, T =
100(2) K, μ(CuKα) = 1.605 mm-1, Dcalc = 1.518 g/cm3, 19563 reflections
measured (7.892° ≤ 2Θ ≤ 147.71°), 9489 unique (Rint = 0.1261, Rsigma = 0.1672)
which were used in all calculations. The final R1 was 0.1404 (I > 2σ(I)) and wR2
was 0.4052 (all data).
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H NMR titration binding studies with TBACl

Proton NMR titrations binding studies were performed on Bruker 400 MHz FTNMR spectrometer at 298 K. Solution of receptors 5.1-5.4 in DMSO-d6/0.5% H2O
or acetonitrile were prepared in 2 mM and 1 mM concentrations, respectively. The
guest anion, tetra-n-butylammonium (TBA) chloride, was prepared with the same
receptor solution, to ensure the overall receptor concentration stays constant whilst
the guest anion concentration changes. Using small aliquots of the guest salt, the
receptor solution was titrated, and after each addition, chemical shifts were reported
in ppm in refence to residual solvent peaks. The isotherm based on the NH and CH
chemical shifts were globally fitted using the online fitting program Bindfit.50

5.4.4
5.4.4.1

Anion transport studies:
Ion selective electrode (ISE) assays

a- Cl/NO3 exchange assay:
Unilamellar vesicles were prepared as reported.51-53 Briefly, ~ 30 mg of POPC (1palmitoyl-2-oleoylphosphatidylcholine) was dissolved in 1 mL chloroform in a
round-bottomed flask and the solvent was removed in vacuo to form a thin lipid
layer. The thin film was dried under high vacuum for at least 6 h and suspended on
the internal solution (4 mL) and vortexed using a lab dancer to form large
multilamellar vesicles, which was subjected to nine freeze-thaw cycles alternating
between water (at room temperature) and liquid nitrogen. Further, the formed lipid
was left to rest for 30 minutes and then subjected to extrusion through a 200 nm
polycarbonate membranes 25 times to form the unilamellar vesicles. The formed
vesicles were subjected to dialysis for 4 h in the desired external solution to remove
any unencapsulated internal salts. Finally, using the required external solution, the
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lipid was diluted to 1.0 mM. The pH of the internal and external solutions was
maintained at 7.2 using phosphate buffer with a 500 mM total ionic strength. Test
compound in DMSO (40 μL) was added to start the experiment and chloride
selective electrode was used to monitor the chloride efflux. Detergent (50 μL) was
added after 300 seconds to lyse the vesicles, while the 100% chloride efflux reading
was taken at 420 seconds.

-

Hill plots for Cl/NO3:

Hill plots were performed for Cl/NO3 exchange assay by conducting transport assay
at different concentrations of tested compounds. Receptor concentration vs chloride
efflux at 270 s (the endpoint of transport assay) were plotted and fitted to the Hill
equation using Origin 2019b:
𝑦 = 𝑉𝑚𝑎𝑥

𝑥𝑛
𝑥𝑛
=
100%
𝑘𝑛 + 𝑥𝑛
(𝐸𝐶50 )𝑛 + 𝑥 𝑛

Where y is the chloride efflux at 270 s (%) and x is the tested compound
concentration (mol% relative to lipid concentration)

Vmax is the maximum efflux possible and considered as 100% as this is
experimentally the maximum chloride efflux possible.
k (EC50 value) is the carrier concentration needed to reach Vmax/2.
Each data point on each Hill plot are an average of at least two repeated runs. Error
bars represent standard deviation about the mean.
Hill plots for receptors 5.1 and 5.5 were not performed due to low potency and
solubility issues of ionophore 5.1 and 5.5, respectively.
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b- KCl efflux – cationohore coupling:
In this assay, 300 mM total ionic strength of both K gluconate external solution and
KCl internal solution were marinated. The vesicles were made in a similar way to
Cl/NO3 exchange assay except that gel filtration, using sephadex, replaced dialysis
to allow exchange of any unencapsulated KCl for KGlu. External KGlu solution
(10 mL) was used to dilute the lipid solution obtained after sephadex to obtain a
lipid stock of known concentration. A cationohore, monensin or Valinomycin, (10
μL, 0.5 mM) was added first to the lipid solution at concentration 0.1 mol% with
respect to lipid concentration. Receptor was added after 30 seconds of the
cationohore addition to start the experiment.
5.4.4.2

General preparation for HPTS assays:

Base-pulse 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (HPTS) assays
were conducted using unilamellar 1-palmitoyl-2-oleoylphosphatidylcholine
vesicles (POPC) with a mean diameter of 200 nm loaded with the pH sensitive
fluorescence dye HPTS (1 mM).51-53 A chloroform solution of POPC (~ 30 mg/mL)
was evaporated under vacuum and dried for at least 6 h. The thin film was hydrated
by the internal solution containing HPTS (1 mM) and was subjected to nine freezethaw cycles followed by extrusion 25 times through a 200 nm polycarbonate
membrane. Size exclusion chromatography using sephadex G-25 column and
HPTS-free external solution as an eluent was conducted to remove unentrapped
HPTS from the vesicles` solution. The internal and external solutions used were
identical salt solution potassium gluconate (KGlu) or KCl (100 mM) buffered with
10 mM HEPES at pH 7.0. Finally, for each measurement, external solution (KCl or
KGlu) was used to dilute the lipid stock to obtain 2.5 mL lipid suspension
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containing 0.1 mM lipid. A base pulse of KOH (25 μL, 0.5 M) at a final
concentration of 5 mM was added to generate a transmembrane pH gradient. After
the tested receptors were added, HPTS fluorescence ratio (λex = 460 nm, λem = 510
nm divided by λex = 403 nm, λem = 510 nm) was recorded. Assisting ionophore
(carbonyl cyanide phenylhydrazone (CCCP) or valinomycin) was used as a 5 μL
DMSO. Bovine serum albumins (BSA) was added to vesicles at 1 mol% (with
respect to lipid) and allowed to stir for 30 minutes to test if the transport is fatty
acid independent, while, oleic acid (1 mol% and 10 mol%) was used as a source of
fatty acid to test if the transport is fatty acid dependent. Detergent (25 μL) was
added at 200 seconds to destroy the pH gradient to calibrate the assay.

Results are the average of at least three repeats and the fractional fluorescence
intensity (If) was determined using the following formula:
𝐼𝑓 =

𝑅𝑡 − 𝑅0
𝑅𝑑 − 𝑅0

Where
-

Rt is the fluorescence ratio at time t.

-

R0 is the fluorescence ratio at time 0

-

Rd is the fluorescence ratio after detergent addition.

Hill plots were determined for KCl and KGlu transport assays by conducting
transport assays at different tested receptors concentrations. Receptor concentration
vs fractional fluorescence intensity If at 200 s (the endpoint of transport assay) were
plotted and fitted to the Hill equation using Origin 2019b:
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The following formula was used to calculate hill coefficients (n) and EC50 (200 s)
values by fitting the curves to the following equation:
𝑦 = 𝑦0 + (𝑦𝑚𝑎𝑥 − 𝑦0 )

𝑥𝑛
𝑘𝑛 + 𝑥𝑛

Where:
-

y is If (200 s) value of the ionophore at concentration x (receptors concentration
is expressed as ionophore to lipid molar ratio).

-

y0 is If value at 200 s, without addition of the ionophore.

-

ymax is the maximum If value.

-

n is the Hill coefficient, and K is the EC50 (200 s) value.

5.4.4.3

Chloride vs anions selectivity assay:

Unilamellar vesicles were prepared in a similar pattern to KCl-KOH assay as
reported in section 5.4.4.2. Internal solution of each experiment contained KCl (100
mM) and HPTS (1 mM) while five external solutions were used at 100 mM with
different salts KCl, KBr, KI, KNO3 and KClO4. Both external and internal solutions
are buffered with HEPES (10 mM) to pH 7.0. HPTS is a pH responsive probe that
has two wavelengths corresponding to the acidic and basic forms, 403 nm and 460,
respectively. Fluorescence ratio between acidic and basic forms was measured for
the five receptors against chloride/anion (X-) selectivity. If the anion X- is being
transported into the vesicles, it would transport as HX and so lowered the pH inside
the vesicles, resulting in a negative Normalized HPTS value. However, if the
chloride is being transported out along with the proton gradient, so the pH inside
the vesicles would be decreased, causing a positive Normalized HPTS value.
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5.4.4.4

Calcein leakage assays:

A chloroform solution of POPC was evaporated under vacuum and dried for at least
6 h as reported.43 The thin film was hydrated by the internal solution containing
calcein disodium salt (100 mM) and NaCl (100 mM) buffered to pH 7.4 with
HEPES (10 mM). Then, the lipid suspension was subjected to nine freeze-thaw
cycles followed by extrusion 25 times through a 200 nm polycarbonate membrane.
Size exclusion chromatography using sephadex G-25 column and calcein-free
external solution, containing NaCl (100 mM) and Na2SO4 (100 mM) buffered to
pH 7.4 with HEPES (10 mM).
The resulting suspension of dye-encapsulated LUVs with a mean diameter of 200
nm was diluted with the external solution to obtain 2.5 mL lipid suspension
containing a 0.1 mM lipid concentration. After the tested receptors 5.1-5.5 were
added at 1 mol%, calcein fluorescence (λex = 490 nm, λem = 520 nm) was recorded
at 25 °C. Detergent (25 μL) was added at 200 seconds to lyse the vesicle and to
calibrate the assay.
The fractional calcein release (FR) was calculated as follows (with It = fluorescence
intensity at time t, I0 = fluorescence intensity at time 0 and Imax = fluorescence
intensity after addition of detergent):

𝐹𝑅 =

5.4.5

𝐼𝑡 − 𝐼0
𝐼𝑚𝑎𝑥 − 𝐼𝑜

Reduction kinetic studies

Three reducing agents were used in the current study, namely: the tripeptide
glutathione (GSH), dithiothreitol (DTT) and HCl of tris(2-carboxyethyl)phosphine
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(TCEP). The reduction kinetic study of complexes 5.13, 5.14, 5.16 and 5.17 has
been done in organic solvent (DMSO), in liposomes with external addition of the
reducing agent and in GSH encapsulated liposomes and was monitored by UV-Vis
and fluorescence spectroscopies. Absorbance studies UV-Vis spectra were
recorded on an Agilent Cary 100 UV-Vis spectrophotometer, equipped with a
temperature-controlled multicell holder and a temperature control unit.
Fluorescence spectra were conducted on an Agilent Cary Eclipse fluorescence
spectrophotometer, equipped with a temperature control unit and a magnetic stirrer.
In the current study GSH was used in 6:1, relative to tested compound, while DTT
and TCEP were used in 3:1, relative to tested compound.

Reactivity with different thiols was quantified by measuring the increase in
fluorescence at 365 nm (285 nm excitation) for probe 5.2 and complexes 5.13 and
5.16 and at 400 nm (350 nm excitation) for probe 5.3 and complexes 5.14 and 5.17
over time and the increase in absorbance at 325 nm for all tested compounds over
time. Receptors 5.2 and 5.3 and complexes 5.13, 5.14, 5.16 and 5.17 were dissolved
in DMSO at room temperature to afford the probe concentration at 0.5 mM. GSH,
DTT and TCEP stock solutions (3.0 mM, 1.5 mM, 1.5 mM, respectively) were
freshly prepared in deionized water for the DMSO experiments and in the external
solution for the experiments conducted in liposomes. Generally, 5 μL (0.5 mM,
final concentration = 1 μM) of tested compounds were used in fluorescence
experiments, while low absorbance was detected for this concentration in UV-Vis,
loading volume of tested compounds was changed to 25 μL (0.5 mM, final
concentration = 5 μM). The absorbance or the emission spectra at a certain
wavelength (noted for each compound above) was plotted against the wavelength
using OriginPro 9.1.
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Reduction kinetics in DMSO:
UV-Vis: In a quartz cuvette and at 25 °C, tested compound (25 μL, 0.5 mM) was
added to DMSO 2450 μL. The reducing agent (25 μL) GSH (3.0 mM), DTT (1.5
mM) or TCEP (1.5 mM) was added with stirred for 30 seconds. A baseline
absorbance was measured on 2475 μL DMSO and 25 μL of the reducing agent, and
spectra were collected at 1 minute intervals over a period of 15 minutes. After 15
minutes, there was no significant change in the absorbance intensity. Results are
the average of at least two repeats.

Fluorescence: DMSO (2490 μL) and tested compound (5 μL) were added to a
disposable cuvette with stirring and at 25 °C. Reducing agent (5 μL) GSH (3.0
mM), DTT (1.5 mM) or TCEP (1.5 mM) was added and stirred for 30 seconds and
spectra was collected every minute for 30 minutes. Results are the average of at
least three repeats.

Reduction kinetics in liposomes:
Unilamellar KCl (100 mM) vesicles, buffered with 10 mM HEPES at pH 7.0, were
prepared as mentioned earlier in section S6.1, however, without addition of HPTS
probes. The and UV-Vis and fluorescence properties of receptors 5.2 and 5.3 were
exploited to monitor the reduction kinetics of complexes 5.13, 5.14, 5.16 and 5.17.
It was noted that both transporters 5.2 and 5.3 retained their UV-Vis properties and
had the same λmax as in organic solvent experiment (DMSO, S7.1). Transporter 5.2
retained its fluorescence nature in the KCl-liposomes, while transporter 5.3
fluorescence diminished, when it was added to liposomes. Thus reduction kinetics
of complexes 5.13 and 5.16 was monitored by UV-Vis and fluoresence, while
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reduction complexes 5.14 and 5.17 to the free anion transporter 5.3 could be only
monitored by UV-Vis.

UV-Vis: In a quartz cuvette and at 25 °C, tested compound (25 μL, 0.5 mM) was
added to 2450 μL of the liposomal suspension. The reducing agent (25 μL) GSH
(3.0 mM), DTT (1.5 mM) or TCEP (1.5 mM) was added with stirred for 30 seconds.
A baseline absorbance was measured on 2450 μL liposomal suspension 25 μL of
reducing agent, and 25 μL DMSO. Spectra were collected at 5 minutes intervals
over a period of 3-4 h. Results are the average of at least two repeats.

Fluorescence: Fluorescence spectra were recorded on excitation wavelength 285
nm and emission wavelengths 300-500 (λex = 285 nm, λem = 300-500 nm).
Liposomal suspension (2490 μL) and tested compound (5 μL) were added to a
standard disposable cuvette with stirring and at 25 °C. Reducing agent (5 μL) GSH
(3.0 mM), DTT (1.5 mM) or TCEP (1.5 mM) was added and stirred for 30 seconds
and spectra was collected every minute for 1.5-3.0 h. Results are the average of at
least three repeats.

Reduction kinetics in encapsulated GSH Liposomes:
Assuming the fraction of the interior volume of 200 nm unilammelar vesicles was
0.059%, two different 10 mM (final concentration in 2.5 mL = 6 μM) and 50 mM
(final concentration in 2.5 mL = 30 μM) GSH encapsulated KCl liposomes,
buffered with 10 mM HEPES at pH 7.0, were made. A chloroform solution of
POPC (~ 30 mg/mL) was evaporated under vacuum and dried for at least 6 h. The
thin film was hydrated by the internal solution containing GSH (10 mM or 50 mM)
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and was subjected to nine freeze-thaw cycles followed by extrusion 25 times
through a 200 nm polycarbonate membrane. Size exclusion chromatography using
sephadex G-25 column and HPTS-free external solution as an eluent was conducted
to remove unentrapped GSH from the vesicles` solution.
The internal and external solutions used were KCl (100 mM) buffered with 10 mM
HEPES at pH 7.0. Finally, for each measurement, external solution (KCl) was used
to dilute the lipid stock to obtain 2.5 mL lipid suspension containing 0.1 mM lipid.
A base pulse of KOH (25 μL, 0.5 M) at a final concentration 5 mM was added to
generate a transmembrane pH gradient. After the tested receptors were added,
compound 5.2 fluorescence spectra of excitation = 285 nm and emission = 300-500
nm were recorded. Compound 5.3 and its complexes 5.14 and 5.17 were excluded
as receptor 5.3 fluorescence properties diminished fluorescence in liposomal
solution.
UV-Vis and fluorescence reduction kinetic experiments were used as in the
previous section where 50 mM GSH encapsulated vesicles used in UV-Vis study
and 10 mM GSH encapsulated vesicles used in fluorescence studies,
correseponding to 1:6 compound:GSH in each case.

5.4.6

Transport studies upon reduction of complexes 5.13, 5.14 5.16 and 5.17

Base-pulse 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (HPTS) assays
were conducted using unilamellar 1-palmitoyl-2-oleoylphosphatidylcholine
vesicles (POPC) with a mean diameter of 200 nm loaded with the pH sensitive
fluorescence dye HPTS (1 mM).51-53 A chloroform solution of POPC (~ 30 mg/mL)
was evaporated under vacuum and dried for at least 6 h. The thin film was hydrated
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by the internal solution containing HPTS (1 mM) and was was subjected to nine
freeze-thaw cycles followed by extrusion 25 times through a 200 nm polycarbonate
membrane. Size exclusion chromatography using sephadex G-25 column and
HPTS-free external solution as an eluent was conducted to remove unentrapped
HPTS from the vesicles` solution. The internal and external solutions used were
identical salt solution potassium gluconate (KGlu) or KCl (100 mM) buffered with
10 mM HEPES at pH 7.0. Finally, for each measurement, external solution (KCl or
KGlu) was used to dilute the lipid stock to obtain 2 mL lipid suspension containing
0.1 mM lipid. A base pulse of KOH (25 μL, 0.5 M) at a final concentration 5 mM
was added to generate a transmembrane pH gradient. After the tested receptors were
added, HPTS fluorescence ratio (λex = 460 nm, λem = 510 nm divided by λex = 403
nm, λem = 510 nm) was recorded. Assisting ionophore (carbonyl cyanide
phenylhydrazone (CCCP) or valinomycin) was used as a 5 μL DMSO. Bovine
serum albumins (BSA) was added to vesicles at 1 mol% (with respect to lipid) and
allowed to stir for 30 minutes to test if the transport is fatty acid independent, while,
oleic acid (1 mol% and 10 mol%) was used as a source of fatty acid to test if the
transport is fatty acid dependent. Detergent (25 μL) was added at 200 seconds to
destroy the pH gradient to calibrate the assay.
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Chapter 6:
Fluorescent anion transporters

FOREWORD TO CHAPTER 6
This chapter is a communication prepared for submission to the Chemical
Communications. This chapter describes efficient fluorescent anion transporters for
biological evaluation. Using state-of-art organic chemistry four anion transporters
based on coumarin bisurea scaffold were synthesized and fully characterized. This
chapter also describes full transport and binding properties of these fluorescent
receptors. The coumarin bisurea anion transporters showed superior anion transport
efficiencies compared to previously reported examples making them better
candidates for cellular fluorescent imaging.
Supporting information for this chapter can be found in Appendix E (p. 315).
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6.1 Introduction
The transport of ions across phospholipid bilayer membranes in biological systems
is a crucial process in many biological processes including, cell migration and
proliferation, and maintaining cellular pH, membrane potential and cellular
secretions.1, 2 Channelopathies are a group of diseases characterised by ion channel
impairment, which include cystic fibrosis, epilepsy and cancer.3-5 For example,
cystic fibrosis transmembrane conductance regulator (CFTR) is a channel present
in epithelial cells that is responsible for facilitating the transport of chloride and
bicarbonate through the cell membrane. Genetic problems result in dysfunctional
channels and reduced anion transport resulting in the symptoms of cystic fibrosis,
while impairment of sodium, potassium and T-type calcium channels is linked with
epilepsy.6 Channel replacement therapy is a new approach to treating
channelopathies in which the function of a faulty channel is replaced by an
ionophore that can facilitate the flux of ions through a membrane by forming a
lipophilic complex.7
A number of anionophores and anion exchangers show anti-cancer activity,
including the natural product prodigiosin 6.11, squaramide derivatives 6.12 and ophenylenediamine-based bisureas.8-12 Studies have shown that chloride transporters
can trigger apoptosis in cells whilst compounds that can co-transport H+/Cl- can
also interfere with autophagy presumably by deacidifying acidic organelles.8, 13
However, our understanding of the action of anionophoes within cells is still limited
with some studies showing particular classes of compounds show toxicity whilst
other studies show little toxicity but potent anion transport properties.5, 8, 13, 14
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A previous study based on a series of fluorescent (thio)urea-based anionophores
was conducted to further understand where anionophores localise in cells using
fluorescence imaging techniques.15 However, these transporters showed modest
anion binding and transport activities. The most active receptor that possessed the
highest association constants among the tested compounds showed low transport
activity in the chloride/nitrate exchange assay. This assay was designed to measure
the chloride flux from 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
vesicles.15, 16 We have conducted another study using squaramide-based fluorescent
anionophores to investigate the anion transport activity in the A549 cancer cell
line.17 However, these compounds (clog P = 4.9-5.8) elicited only moderate
transport activity compared to the parent squaramide derivatives presumably due
to replacing one of the active aniline moiety (containing acidic NH that interacts
with the anion) with the bulky naphthalimide fluorophore.
To further improve the anion transport properties and to develop potent fluorescent
anion transporters that can be used in lower doses, we designed and synthesized
new fluorescent 4-methylcoumarin-bisurea conjugates 6.1-6.4 (Figure 6.1). We
have previously shown that ortho-phenylene diamine based bisureas are highly
potent anion transporters.11, 12, 18, 19

Figure 6.1: Structure of designed fluorescent transporters 6.1-6.4 and some biologically active
anion transporters 6.11 and 6.12.
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The 4-methylcoumarin scaffold is a small molecular weight fluorophore (more
anion binding moieties can be added) with extended spectral range, high emission
quantum yields and confers the advantage of better solubility than 1,8naphthalimide fluorophore. The anion binding and transport activities were
evaluated for transporters 6.1-6.4 and their effect on and localisation in cells
studied.

6.2 Results and discussion
The synthetic strategy started with protection of amino group in m-aminophenol
6.5 using ethyl chloroformate to afford ethyl(3-hydroxyphenyl)carbamate 6.6 (96%
yield), which was used in the next step without any further purification.20 7Carbethoxyamino-4-methylcoumarin 6.7 was prepared in 75% yield by application
of von Pechmann condensation of compound 6.6 and ethyl acetoacetate in 70%
sulfuric acid.20 Nitration of 6.7 using aluminium nitrate nonahydrate in acetic
anhydride gave two isomers of nitro 7-carbethoxyamino-4-methylcoumarin, which
were separated by flash column chromatography to afford the desired 6-nitro-7carbethoxyamino-4-methylcoumarin 6.8 in 36% yield. Compound 7 was
hydrolysed under standard acidic conditions to achieve 6-nitro-7-amino-4methylcoumarin 6.9 (80% yield), which was reduced using tin/HCl as reported to
give the key intermediate 6,7-diamino-4-methylcoumarin 6.10, in 36% yield
(Scheme 6.1).21
Transporters 6.1, 6.2 and 6.4 were prepared by nucleophilic addition of the 6,7diamino-4-methylcoumarin 6.10 with the corresponding aryl isocyanate in DCM
overnight at 45 °C under an inert atmosphere. Interestingly, attempts to prepare
transporter 6.3 using the same procedure failed. Optimization of the reaction
150

Chapter 6

Fluorescent anion transporters

involved using different solvents (no solvent, toluene, DMSO and CHCl3),
changing the reaction temperature and using a base. The optimal conditions were
found by using no solvent and adding excess of the 4-trifluoromethylphenyl
isocyanate under inert condition. By applying these conditions, transporter 6.3 was
obtained, however in low yield (22%) (Scheme 6.1).

Scheme 6.1: Reagents and conditions: a) ethyl chloroformate/DEE; b) ethyl acetoacetate,
70% H2SO4; c) Al(NO3)3 nonahydrate, acetic anhydride.; d) Conc H2SO4, glacial acetic
acid, reflux.; e) Sn/HCl, reflux.; f) suitable isocyanate, DCM, 45 °C, or suitable isocyanate,
45 °C.

The structure of compound 6.1 was confirmed by single crystal X-ray diffraction
(Figure 6.2). Single crystals were obtained by slow evaporation of a DMF/ethanol
solution of 6.1 at room temperature. The crystal structure (Figure 6.2) showed that
coumarin rings are stacked on the top of each other in an antiparallel manner and
stabilized by the intermolecular hydrogen bonds.
Anion binding abilities of potential transporters 6.1-6.4 in solution were
investigated using
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tetrabutylammonium chloride (Figure 6.3, Table 6.1). The change in chemical shift
of the four urea NHs against the equivalents of anion added was fitted globally to
1:1 and 1:2 (host: guest) binding modes using BindFit.22 The results demonstrate
moderate chloride affinity in the range of 50 – 250 M-1 in this highly competitive
media similar to the previously reported o-phenylenebisureas.

Figure 6.2: X-ray crystal structure of 6.1 a) ORTEP diagram showing 50% probability
anisotropic displacement ellipsoids at 100 K. b) space-filling models.

Figure 6.3: Stack plot of the 1H NMR spectrum of receptor 6.3 (2.0 x 10-3 M) upon titration
with chloride (0-17 eq.) added as its tetrabutylammonium salt in DMSO-d6/0.5%H2O at 25
°C.
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Table 6.1: Anion binding properties of compounds 6.1–6.4.
6.1
c

6.2

6.3

6.4

Log P

3.67

2.77

4.80

5.96

1:1 (Ka),

81

146

177

96

covfit [b]

4.6 x 10-4

2.2 x 10-3

2.0 x 10-3

4.4 x 10-3

1:2 (Ka)

-

K₁₁: 186; K12: 2

K₁₁: 239; K12: 9

K₁₁: 178; K12: 5

β21[c]

-

372

2.2 x 103

890

Covfit

[b]

-

1.8 x 10

-4

2.0 x 10

-4

3.2 x 10-4

[a] clog P values calculated using VCCLab. [b] The covariance of the fit (covfit) is
calculated by dividing the covariance of the residual (experimental data − calculated
data) with the covariance of the experimental data. [c] The association constant (β21)
for the 2:1 and 1:2 host:guest complex calculated by multiplying K11 and K12 and K11
and K21, respectively.

Receptors 6.1-6.4 were investigated for their chloride transport properties across
lipid bilayer via liposome-based techniques using a chloride ion selective electrode
(ISE) (Figures 6.4-6.6, Table 6.2). Briefly, unilamellar POPC vesicles with
diameter 200 nm were prepared as reported and loaded with 489 mM KCl, buffered
to pH = 7.2 and suspended in 489 mM KNO3 solution which is buffered to pH =
7.2. The chloride efflux, as indication of Cl-/NO3- exchange process, was measured
using ISE upon addition of DMSO solution of transporters 6.1-6.4 to the prepared
liposomes.16
Hill plots were performed by monitoring chloride efflux at different concentrations
of tested compounds (expressed as mol% with respect to lipid concentration) to
calculate EC50 (defined as the concentration required to achieve 50% the chloride
efflux at 270 s) and Hill coefficient. The EC50 is used as a measure of anion
transporter potency, while Hill coefficient has been linked to the stoichiometry of
the formed complex during the transport across the lipid bilayer.23 As illustrated in
Table 6.2 and Figure 6.5, the unsubstituted coumarin-bisureas hybrid 6.1 emerged
as the least active transporter with EC50 = 4.3 x 10-1 mol%, followed by transporter
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6.4 (EC50 = 1.5 x 10-2 mol%) (Figure 3d, Table 1). Transporters 6.2 and 6.3, with
p-CN and p-CF3 substituents respectively, emerged as the most active transporters
with low EC50 values of 7.0 x 10-3 and 7.4 x 10-3 mol% respectively. Transporters
6.2-6.4 (EC50 = 1.5 x 10-2 - 7.0 x 10-3 mol%) (Figure 6.5, Table 6.2) showed superior
transport activity across the lipid bilayer than the previously reported fluorescent
naphthalimide-(thio)ureas with at least 10 times lower EC50 value than the
previously reported fluorescent anion transporters.15, 17

Table 6.2: Transport and anion binding properties of compounds 6.1–6.4.

Cl/NO3 (EC50, mol%) [a]
n[b]
KCl (EC50, mol%) [c]
n[b]

6.1

6.2

6.3

6.4

4.3 x 10-1

7.0 x 10-3

7.4 x 10-3

1.5 x 10-2

1.2

1.2

1.2

0.93

3.8 x 10
0.99

-2

5.1 x 10
1.2

-4

6.3 x 10
1.2

-4

9.7 x 10-4
1.1

[a] EC50 from the Cl/NO3 exchange assay. [b] Hill coefficient as an indicator of
the stoichiometry the complex mediating transport. [b] EC50 from the KCl assay
measuring H+/Cl− symport.

By utilizing the cationophore coupled-KCl assay,16 valinomycin (Vln) or monensin
(Mon) were used to investigate the mechanism of anion transport of the fluorescent
transporters 6.1-6.4 (Figures 6.4b-c). This assay was used to determine whether the
anionophore transports only chloride in a uniport process resulting in a net flow of
charge across the membrane (an electrogenic transporter) if the anionophore
couples to valinomycin, or if the anionophore couples to monensin it shows it is
functioning as an H+/Cl- cotransporter resulting in an electroneutral transport
process (no net flow of charge).
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Figure 6.4: a-c) Schematic representation of ISE-based assays used to investigate the
mechanism of anion transport of receptors 1-4 a) Cl-/NO3- antiport, b) and c) cationophore
coupled-KCl, valinomycin and monensin to measure the Cl- uniport and M+/Cl+ transport,
respectively.
100

DMSO
6.1 (0.10 mol%)
6.2 (0.05 mol%)
6.3 (0.05 mol%)
6.4 (0.05 mol%)

Chloride efflux (%)

80
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Time / s

Figure 6.5: Chloride efflux achieved by transporters 6.1–6.4 (0.10 mol% for transporter
6.1 and 0.05 mol% for transporters 6.2-6.4) from unilamellar POPC vesicles containing
489 mM KCl buffered to pH 7.2 with 5 mM potassium phosphate salts, suspended in 489
mM KNO3 buffered to pH 7.2 with 5 mM phosphate salts. At the endpoint of each
experiment (300 s), the detergent was added to lyse the vesicles and calibrate the electrode
to 100% chloride efflux. Each point represents the average of at least two trials.

If the anionphore couples to both cationophores it can unfacilitate either chloride
or HCl transport (Figure 6.4). Compounds 6.4-6.4 were found to be highly efficient
electroneutral H+/Cl- co-transporters (Figure 6.6), while transporter 6.1 is less
selective and can also function as a chloride uniporter. The selectivity for HCl cotransport may be the result of the high affinity of the bis-urea motif for phosphate
resulting in strong phospholipid headgroup interactions (which is presumably lower
for transporter 6.1 which lacks electron withdrawing substituents).24
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Figure 6.6: Chloride efflux achieved by transporter 6.3 at 0.05 mol% (rtl) in the absence
or presence of cationophores (monensin or valinomycin) monitored over a period of 5 min.
POPC vesicles are loaded with 300 mM KCl with 5 mM phosphate salts (pH 7.2) and
suspended in a 300 mM potassium gluconate solution with 5 mM phosphate salts (pH 7.2).
Electrogenic K+ transport by valinomycin can only occur if it is balanced by electrogenic
Cl– transport by 6.3. Electroneutral K+/H+ antiport by monensin can only occur if the pH
gradient is dissipated by electroneutral H+/Cl– transport by 6.3.

To further determine the ion transport activity and selectivity of the coumarinbisurea derivatives 6.1-6.4, different conditions were applied using 8hydroxypyrene-1,3,6-trisulfonic acid (HPTS) assay (Figure 6.7).16 The HPTS-KCl
assays measures the activity of anion transporters in facilitating H+/Cl- cotransport
leading to dissipation of pH gradients (Figure 6.7a). The unsubstituted bisureabased fluorescent receptor 6.1 was found to have the lowest activity in HPTS-KCl
(Figure 6.7a) with EC50 = 3.8 x 10-2 mol% (Figure 6.8, Table 6.2). Appending
electron withdrawing groups increased the ability to dissipate the pH gradient, with
EC50 = 5.1 - 9.7 x 10-4 mol% (Figure 6.8, Table 6.2).
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Figure 6.7: Schematic representation of the HPTS-based assays used in the current study
a) H+/Cl- symport or OH-/Cl- antiport b) the presence of cccp (protonophore) to asses Cluniport c) the presence of valinomycin to measure the proton flux d) the effect of fatty
acid presence as a fuel on the transport.
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Figure 6.8: H+/Cl- symport or OH-/Cl- antiport facilitated by compounds 6.1-6.4 (0.02
mol% (rtl) for transporter 6.1 and 0.002 mol% (rtl) for transporters 6.2-6.4 from unilamellar
POPC vesicles loaded with 100 mM KCl buffered to pH 7.0 with 10 mM HEPES buffer
and 1 mM HPTS internal sensor. The vesicles were suspended in an external solution of
100 mM KCl buffered to pH 7.0 with 10 mM HEPES buffer and a base pulse of KOH (25
μL, 0.5 M) was added to generate a transmembrane pH gradient. At the endpoint of each
experiment (200 s), the detergent was added to lyse the vesicles and collapse the pH
gradient for calibration of HPTS fluorescence.
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The addition of the K+ transporter valinomycin or proton transporter CCCP did not
significantly affect the transport rates of 6.1-6.4 in the HPTS assay, consistent with
the inability of these compounds to facilitate uniport processes (Figures 6.7b, 6.9).
The transport of fatty acid carboxylates across lipid bilayer membranes by
anionophores can result in pH dissipation across the bilayer as the transported
carboxylate protonates and then diffuses back across the bilayer and deprotonates.
We used oleic acid (1 mol%) (as a source of fatty acid) and BSA (bovine serum
albumin) to sequester fatty acids from liposomes in HPTS-KCl (HCl symport) to
investigate whether the fatty acids could play a role in the pH dissipation facilitated
by receptors 6.1-6.4 (Figure 6.7c-d, Figure 6.9).
The addition of fatty acid lowered the transport activity of tested compounds 6.16.4, which is presumably due to their ability to bind to the carboxylate headgroups
as reported11 and thus lowering the chloride transport activity. BSA-treated
liposomes were used to remove all fatty acids from the HPTS-KCl liposomes
(Figure 6.9). Transport activity of the fluorescent receptors 6.1-6.3 was not affected
by the fatty acid removal, suggesting that these transporters independently could
transport HCl or proton. However, transporter 6.4 showed an increase in the pH
dissipation which might indicate that the activity of this particular receptor is
greatly compromised by the presence of fatty acids (Figure 6.9).
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Figure 6.9: Using the KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied including using
BSA-treated lipid (to test if the transport is fatty acid dependent) addition of oleic acid at
1 mol% (as a source of fatty acid), addition of the protonphore cccp at 1 mol% (to measure
of chloride uniport solely), or addition of valinomycin at 0.05 mol% (as a measure of H +
flux), on the rate of chloride transport of receptor 6.3 (0.001 mol%).

6.3 Conclusions
We designed and synthesized a series of novel bisureas-anion transporters bearing
the fluorescent 4-methyl coumarin. The fluorescent anion receptors were tested for
their anion binding properties in solution and elicited a relatively strong chloride
binding affinity in DMSO-d6/0.5%H2O with Ka = 81 - 177 M-1. These receptors
showed a superior Cl-/NO3- exchange ability in ISE-based affinity and H+/Clcotransport activity than the previously reported fluorescent anion transporters.

6.4 Experimental section
6.4.1

Chemistry

General methods and material
All reagents and solvents were purified and dried by standard techniques. Reactions
were monitored by TLC analysis using silica gel GF/UV 254. NMR spectra were
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recorded on Bruker 400 MHz FT-NMR spectrometer and Varian Gemini-300BB
300 MHz FT-NMR spectrometers (Varian Inc., Palo Alto, CA). 1H spectra were
run at 300 and 400 MHz and 13C spectra were run at 75 and 101 MHz, in the stated
solvent. Chemical shifts (δH) are reported relative to TMS as internal standard and
coupling constant (J) values are reported in Hertz. The abbreviations used are as
follows: s, singlet; d, doublet; t, triplet; m, multiplet. Electrospray ionization (ESI
single quadrupole) mass spectra have their ion mass to charge values (m/z). Peaks
assigned to the molecular ion are denoted as [M+H] or [M+Na]. Column
chromatography was performed using silica gel 60 (0.063-0.200 mm). Low
resolution mass spectra (LRMS) and high-resolution mass spectra (HRMS) were
recorded

using

positive/negative

ion

electrospray

ionization

(ESI)

on

Bruker amaZon SL mass spectrometer.

Ethyl (3-hydroxyphenyl)carbamate (6.6):20 To a suspension of m-aminophenol
(10.0 g, 92.0 mmol) in diethyl ether (400 mL), ethyl chloroformate (10.0 g, 92.0
mmol) was added at once and a white precipitate appeared immediately. The
reaction mixture was stirred for 2 h and the resulting salt was removed by
filteration, while the solvent was removed under vacuum to give 8 g of white solid
which was used in the next step without any further purification.20

Ethyl (4-methyl-2-oxo-2H-chromen-7-yl)carbamate (6.7):20 To a mixture of
ethyl (3-hydroxyphenyl)carbamate 6.6 (8.0 g, 44.0 mmol) and ethyl acetoacetate
(6.8 mL, 53.0 mmol), 100 mL of 70% H2SO4 was added. The reaction mixture was
stirred for 4 h at room temperature. The resulting solid was collected by filteration,
washed with water (2 x 30 mL) and recrystallized from ethanol to give 6.7 (8.2 g,
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75%) as colourless needles. 1H NMR (400 MHz, DMSO-d6) δ: 1.40 (t, J = 7.0 Hz,
3H, CH2CH3), 2.50 (s, 3H, CH3), 4.31 (q, J = 7.0 Hz, 2H, CH2CH3), 6.32 (s, 1H,
ArH), 7.51 (dd, J = 2.0, 9.0 Hz, 1H, ArH), 7.65 (d, J = 2.0 Hz, 1H, ArH), 7.77 (d,
J = 9.0 Hz, 1H, ArH), 10.24 (s, 1H, NH); 13C NMR (101 MHz, DMSO-d6) δ: 14.9,
18.4, 61.1, 104.8, 112.3, 114.6, 114.7, 126.3, 143.3, 153.6, 153.8, 154.3,160.5.

Ethyl (4-methyl-6-nitro-2-oxo-2H-chromen-7-yl)carbamate (6.8):21 To a
suspension of 7-carbethoxyamino-4-methylcoumarin 6.7 (4.1 g, 16.6 mmol) in
acetic anhydride (100 mL), aluminium nitrate nonahydrate (5.6 g, 6.5 mmol) was
added portionwise and the reaction mixture was stirred for 16 h. The mixture was
slowly poured into ice cold water (200 mL) and the resulting yellow residue was
purified via flash chromatography (hexane: ethyl acetate = 9:1) to give 6.8 (1.7 g,
36%). 1H NMR (500 MHz, DMSO-d6) δ: 1.27 (t, J = 7.0 Hz, 3H, CH2CH3), 2.45
(s, 3H, CH3), 4.18 (q, J = 7.0 Hz, 2H, CH2CH3), 6.46 (s, 1H, ArH), 7.72 (s, 1H,
ArH), 8.35 (s, 1H, ArH), 10.10 (s, 1H, NH);

13

C NMR (126 MHz, DMSO-d6) δ:

14.7, 18.3, 62.2, 109.9, 114.9, 115.7, 123.9, 136.1, 136.9, 152.8, 153.5, 156.3,
159.3; LRMS ESI- (m/z): 291 (100%, M-H)-.

7-Amino-4-methyl-6-nitro-2H-chromen-2-one

(6.9):21

6-Nitro-7-

carbethoxyamino-4-methylcoumarin 7 (1.7 g, 5.8 mmol) was heated at reflux in a
mixture of concentrated sulfuric acid (6 g) and glacial acetic acid (6 g) for 4 h. After
cooling the reaction mixture, was poured into ice water (30 mL) and let stand
overnight. Ice was added, and neutralization of the acidic solution was
accomplished using NaOH (50%). The formed yellow precipitate was filtered,
washed thoroughly 3 times with ice water (3 x 10 mL) and dried to give 6.9 (1.0 g,
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80%) as a yellow powder. 1H NMR (400 MHz, DMSO-d6) δ: 2.38 (s, 3H, CH3),
6.18 (s, 1H, ArH), 6.81 (s, 1H, ArH), 7.80 (br. s, 2H, NH2), 8.33 (s, 1H, ArH); 13C
NMR (101 MHz, DMSO-d6) δ: 18.2, 103.3, 110.4, 111.6, 124.9, 128.8, 148.6,
153.4, 157.6, 159.7. LRMS ESI- (m/z): 219 (100%, M-H)-.

6,7-Diamino-4-methyl-2H-chromen-2-one (6.10):21 Conc. hydrochloric acid (15
mL) was added in three portions over 20 minutes to a mixture of tin powder (1.1 g,
9.2 mmol) and 6-nitro-7-amino-4-methyl-coumarin 6.9 (1 g, 4.5 mmol) and the
reaction mixture was heated at reflux for 3 h. After cooling, the reaction mixture
was poured into ice water (50 mL) and let stand overnight. Ice was added, and
neutralization of the acidic solution was accomplished using NaOH (50%). The
formed precipitate was extracted with ethyl acetate (3 x 200 mL) and all the organic
layers washed with water (2 x 10 mL), brine (1 x 10 mL) and dried over magnesium
sulfate. Ethyl acetate was removed under vacuum to give 6.10 (0.31 g, 36%) as a
dark yellow powder.1H NMR (300 MHz, DMSO-d6) δ: 2.26 (s, 3H, CH3), 4.72 (br.
s, 2H, NH2), 5.63 (br. s, 2H, NH2), 5.87 (s, 1H, ArH), 6.44 (s, 1H, ArH), 6.76 (s,
1H, ArH); 13C NMR (75 MHz, DMSO-d6) δ: 18.1, 99.0, 107.1, 107.6, 109.2, 131.9,
141.3, 148.1, 153.1, 161.1. LRMS ESI- (m/z): 191 (100%, M-H)-. HRMS (ESI+)
calcd for C10H10N2NaO2 (M + Na+): 213.0635, found: 213.0634.

Synthesis of target compounds 6.1-6.4:
General procedure A:
6,7-Diamino-4-methylcoumarin 6.10 (80 mg, 0.42 mmol) was suspended in
CH2Cl2 and added dropwise to the corresponding isocyanate derivative solution
with stirring. The suspension was stirred at 45 °C overnight and after cooling the
solvent removed under vacuum. The resulting residue was heated in ethanol (25
162

Chapter 6

Fluorescent anion transporters

mL) and filtered while hot to give anion transporters 6.1, 6.2 and 6.4.
Procedure B:
Under inert atmosphere, 4-(trifluoromethyl)phenyl isocyanate (0.79 g, 4.2 mmol)
was added to 6,7-diamino-4-methylcoumarin 6.10 (80 mg, 0.42 mmol) with
constant stirring. The reaction mixture was held at 45 °C overnight and after cooling
the unreacted 4-trifluoromethylphenyl isocyanate was removed under vacuum and
the remaining residue was heated in ethanol (25 mL) and filtered while hot to give
6.3 as white solid.

1,1'-(4-Methyl-2-oxo-2H-chromene-6,7-diyl)bis(3-phenylurea) (6.1): Using the
general procedure A and phenyl isocyanate (200 mg, 1.68 mmol), compound 6.1
(70 mg, 39%) was isolated as a white solid; m.p: > 300 °C. 1H NMR (400 MHz,
DMF-d7) δ: 2.40 (s, 3H, CH3), 6.22 (s, 1H, ArH), 6.97 (q, J = 7.0 Hz, 2H, ArH),
7.27 (t, J = 7.0 Hz, 4H, ArH), 7.50-7.57 (m, 4H, ArH) 7.79 (s, 1H, ArH), 8.07 (s,
1H, ArH), 8.18 (s, 1H, NH), 8.68 (s, 1H, NH), 9.06 (s, 1H, NH), 9.46 (s, 1H, NH);
13

C NMR (101 MHz, DMF-d7) δ: 17.8, 107.3, 112.6, 114.6, 118.5, 118.7, 122.1,

122.5, 123.3, 125.2, 129.0, 129.1, 139.5, 140.1, 140.7, 152.1, 152.9, 153.2, 160.6.
LRMS ESI- (m/z): 427 (100%, M-H)-. HRMS (ESI-) calcd for C24H19N4O4 (M-H)-:
427.1412, found: 427.1412.

1,1'-(4-Methyl-2-oxo-2H-chromene-6,7-diyl)bis(3-(4-cyanophenyl)urea) (6.2):
Using the general procedure A and p-cyanophenyl isocyanate (242 mg, 1.68
mmol), compound 6.2 (106 mg, 53%) was isolated as a buff solid; m.p: 295-297
°C. 1H NMR (500 MHz, DMSO-d6) δ: 2.39 (s, 3H, CH3), 6.29 (s, 1H, ArH), 7.647.77 (m, 9H, ArH), 8.02 (s, 1H, ArH), 8.25 (s, 1H, NH), 8.65 (s, 1H, NH), 9.57 (s,
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1H, NH), 9.91 (s, 1H, NH); 13C NMR (126 MHz, DMSO-d6) δ: 18.5, 103.8, 104.2,
107.7, 113.1, 114.9, 118.6, 118.7, 119.7, 119.8, 123.7, 124.7, 133.8, 133.9, 138.5,
144.1, 144.8, 151.7, 152.4, 153.4, 154.0, 160.0. LRMS ESI- (m/z): 513 (100%,
M+Cl)-. HRMS (ESI+) calcd for C26H18N6O4Na (M+Na)+: 501.1282, found:
501.1287.

1,1'-(4-Methyl-2-oxo-2H-chromene-6,7-diyl)bis(3-(4-(trifluoromethyl)
phenyl)urea) (6.3): Using the procedure B and p-(trifluoromethyl)phenyl
isocyanate (0.79 g, 4.2 mmol), compound 6.3 (53 mg, 22%) was isolated as white
solid; m.p: > 300 °C. 1H NMR (400 MHz, DMF-d7) δ: 2.64 (s, 3H, CH3), 6.48 (s,
1H, ArH), 7.87 (d, J = 9.0 Hz, 4H, ArH), 7.95-8.05 (m, 4H, ArH), 8.21 (s, 1H,
ArH), 8.40 (s, 1H, ArH), 8.51 (s, 1H, NH), 9.03 (s, 1H, NH), 9.79 (s, 1H, NH),
10.06 (s, 1H, NH);

13

C NMR (101 MHz, DMF-d7) δ: 17.8, 107.6, 112.9, 115.0,

118.4, 118.5, 122.6, 122.9, 123.0 123.3, 123.5, 123.7, 125.0, 126.4, 139.0, 143.7,
144.3, 152.1, 152.7, 153.2, 154.3, 160.5; 19F (376 MHz, DMF-d7) δ: -60.03, -60.15.
LRMS ESI- (m/z): 563 (100%, M-H)-. HRMS (ESI-) calcd for C26H17F6N4O4 (MH)-: 563.1160, found: 563.1160.

1,1'-(4-Methyl-2-oxo-2H-chromene-6,7-diyl)bis(3-(3,5bis(trifluoromethyl)
phenyl)urea)

(6.4):

Using

the

general

procedure

A

and

3,5-

bis(trifluoromethyl)phenyl isocyanate (428 mg, 1.68 mmol), compound 6.4 (78
mg, 27%) was isolated as a buff solid; m.p: > 300 °C. 1H NMR (400 MHz, DMFd7) δ: 2.49 (s, 3H, CH3), 6.31 (s, 1H, ArH), 7.68 (s, 1H, ArH), 7.71 (s, 1H, ArH),
8.05 (d, J = 7.0 Hz, 4H, ArH), 8.23-8.26 (m, 4H, ArH), 8.99 (s, 1H, NH), 9.41 (s,
1H, NH), 10.54 (s, 1H, NH), 10.80 (s, 1H, NH); 13C NMR (101 MHz, DMF-d7) δ:
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17.7, 107.1, 112.8, 114.7, 117.8, 119.7, 121.6, 122.35, 122.41, 124.5, 125.1,
127.77, 127.82, 131.4, 137.1, 142.1, 142.7, 151.4, 152.6, 153.1, 153.8, 160.3; 19F
(376 MHz, DMF-d7) δ: -61.36, -61.44. LRMS ESI+ (m/z): 723 (100%, M+Na)+.
HRMS (ESI+) calcd for C28H16F12N4O4Na (M+Na)+: 723.0872, found: 723.0875.

6.4.2

X-ray crystallography of compound 6.1

Single crystals of transporter 6.1 C26H26N4O5 were crystallised from a mixture of
dimethylformamide and ethanol. A suitable crystal was selected and in Paratone on
a micromount on a SuperNova, Dual, Cu at home/near, Atlas diffractometer. The
crystal was kept at 100 K during data collection. Using Olex225, the structure was
solved with the ShelXS26 structure solution program using Direct Methods and
refined with the ShelXL27 refinement package using Least Squares minimization.

Crystal Data for C26H26N4O5 (M =474.51 g/mol): monoclinic, space group P2/c
(no. 13), a = 28.2772(10) Å, b = 11.1135(9) Å, c = 7.9823(3) Å, β = 90.234(4)°,
V = 2508.5(2) Å3, Z = 4, T = 100(2) K, μ(Cu Kα) = 0.728 mm-1, Dcalc =
1.256 g/cm3, 19257 reflections measured (7.956° ≤ 2Θ ≤ 145.31°), 4894 unique
(Rint = 0.0918, Rsigma = 0.0957) which were used in all calculations. The final R1
was 0.0661 (I > 2σ(I)) and wR2 was 0.2088 (all data).

6.4.3

1

H NMR titration binding studies with TBACl

Proton NMR titrations binding studies were performed on Bruker 400 MHz FTNMR spectrometer at 298 K. Solution of receptors 6.1-6.4 in DMSO-d6/0.5% H2O
were prepared in 2 mM concentrations. The guest anion, tetra-n-butylammonium
(TBA) chloride, was prepared with the same receptor solution, to ensure the overall
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receptor concentration stays constant whilst the guest anion concentration changes.
Using small aliquots of the guest salt, the receptor solution was titrated, and after
each addition, chemical shifts were reported in ppm in refence to residual solvent
peaks. The isotherm based on the four NH chemical shifts were globally fitted using
the online fitting program Bindfit.28
6.4.4
6.4.4.1

Anion transport studies:
Ion selective electrode (ISE) assays

a) Cl/NO3 exchange assay:
Unilamellar vesicles were prepared as reported.15, 29, 30 Briefly, ~ 30 mg of POPC
(1-palmitoyl-2-oleoylphosphatidylcholine) was dissolved in 1 mL chloroform in a
round-bottomed flask and the solvent was removed in vacuo to form a thin lipid
layer. The thin film was dried under high vacuum for at least 6 h and was suspended
on the internal solution (4 mL) and vortexed using a lab dancer to form large
multilamellar vesicles, which was subjected to nine freeze-thaw cycles alternating
between water (at room temperature) and liquid nitrogen. Further, the formed lipid
was left to rest for 30 minutes and then subjected to extrusion through a 200 nm
polycarbonate membranes 25 times to form the unilamellar vesicles. The formed
vesicles were subjected to dialysis for 4 h in the desired external solution to remove
any unencapsulated internal salts. Finally, using the required external solution, the
lipid was diluted to 1.0 mM. The pH of the internal and external solutions was
maintained at 7.2 using phosphate buffer with a 500 mM total ionic strength. Test
compound in DMSO (10 μL) was added to start the experiment and chloride
selective electrode was used to monitor the chloride efflux. Detergent (50 μL) was
added after 300 seconds to lyse the vesicles, while the 100% chloride efflux reading
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was taken at 420 seconds.
Hill plots for Cl/NO3:
Hill plots were performed for Cl/NO3 exchange assay by conducting transport assay
at different concentrations of tested compounds. Receptor concentration vs chloride
efflux at 270 s (the endpoint of transport assay) were plotted and fitted to the Hill
equation using Origin 2019b:
𝑦 = 𝑉𝑚𝑎𝑥

𝑥𝑛
𝑥𝑛
=
100%
𝑘𝑛 + 𝑥𝑛
(𝐸𝐶50 )𝑛 + 𝑥 𝑛

Where y is the chloride efflux at 270 s (%) and x is the tested compound
concentration (mol% relative to lipid concentration)

Vmax is the maximum efflux possible and considered as 100% as this is
experimentally the maximum chloride efflux possible.
k (EC50 value) is the carrier concentration needed to reach Vmax/2.
Each data point on each Hill plot are an average of at least two repeated runs. Error
bars represent standard deviation about the mean.
b) KCl efflux – cationohore coupling:
In this assay, 300 mM total ionic strength of both K gluconate external solution and
KCl internal solution were marinated. The vesicles were made in a similar way to
Cl/NO3 exchange assay except that gel filtration, using sephadex, replaced dialysis
to allow exchange of any unencapsulated KCl for KGlu. External KGlu solution
(10 mL) was used to dilute the lipid solution obtained after sephadex to obtain a
lipid stock of known concentration. A cationohore, monensin or valinomycin, (10
μL, 0.5 mM) was added first to the lipid solution at concentration 0.1 mol% with
respect to lipid concentration. Then, receptor was added after 30 seconds of the
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cationohore addition to start the experiment.
6.4.4.2

General preparation for HPTS assays

Base-pulse 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt (HPTS) assays
were conducted using unilamellar 1-palmitoyl-2-oleoylphosphatidylcholine
vesicles (POPC) with a mean diameter of 200 nm loaded with the pH sensitive
fluorescence dye HPTS (1 mM).15, 29, 30 A chloroform solution of POPC (~ 30
mg/mL) was evaporated under vacuum and dried for at least 6 h. The thin film was
hydrated by the internal solution containing HPTS (1 mM) and was was subjected
to nine freeze-thaw cycles followed by extrusion 25 times through a 200 nm
polycarbonate membrane. Size exclusion chromatography using sephadex G-25
column and HPTS-free external solution as an eluent was conducted to remove
unentrapped HPTS from the vesicles` solution. The internal and external solutions
used were identical salt solution potassium chloride KCl (100 mM) buffered with
10 mM HEPES at pH 7.0. Finally, for each measurement, external solution (KCl)
was used to dilute the lipid stock to obtain 2.5 mL lipid suspension containing 0.1
mM lipid. A base pulse of KOH (25 μL, 0.5 M) at a final concentration 5 mM was
added to generate a transmembrane pH gradient. After the tested receptors were
added, HPTS fluorescence ratio (λex = 460 nm, λem = 510 nm divided by λex = 403
nm, λem = 510 nm) was recorded. Assisting ionophore (carbonyl cyanide
phenylhydrazone (CCCP) or valinomycin) was used as a 5 μL DMSO. Bovine
serum albumins (BSA) was added to vesicles at 1 mol% (with respect to lipid) and
allowed to stir for 30 minutes to test if the transport is fatty acid independent, while,
oleic acid (1 mol%) was used as a source of fatty acid to test if the transport is fatty
acid dependent. Detergent (25 μL) was added at 200 seconds to destroy the pH
gradient to calibrate the assay.
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Results are the average of at least three repeats and the fractional fluorescence
intensity (If) was determined using the following formula:
𝐼𝑓 =

𝑅𝑡 − 𝑅0
𝑅𝑑 − 𝑅0

Where
-

Rt is the fluorescence ratio at time t.

-

R0 is the fluorescence ratio at time 0

-

Rd is the fluorescence ratio after detergent addition.

Hill plots were determined for KCl transport assay by conducting transport assays
at different tested receptors concentrations. Receptor concentration vs fractional
fluorescence intensity If at 200 s (the endpoint of transport assay) were plotted and
fitted to the Hill equation using Origin 2019b:

The following formula was used to calculate Hill coefficients (n) and EC50 (200 s)
values by fitting the curves to the following equation:
𝑦 = 𝑦0 + (𝑦𝑚𝑎𝑥 − 𝑦0 )

𝑥𝑛
𝑘𝑛 + 𝑥𝑛

Where:
-

y is If (200 s) value of the ionophore at concentration x (receptors concentration
is expressed as ionophore to lipid molar ratio).

-

y0 is If value at 200 s, without addition of the ionophore.

-

ymax is the maximum If value.
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-

n is the Hill coefficient, and K is the EC50 (200 s) value.
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impact factor 6.054). This paper describes the design and synthesis of three dualtailed sulfonamide series as potent carbonic anhydrase inhibitors. All compounds
were evaluated for inhibitory action against pharmacologically relevant human (h)
CAs isoforms I, II, IV, and VII and showed a significant selectivity to CA II, which
is implicated in glaucoma. X-ray crystallographic analysis of three compounds
bound to CA II showed the validity of the adopted drug design strategy as specific
moieties within in the ligand structure interacted directly with the hydrophobic and
hydrophilic halves of the CA II active site. Four compounds were evaluated for
their intraocular pressure (IOP) lowering effects in a rabbit model of the glaucoma
and two of them showed significant efficacy when compared to the clinically used
drug dorzolamide. Supporting information to this chapter can be found in Appendix
F (p. 343).
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7.1 Introduction
Glaucoma is an optic neuropathy disease that affects more than 64 million people
worldwide and is implicated with 5 million instances of blindness which accounts
for 12% of blindness, globally.1,

2

Despite profound advances in the area, the

understanding of the primary causes of glaucoma is still not complete.1 Glaucoma
is categorized into two major classes according to the anatomic configuration of the
aqueous humor, namely open angle glaucoma (OAG), which is prevalent in Europe
and Africa and angle-closure glaucoma (CAG), which mainly affects Asian
countries.2 Risk factors of OAG are age-related and are associated with high intra
ocular pressure (IOP) and thin central cornea.3
Current approaches used in the clinic to manage OAG mainly include IOP lowering
drugs and surgery. There are fundamentally five drug classes used to lower IOP,
namely, carbonic anhydrase inhibitors, cholinomimetics, sympathomimetic, βblockers and prostaglandin analogues.4 Limitations in determining IOP reduction
in vitro make common drug discovery approaches such as cell-based assay or high
throughput screening not useful to assess the drop in IOP.1 Whilst some promising
candidates are under clinical trials as anti-glaucoma agents, the development of
new, safe and effective glaucoma drugs is in high demand.1
Carbonic anhydrases (CA, EC 4.2.1.1) constitute a superfamily of ubiquitous
metalloenzymes which principally act as catalysts in the CO2 hydration reaction.
The 15 isoforms identified in human belong to the α-class of the 8 genetically
diverse families of CA discovered to date (α-, β-, γ-, δ-, ζ-, η-, θ- and ι-CAs). These
15 isozymes differ in multiple factors including catalytic activity, structural fold,
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tissue and subcellular localization and response to different kinds of modulators.510

Abnormal expression of hCAs isoforms such as II and IV were detected in

glaucoma.7, 10, 11
Great effort has been made in the design and synthesis of selective CA inhibitors
(CAI) with anti-glaucoma activity. Primary sulfonamides such as acetazolamide
(7.1, AAZ) (Figure 7.1) have been clinically used for almost 70 years as systemic
anti-glaucoma agents despite a range of side effects due to the lack of enzymatic
selectivity.9 The second generation antiglaucoma drugs, such as dorzolamide (7.2,
DRZ) and brinzolamide (7.1, BRZ) (Figure 7.1), act topically thus leading to a
significant side effects reduction.12 They contain an amino group which can be
converted to a HCl salt, conferring better water solubility.

Figure 7.1: Structures of clinically used CAIs and other inhibitors derived from
sulfanilamide (SA).
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The design and development of selective CAI is challenging. Many strategies have
been adopted including the widely used ring and tail approaches.12-14 CA inhibitors
such as AAZ (7.1), DRZ (7.2) and BRZ (7.3) are examples of the ring approach,
in which a primary sulfonamide group is attached to varied types of main aromatic
rings (Figure 7.1).12 In the tail approach, a variety of molecular tails are attached to
the scaffold bearing the zinc binding group to confer better physicochemical
properties, such as increased water solubility, or to tune the inhibition profiles
against the target CAs by interaction with the most diverse section of the CA active
site, the medium-outer portion.16-19 Sulfanilamide (7.4, Figure 7.1), clinically used
as an antibacterial, has been the lead CA inhibitor in many drug-design strategies
whereby a variety of tail functionalities were used, such as tosylureido (ts-SA, 7.5),
cyanoamide (CA-SA, 7.7), or dual-tailed arylsulfone (SO-SA, 7.6) (Figure 7.1).15,16

7.2 Results and discussion
7.2.1

Drug design and chemistry

In the current study, a new class of 3-oxo-N-(4-sulfamoylphenyl)butanamides was
proposed based on the dual tail approach (Figure 7.2). Considering the
benzenesulfonamide as zinc-binding motif (orange in Figure 7.2), aryl groups were
included in the derivatives tails to interact with the CA hydrophobic region (red in
Figure 7.2), whereas H-bonds acceptor moieties were included for the interactions
with Gln and Asn residues present in the hydrophilic half of the active site (blue in
Figure 7.2).
The synthesized compounds were thus investigated for their inhibitory effect
against the cytosolic isoforms hCA I, II and VII and the transmembrane hCA IV.
The best inhibitors in terms of potency and selectivity against the CAs implicated
175

Carbonic anhydrase inhibitors Chapter 7

in glaucoma were assessed in vivo for their IOP lowering action using DRZ as a
standard. Evidence for the mode of binding of these dual tailed sulfonamides to
hCA II was achieved at the molecular level by X-ray crystallographic analysis with
three of the most potent CA II inhibitors.

Figure 7.2: Design of dual-tailed sulfonamides targeting hCAs. The molecular surface of
hydrophobic and hydrophilic halves of the CA active site are coloured in red and blue,
respectively. The Zn(II) ion is represented as an orange sphere (pdb 1CA2).

The key intermediate 7.9 was synthesized by reacting sulfanilamide 7.4 with ethyl
acetoacetate 7.8 (Scheme 7.1).17 Knoevenagel condensation of acetoacetanilide 7.9
with the aldehydes in the presence of catalytic piperidine and acetic acid afforded
7.10-7.16 derivatives in yields of 30-62% (Scheme 7.1).
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Scheme 7.1: Reagents and conditions: a) neat reaction, reflux, 15 min; b) MS 4 Å,
piperidine, acetic acid, ethanol, RT, 8 h; c) NaNO2/HCl, 0 °C; d) sodium acetate trihydrate,
ethanol, 0 °C; e) SO2Cl2, 0 °C, 1 h then RT for 4 h.

In a typical example, analysis of the 1H NMR and 13C NMR spectra of 7.13 revealed
the disappearance of the resonances at 3.60 ppm and 52.8 ppm, respectively,
assigned to the methylene group in 7.9, indicating the formation of arylidene 7.13.
The 1H NMR spectrum showed two singlets at 2.37 and 3.70 ppm, assigned to CH3
and OCH3, respectively. The arylidene H was assigned to the singlet at δ 7.61. The
protons ortho to the methoxy group in the aryl substituent were assigned the
resonance at 6.83 ppm, while the protons meta to the methoxy group were assigned
to the resonance at 7.49 ppm. The p-sulfamoyl aryl substituents were assigned to
the two doublets at 7.70 ppm (meta to the sulfamoyl group) and 7.77 ppm (ortho to
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the sulfamoyl group). The halogenated derivative 7.25 was synthesized by
chlorination of the key intermediate 7.9 using sulfuryl chloride (Scheme 7.1).18
Access to derivatives of the type 7.17-7.24 and 7.26-7.30 was accomplished via
classic

Japp-Klingemann

sulfamoylphenyl)butanamide

coupling
7.9

reaction
and

of

3-oxo-N-(4-

2-chloro-3-oxo-N-(4-

sulfamoylphenyl)butanamide 7.25, respectively with diazonium salts in the
presence of sodium acetate trihydrate and ethanol (Scheme 7.1).19 Analysis of the
1

H NMR spectra of 7.17-7.24 and 7.26-7.30 showed the disappearance of the

resonances at ~3.60 and 5.42 ppm assigned to the methylene and methane in 7.9,
respectively. It should be mentioned that derivatives 7.26-7.30 may react nonspecifically with nucleophiles present in biomolecules due to the presence of an
activated chlorine atom, although we did not see this behavior with CAs.

7.2.2

Carbonic anhydrase inhibition

Compounds 7.9, 7.10-7.16, 7.17-7.24 and 7.26-7.30 were evaluated for their
inhibition against the cytosolic CA I, II and VII and the membrane-bound CA IV
using a stopped-flow CO2 hydrase assay method.20 The clinically used
acetazolamide (7.1, AAZ) was used as the standard in the kinetic evaluation.
The ubiquitous CA I was inhibited efficiently by compounds 7.9 and 7.10-7.16 with
inhibition constants (Ki values) spanning a narrow range between 7.3 and 75.5 nM
with the 2-chlorophenyl derivative 7.12 showing the best activity with a Ki value
of 7.3 nM against CA I. An inhibition decline was observed for compounds of
subset 7.17-7.24 and 7.26-7.30, with the exception of 7.17, 7.24, 7.28 and 7.30
whose Ki values spanned the range 44.1-86.1 nM (Table 7.1).
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Table 7.1: Inhibition data of compounds 7.9, 7.10-7.16, 7.17-7.24 and 7.26-7.30
against isoforms hCA I, II, IV and VII by a stopped-flow CO2 hydrase assay.20

Cmp
7.9
7.10
7.11
7.12
7.13
7.14
7.15
7.16
7.17
7.18
7.19
7.20
7.21
7.22
7.23
7.24
7.26
7.27
7.28
7.29
7.30
AAZ
DRZ
BRZ
a

R

Ar

H
C6H5
4-ClC6H4
2-ClC6H4
4-OCH3C6H4
3-NO2C6H4
2-Cl-4-F-C6H4
2-thienyl
COCH3
C6H5
COCH3
4-FC6H4
COCH3
4-ClC6H4
COCH3
4-BrC6H4
COCH3
4-CNC6H4
COCH3
4-OCH3C6H4
COCH3
3-NO2C6H4
COCH3 3,4-diOCH3C6H3
Cl
C6H5
Cl
4-FC6H4
Cl
4-ClC6H4
Cl
4-BrC6H4
Cl
4-OCH3C6H3
-

CA I
69.2±5.5
68.7±3.9
41.1±1.8
7.3±0.61
15.3±1.2
75.5±5.0
52.7±3.9
49.1±4.8
82.2±6.4
2669±231
2642±114
>10000
512.9±38
703.7±49
750.6±62
59.3±2.8
227.1±11.6
295.6±14.5
44.1±2.3
925.7±57
86.1±3.3
250±13
>50000
730±24

Ki (nM)a
CA II
CA IV
39.5±1.7 885.3±41
4.4±0.16 957.5±53
0.61±0.02 145.0±7.0
0.36±0.03 382.8±19
0.45±0.02 608.5±26
6.9±0.11 387.0±24
5.6±0.25 222.5±15
2.9±0.10 810.4±63
4.3±.31
>10000
8.1±0.65
>10000
5.2±0.20
>10000
370.5±16
>10000
52.2±1.4
>10000
273.1±13
>10000
71.4±3.9
>10000
5.0±0.14
1477±96
40.6±2.1 7364±124
34.8±1.1 7380±210
3.0±0.24 906.5±64
262.1±17
>10000
21.1±0.93 6415.6±320
25.0±1.1
74.0±4.1
9±0.51
8500±245
3±0.12
3950±341

CA VII
273.1±15
44.4±1.9
4.3±0.14
2.9±0.09
3.1±0.12
46.3±3.0
23.5±1.6
5.3±0.24
647.0±33
3323±159
1690±73
>10000
761.5±54
3589.4±23
8
792.4±55
4.4±0.31
68.1±4.5
46.6±3.0
6.1±0.52
1034.1±76
55.2±3.1
2.5±0.14
3.5±0.13
2.8±0.11

Mean ± SD, from three replicates, by a stopped flow technique.

In contrast, the other derivatives of the two subsets showed inhibition of CA I in
the high nanomolar to low micromolar range (227.1-2669 nM) up to no inhibition
observed below 10 μM for 7.20. Thus, incorporation of halo-substituted phenyl
moieties in the scaffolds 7.17-7.24 and 7.26-7.30 produced a detrimental effect on
the inhibition of CA I.
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The target CA II was potently inhibited by compounds 7.10-7.16 with low to sub
nanomolar Ki values (0.36-6.9 nM) whereas 7.9 showed a Ki of 39.5 nM. Of note
is the subnanomolar CA II inhibition by 7.11-7.13, significantly lower than that of
AAZ (7.1), which endow them with significant potential for the treatment of a
wealth of diseases implicating CA II abnormal levels or activities. More complex
SAR were instead produced with the inhibition data against CA II of compounds
from subsets 7.17-7.24 and 7.26-7.30. While the absence of, or presence of specific
substituents certain substituents (e.g. o-chloro, p-chloro or p-methoxy) on the outer
phenyl ring enabled the compounds to hold a low nanomolar efficacy (Ki values in
the range 3.0-8.1 nM for 7.17-7.19, 7.24 and 7.28), some others led to a drop of
inhibition effectiveness culminating with Ki values of 370.5 and 262.1 nM arising
from the incorporation of a para-bromo substituent in the 7.17-7.24 and 7.26-7.30
scaffolds.
The membrane bound CA IV was the least inhibited isoform here screened by
compounds 7.9, 7.10-7.16, 7.17-7.24 and 7.26-7.30. Whereas compounds 7.9 and
7.10-7.16 retained a submicromolar inhibition with Ki values spanning 145.0 885.3 nM, derivatives from subsets 7.17-7.24 and 7.26-7.30 reported some
micromolar Ki values against CA IV (0.91-7.38 μM), but mostly did not produced
inhibition below 10 μM (7.17-7.22, 7.29).
The cytosolic isoform CA VII, generally defined as a brain-associated isozyme,
was efficiently inhibited by compounds 7.10-7.16, though by an order of magnitude
lower than CA II with Ki values spanning 2.9 - 46.6 nM, with 7.11-7.13 being again
the most potent inhibitors (Ki values of 4.3, 2.9 and 3.1 nM, respectively). Again, a
drop-in inhibition was observed with compounds from subset 7.17-7.24, where Ki
values were in the range 647.0 - >10000 nM, with the exception of the 3,4180
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dimethoxyphenyl derivative 7.24, which held 4.4 nM Ki. In contrast, most
compounds bearing a chloro substituent in place of the acetyl group from subset
7.26-7.30 showed an effective CA VII inhibition in the range 6.1-68.1 nM, except
7.29, the p-Br-phenyl derivative, that displayed a Ki of 1034.1 nM.

7.2.3 Protein X-ray crystallography
To gain insights into the ligand-target interactions driving such intense hCA II
inhibition, the X-ray co-crystallographic analysis of the adducts of hCA II with
7.10, 7.13 and 7.16 was achieved at resolutions of 1.67, 1.32 and 1.48 Å,
respectively (Figure 7.3). The sulfonamide coordination to the Zn(II) is present in
all adducts, as well as the two H-bond networks involving the SO2NH- group and
Thr199. The phenyl ring bearing the sulfonamide moiety of 7.11, 7.13 and 7.16
forms hydrophobic interactions with Val121, Val143 and Leu198. As originally
designed, the carbonyl group of the amide and acetyl moieties are oriented towards
the hydrophilic half of the hCA II active site where they establish H-bond networks.
In detail, the amidic oxo group of 7.11, 7.13 and 7.16 H-bonded to the Gln92 side
chain NH2. In contrast, the oxo-acetyl group of 7.11 and 7.16 are directly H-bonded
to the Asn67 side chain NH2 and by a water-bridge with Asn62, whereas the hCA
II/7.13 adduct possesses a sole water-bridged H-bond between the acetyl group and
Asn67. The outer aromatic ring of 7.11, 7.13 and 7.16 were bound within the
hydrophobic pocket of the hCA II active site by π-alkyl interactions with Leu198,
Pro202, Leu204, Val135 and Phe131, as hypothesized in the drug design phase.
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Figure 7.3: Active site view of the hCA II adduct with A) 7.10 (pdb 6UFB), B)
7.13 (pdb 6UFC) and C) 7.16 (pdb 6UFD). Hydrogen bonds are represented as black
dashed lines.

7.2.4 Anti-glaucoma activity (IOP lowering activity)
The IOP lowering properties of the most potent CA II inhibitors, 7.11-7.13 and
7.16, were assessed in a rabbit model of glaucoma (Figure 7.4). DZA hydrochloride
1% was used as the standard, and control experiments utilised the vehicle (0.9%
NaCl + 0.1% DMSO + 0.1% EtOH). A 1% solution of the compounds were
administered as eye drops to rabbits with high IOP, induced by the injection of 0.05
mL of hypertonic saline solution (5% NaCl in distilled water) into the vitreous of
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both eyes. At 60 min post-instillation compounds 7.11 and 7.13 decreased IOP by
9.0 and 10.0 mmHg, while the standard DRZ was less effective with an IOP
reduction of 8.5 mmHg (Figure 7.4). In contrast, 7.12 and 7.16 produced an IOP
reduction of 6.4 and 7.5 mmHg, respectively. At the 120 min mark after the
administration, 7.11 and 7.13 triggered an even more marked IOP drop to 12.8 and
12.3 mmHg. DRZ retained a comparable action, with the IOP reduction settling at
9.0 mmHg. Derivative 7.16 showed an enhanced efficacy after 120 min postinstillation, with a reduction of 8.9 mmHg, compared to DRZ. In contrast, 7.12
reported a rapid reduction of efficacy (only 3.6 mmHg reduction) 120 min after
post-administration. Oddly, 7.12 uniquely protracted its action after 240 min postinstillation at 2.0 mmHg, whereas the IOP lowering activity of 7.11 and 7.13 settled
at 1.3 and 1.5 mmHg, respectively.

Figure 7.4. Drop of intraocular pressure (ΔIOP, mmHg) versus time (min) in hypertonic
saline-induced ocular hypertension in rabbits, treated with 50 μL of 1% solution of
compounds 7.11-7.13 and 7.16 and DRZ as the standard. Data are analyzed with 2way
Anova followed by Bonferroni multiple comparison test. * p<0.05 7.11, 7.16, DRZ vs
vehicle at 60' and DRZ vs vehicle at 120'; ** p<0.01 7.13 and vs vehicle at 60' and 7.16 vs
vehicle at 120'; **** p<0.001 7.11 and 7.13 vs vehicle at 120'.
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7.3 Conclusions
Three series of dual-tailed sulfonamide CA inhibitors 7.10-7.16, 7.17-7.24 and
7.26-7.30 were designed, synthesized and evaluated for their inhibitory profiles
against four carbonic anhydrase isoforms: hCA I, II, IV, and VII. The tested
compounds showed selectivity to CA II and compounds 7.10-7.16 emerged as the
most potent CA II inhibitors with low to sub nanomolar Ki values (0.36-6.9 nM).
To further understand and rationalize the strong inhibitory profile of the compounds
against CA II, X-ray crystallographic studies were performed which showed
defined moieties within the ligand structures specifically interact with the
hydrophobic and hydrophilic halves of the CA II active site. As CA II up-regulation
is implicated with glaucoma, the most active CA II inhibitors 7.11-7.13 and 7.16
(Ki values of 0.36-2.9 nM) were evaluated for their IOP lowering action against
DRZ as the standard. Compound 7.16 showed a comparable IOP lowering effect
to DRZ (IOP reduction = 8.5 mmHg), while compounds 7.11 and 7.13 were more
potent than DRZ with IOP reduction of 12.8 and 12.3 mmHg, respectively.
Therefore, this study presents compounds 7.11 and 7.13 as potential promising
candidates for the development of therapeutic anti-glaucoma strategies.

7.4

Experimental Protocol

7.4.1

Chemistry

Melting points were measured with a Gallenkamp (Griffin) apparatus and are
uncorrected. Reactions were monitored by TLC analysis using silica gel GF/UV
254 and visualized with UV light. Flash chromatography was performed using
Merck silica gel 60 (70–230 mesh) under positive air pressure. Infrared (IR) spectra
were obtained on a Shimadzu IRAfinity-1 FTIR spectrometer. NMR spectra were
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recorded on Bruker 400 and 500 MHz FT-NMR spectrometers. 1H spectra were run
at 400 and 500 MHz, while 13C spectra were run at 100 and 125 MHz. Chemical
shifts (δH) are reported relative to TMS as the internal standard and coupling
constant (J) values are reported in Hertz. The abbreviations used are as follows: s,
singlet; d, doublet; t, triplet; m, multiplet. All reagents and solvents were purified
and dried by standard techniques. The purity of tested compounds was greater than
95% as determined by HPLC analysis using a Shimadzu CLASS-VP LC10
analytical HPLC system equipped with a Photo Diode Array Detector and
autosampler (see Supporting Information). Low resolution mass spectrometry (MS)
was performed on a Shimadzu LC-2010 Electrospray ionization (ESI) Mass
Spectrometer. Samples were prepared using HPLC grade methanol. The principal
ion peaks m/z values are reported with their relative intensities in parentheses. High
resolution mass spectra (HRMS) were obtained using a Waters Quadrupole-Time
of Flight (Q-Tof) mass spectrometer via ESI with Leucine-Enkephalin as internal
standard. All compounds were screened for PAINS alerts using the SwissADME
server (www.swissadme.ch). Derivatives 7.17-7.24 showed alerts due to imine
functionality, however, these compounds are not the major lead outcomes from this
study and are not taken further. The activity results can still be used in the context
of SAR as an enzyme assay was used, and thus binding results are still valid. It
should be noted that drugs developed in this area are for topical use, and not
systemic use.

3-Oxo-N-(4-sulfamoylphenyl)butanamide (7.9)17, 21
Sulfanilamide 4 (3.44 g, 20 mmol) was added to a boiling ethyl acetoacetate 7.8
(7.77 mL, 61 mmol) and the mixture was heated at reflux for 20 minutes. After
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cooling, HCl 10% (10 mL) was added and the mixture was stirred for 30 minutes,
the solid material filtered out and crystalized from aqueous ethanol to give 7.9 (3.02
g, 59%) as white crystals; m.p. 180 °C (Lit. 183-186 °C).22 The product contains
about 10% of enol form as analysed by 1H NMR. 1H NMR (500 MHz, DMSO-d6)
δ: 2.21 (s, 3H, CH3), 3.60 (s, 2H, CH2), 7.25 (br. s, 2H, NH2), 7.71 (d, J = 9.0 Hz,
2H, ArH), 7.76 (d, J = 9.0 Hz, 2H, ArH), 10.43 (s, 1H, NH). Enol form signals:
1.93 (s, 3H, CH3), 5.23 (s, 1H, =CH), 10.26 (s, 1H, NH), 13.59 (br. s, 1H, OH); 13C
NMR (126 MHz, DMSO-d6): 30.7 (CH3), 52.8 (CH2), 119.1, 127.2, 139.0, 142.2,
166.1, 203.1; MS (ESI-) 255 (100%, M-H)-, 291 (34%, M+Cl); HRMS (ESI-) calcd
for C10H11N2O4S: 255.0440, found 255.0437.

General

procedure

A

for

sulfamoylphenyl)butanamides

preparation
7.10-7.16:

A

of

2-arylidene-3-oxo-N-(4-

suspension

of

3-oxo-N-(4-

sulfamoylphenyl)butanamide 7.9 (256 mg, 1 mmol), the appropriate aldehyde (1
mmol) piperidine (10 µL, 0.1 mmol) and acetic acid (6 µL, 0.1 mmol) in absolute
ethanol (10 mL) and was stirred for 6-8 h at room temperature. The mixture was
slowly poured into brine (20 mL) and extracted with dichloromethane (3 × 10 mL),
dried (anhyd. MgSO4), the solvent removed under reduced pressure, and the
resulting residue purified via flash chromatography (petroleum ether: ethyl acetate
= 5:5) to give 7.10-7.16.

(E)-2-Benzylidene-3-oxo-N-(4-sulfamoylphenyl)butanamide (7.10): Using the
general procedure A and benzaldehyde (106 mg, 1 mmol), compound 7.10 (153
mg, 45%) was isolated as a white solid, m.p. 172 °C. 1H NMR (500 MHz, DMSOd6) δ: 2.47 (s, 3H, CH3), 7.30 (br. s, 2H, NH2), 7.39-7.41 (m, 3H, ArH), 7.42 (d, J =
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7.0 Hz, 2H, ArH), 7.76 (s, 1H, arylidineH), 7.76-7.79 (m, 4H, ArH), 10.76 (s, 1H,
NH);

13

C NMR (126 MHz, DMSO-d6): 26.9 (CH3), 119.6, 127.5, 129.7, 130.4,

131.4, 133.8, 138.1, 139.6, 140.9, 142.3, 166.8 (CONH), 197.1 (COCH3); MS (ESI) 343 (100%, M-H)-, 379 (25%, M+Cl); HRMS (ESI-) calcd for C17H15N2O4S:
343.0753, found 343.0757.

(E)-2-(4-Chlorobenzylidene)-3-oxo-N-(4-sulfamoylphenyl)butanamide

7.11:

Using the general procedure and 4-chlorobenzaldehyde (140 mg, 1 mmol),
compound 7.11 (204 mg, 54%) was isolated as a white solid, m.p. 183 °C. 1H NMR
(500 MHz, CD3OD) δ: 2.46 (s, 3H, CH3), 7.31 (br. s, 2H, NH2), 7.52 (d, J = 8.4 Hz,
2H, ArH), 7.64 (d, J = 8.4 Hz, 2H, ArH), 7.76-7.80 (m, 5H, 4ArH+arylidineH),
10.77 (s, 1H, NH); 13C NMR (126 MHz, DMSO-d6): 26.5 (CH3), 119.2, 127.0,
129.3, 131.5, 132.3, 135.5, 138.1, 139.0, 139.2, 141.7, 166.0, 196.5; MS (ESI-) 377
(100%, M (35Cl)-H)-, 379 (34%, M (37Cl)-H)-; HRMS (ESI-) calcd for
C17H1435ClN2O4S: 377.0363, found 377.0367.

(E)-2-(2-Chlorobenzylidene)-3-oxo-N-(4-sulfamoylphenyl)butanamide

7.12:

Using the general procedure and 2-chlorobenzaldehyde (140 mg, 1 mmol),
compound 7.12 (136 mg, 36%) was isolated as a white solid, m.p. 192 °C. 1H NMR
(500 MHz, CD3OD) δ: 2.50 (s, 3H, CH3), 7.24 (td, J = 7.7, 1.3 Hz, 1H, ArH), 7.37,
(td, J = 7.8, 1.7 Hz, 1H, ArH), 7.51 (dd, J = 8.1, 1.3 Hz, 1H, ArH), 7.65 (dd, J =
7.9, 1.7 Hz, 1H, ArH), 7.69 (d, J = 8.8 Hz, 2H, ArH), 7.83 (d, J = 8.8 Hz, 2H, ArH),
8.01 (s, 1H, arylidineH); 13C NMR (126 MHz, CD3OD): 25.2 (CH3), 119.4, 126.9,
127.0, 129.1, 129.8, 131.5, 131.6, 134.8, 136.9, 139.1, 141.5, 166.4, 196.1; MS
(ESI-): 377 (100%, M (35Cl)-H)-, 379 (35%, M (37Cl)-H), (ESI+): 401 (M+Na);
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HRMS (ESI-) calcd for C17H1435ClN2O4S: 377.0363, found 377.0356.

(E)-2-(4-Methoxybenzylidene)-3-oxo-N-(4-sulfamoylphenyl)butanamide 7.13:
Using the general procedure and 4-methoxybenzaldehyde (136 mg, 1 mmol),
compound 7.13 (217 mg, 58%) was isolated as a white solid, m.p. 162 °C. 1H NMR
(DMSO-d6) δ: 1H NMR (500 MHz, CD3OD) δ 2.37 (s, 3H, CH3), 3.70 (s, 3H,
OCH3), 6.83 (d, J = 9.0 Hz, 2H, ArH), 7.49 (d, J = 9.0 Hz, 2H, ArH), 7.61 (s, 1H,
arylidineH), 7.70 (d, J = 9.0 Hz, 2H, ArH), 7.77 (d, J = 9.0 Hz, 2H, ArH); 13C NMR
(126 MHz, CD3OD): 24.8 (CH3), 54.6 (OCH3), 114.2, 119.3, 125.3, 126.9, 131.9,
134.8, 139.0, 141.4, 141.8, 162.2, 168.0, 196.8; MS (ESI-) 373 (100%, M-H)-,
(ESI+): 397 (M+Na); HRMS (ESI-) calcd for C18H17N2O5S: 373.0858, found
373.0840.

(E)-2-(3-Nitrobenzylidene)-3-oxo-N-(4-sulfamoylphenyl)butanamide

7.14:

Using the general procedure and 3-nitrobenzaldehyde (151 mg, 1 mmol),
compound 7.14 (74 mg, 19%) was isolated as a white solid, m.p. 196 °C. 1H NMR
(DMSO-d6) δ: 1H NMR (400 MHz, DMSO) δ 2.50 (s, CH3, 3H), 7.30 (br. s, 2H,
NH2), 7.72-7.81 (m, 5H, ArH), 7.97 (s, 1H, arylidineH), 8.03 (d, J = 8.5 Hz, 1H,
ArH), 8.26 (d, J = 8.5 Hz, 1H, ArH), 8.56 (s, 1H, ArH), 10.83 (s, 1H, NH);

13

C

NMR (101 MHz, DMSO) δ: 26.8 (CH3), 119.7, 124.5, 125.3, 127.3, 131.1, 135.5,
135.9, 138.4, 139.7, 139.8, 141.7, 148.5, 165.8, 196.9; MS (ESI-) 388 (100%, MH)-, (ESI+): 412 (M+Na); HRMS (ESI-) calcd for C17H14N3O6S: 388.0603, found
388.0605.
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(E)-2-(2-Chloro-4-fluorobenzylidene)-3-oxo-N-(4-sulfamoylphenyl)
butanamide

7.15:

Using

the

general

procedure

and

2-chloro-4-

fluorobenzaldehyde (158 mg, 1 mmol), compound 7.15 (99 mg, 25%) was isolated
as a yellow solid, m.p. 152 °C. 1H NMR (400 MHz, CD3OD) δ: 2.50 (s, 1H, CH3),
δ 7.06 (td, J = 8.5, 2.6 Hz, 1H, ArH), 7.37 (dd, J = 8.5, 2.6 Hz, 1H, ArH), 7.69-7.71
(m, 3H, ArH), 7.84 (d, J = 9.0 Hz, 2H, ArH), 7.95 (s, 1H, arylidineH); 13C NMR
(101 MHz, CD3OD) δ: 25.2 (CH3), 114.3 (d, J2C−F 28), 117.0 (d, J2C−F 31), 119.4,
126.9, 130.7 (d, J3C−F 11), 135.8, 136.0 (d, J3C−F 14), 139.0, 139.0, 139.1, 141.4,
162.2 (d, J1C−F 315), 166.3, 195.9; MS (ESI-:) 395 (100%, M-H)-, 397 (30%, M
(37Cl)-H), (ESI+): 319 (M+Na); HRMS (ESI-) calcd for C17H1335ClFN2O4S:
359.0269, found 395.0271.

(E)-3-Oxo-N-(4-sulfamoylphenyl)-2-(thiophen-2-ylmethylene)butanamide
7.16: Using the general procedure and thiophene-2-carbaldehyde (112 mg, 1
mmol), compound 7.16 (217 mg, 62%) was isolated as a yellow solid, m.p. 185 °C.
1

H NMR (500 MHz, DMSO-d6) δ: 2.43 (s, 1H, CH3), 7.19 (dd, J = 5.0, 3.7 Hz, 1H,

ArH), 7.30 (br. s, 2H, NH2), 7.64 (dd, J = 3.7, 1.3 Hz, 1H, ArH), 7.83-7.85 (m, 5H,
ArH), 8.01 (s, 1H, arylidineH), 10.84 (s, 1H, NH); 13C NMR (126 MHz, DMSOd6): 26.5 (CH3), 119.5, 127.3, 128.6, 133.7, 133.9, 134.7, 136.0, 137.0, 139.4,
142.4, 166.0, 196.1; MS (ESI-) 349 (100%, M-H)-, (ESI+): 373 (M+Na); HRMS
(ESI-) calcd for C15H13N2O4S2: 349.0317, found 349.0311.

General procedure B for preparation of (E)-3-oxo-2-(2-arylhydrazineylidene)N-(4-sulfamoylphenyl)butanamides 7.17-7.24: The diazonium salt was prepared
by slowly adding a cold sodium nitrite solution (0.7 g, 10 mmol) in deionized water
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(5 mL) to a cold solution of the appropriate arylamine (10 mmol) dissolved in 6 M
hydrochloric

acid

(6

mL).

To

a

cold

solution

of

3-oxo-N-(4-

sulfamoylphenyl)butanamide 7.9 (256 mg, 1 mmol) and sodium acetate trihydrate
(408 mg, 3 mmol) in ethanol (10 mL), the appropriate diazonium chloride solution
(15 mmol) was slowly added over a period 30 min at 0-5 °C. The reaction mixture
was stirred for further 3 h at 0-5 °C and 3 h at room temperature. The resulting solid
was filtered, washed with water (2 x 10 mL), dried and recrystallized from
EtOH/DMF to afford 7.17-7.24.

(E)-3-Oxo-2-(2-phenylhydrazineylidene)-N-(4-sulfamoylphenyl)butanamide
7.17: Using general procedure B and aniline (93 mg, 1 mmol), compound 7.17 (165
mg, 46%) was isolated as yellow solid, m.p. 215 °C. 1H NMR (500 MHz, DMSOd6) δ: 2.46 (s, 3H, CH3), 7.16 (t, J = 7.5 Hz, 1H, ArH), 7.28 (br. s, 2H, NH2), 7.41
(t, J = 7.5 Hz, 2H, ArH), 7.54 (d, J = 7.5 Hz, 2H, ArH), 7.80 (d, J = 9.0 Hz, 2H,
ArH), 7.83 (d, J = 9.0 Hz, 2H, ArH), 11.44 (s, 1H, CONH), 13.77 (s, 1H, NNH);
13

C NMR (126 MHz, DMSO-d6): 26.3, 116.4, 120.3, 125.5, 127.3, 127.4, 130.0,

139.9, 140.7, 142.3, 162.5, 198.8; MS (ESI-): 359 (100%, M-H)-; HRMS (ESI-)
calcd for C16H15N4O4S: 359.0809, found 359.0823.

(E)-2-(2-(4-Fluorophenyl)hydrazineylidene)-3-oxo-N-(4-sulfamoylphenyl)
butanamide 7.18: Using general procedure B and 4-fluoroaniline (111 mg, 1
mmol), compound 7.18 (185 mg, 49%) was isolated as a greenish solid, m.p. 248
°C. 1H NMR (400 MHz, DMSO-d6) δ: 2.50 (s, 3H, CH3), 7.25-7.30 (m, 4H, NH2 +
2ArH), 7.59-7.63 (m, 2H, ArH), 7.82 (d, J = 11.0 Hz, 2H, ArH), 7.85 (d, J = 11.0
Hz, 2H, ArH), 11.39 (s, 1H, CONH), 13.65 (s, 1H, NNH); 13C NMR (101 MHz,
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DMSO-d6): 26.3, 116.7 (d, J2C−F 29 Hz), 118.2 (d, J3C−F 10 Hz), 120.3, 127.3, 127.7,
139.0, 139.9, 140.7, 158.7 (d, J1C−F 240 Hz), 162.4, 198.7; MS (ESI-) 377 (100%,
M-H)-; HRMS (ESI-) calcd for C16H14FN4O4S: 377.0714, found 377.0729.

(E)-2-(2-(4-Chlorophenyl)hydrazineylidene)-3-oxo-N-(4-sulfamoylphenyl)
butanamide 7.19: Using general procedure B and 4-chloroaniline (127 mg, 1
mmol), compound 7.19 (217 mg, 55%) was isolated as a yellow solid, m.p. 260 °C.
1

H NMR (500 MHz, DMSO-d6) δ: 2.49 (s, 3H, CH3), 7.32 (br. s, 2H, NH2), 7.44

(d, J = 8.5 Hz, 2H, ArH), 7.56 (d, J = 8.5 Hz, 2H, ArH), 7.80 (d, J = 9.0 Hz, 2H,
ArH), 7.83 (d, J = 9.0 Hz, 2H, ArH), 11.34 (s, 1H, CONH), 13.51 (s, 1H, NNH);
13

C NMR (126 MHz, DMSO-d6): 26.2, 117.9, 120.3, 127.2, 128.8, 128.9, 129.8,

139.9, 140.7, 141.4, 162.1, 198.4; MS (ESI-) 393 (100%, M (35Cl)-H)-, 395 (30%,
M (37Cl)-H)-; HRMS (ESI-) calcd for C16H1435ClN4O4S: 393.0419, found 393.0435.

(E)-2-(2-(4-Bromophenyl)hydrazineylidene)-3-oxo-N-(4-sulfamoylphenyl)
butanamide 7.20: Using general procedure B and 4-bromoaniline (171 mg, 1
mmol), compound 7.20 (258 mg, 59%) was isolated as a yellow solid, m.p. >260
°C. 1H NMR (500 MHz, DMSO-d6) δ: 2.50 (s, 3H, CH3), 7.52 (d, J = 9.0 Hz, 2H,
ArH), 7.59 (d, J = 9.0 Hz, 2H, ArH), 7.82 (d, J = 9.0 Hz, 2H, ArH), 7.85 (d, J = 9.0
Hz, 2H, ArH), 11.32 (s, 1H, CONH), 13.39 (s, 1H, NNH); 13C NMR (126 MHz,
DMSO-d6): 26.4, 117.3, 118.5, 120.5, 127.5, 129.3, 133.0, 140.1, 141.0, 142.1,
162.4, 198.7; MS (ESI-) 437 (100%, M (79Br)-H)-, 339 (100%, M (81Br)-H)-;
HRMS (ESI-) calcd for C16H1479BrN4O4S: 436.9919, found 436.9925.
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(E)-2-(2-(4-Cyanophenyl)hydrazineylidene)-3-oxo-N-(4-sulfamoylphenyl)
butanamide 7.21: Using general procedure B and 4-aminobenzonitrile (118 mg, 1
mmol), compound 7.21 (119 mg, 31%) was isolated as a yellow solid, m.p. >260
°C. 1H NMR (DMSO-d6) δ: 1H NMR (500 MHz, DMSO-d6) δ: 2.50 (s, 3H, CH3),
7.32 (br. s, 2H, NH2), 7.65 (d, J = 9.0 Hz, 2H, ArH), 7.82 (d, J = 9.0 Hz, 2H, ArH),
7.85 (d, J = 9.0 Hz, 2H, ArH), 11.15 (s, 1H, CONH), 12.85 (s, 1H, NNH); 13C NMR
(126 MHz, DMSO-d6) δ: 26.3, 106.1, 116.6, 119.8, 120.5, 127.5, 133.2, 134.5,
140.2, 141.1, 146.6, 161.9, 198.1; MS (ESI-): 384 (100%, M-H)-; HRMS (ESI-)
calcd for C17H14N5O4S: 384.0761, found 384.0776.

(E)-2-(2-(4-Methoxyphenyl)hydrazineylidene)-3-oxo-N-(4-sulfamoylphenyl)
butanamide 7.22: Using general procedure B and 4-methoxyaniline (123 mg, 1
mmol), compound 7.22 (168 mg, 43%) was isolated as a yellow solid, m.p. 255 °C.
1

H NMR (500 MHz, DMSO-d6) δ: 2.50 (s, 3H, CH3), 3.78 (s, 3H, OCH3), 7.02 (d,

J = 8.5 Hz, 2H, ArH), 7.34 (br. s, 2H, NH2), 7.53 (d, J = 8.5 Hz, 2H, ArH), 7.837.88 (m, 4H, ArH), 11.57 (s, 1H, CONH), 14.07 (s, 1H, NNH);

13

C NMR (126

MHz, DMSO-d6) δ: 25.6, 55.2, 114.7, 117.4, 119.7, 125.1, 126.7, 135.1, 139.2,
140.1, 157.1, 162.2, 198.1; MS (ESI-): 389 (100%, M-H)-; HRMS (ESI-) calcd for
C17H17N4O5S: 389.0914, found 389.0933.

(E)-2-(2-(3-Nitrophenyl)hydrazineylidene)-3-oxo-N-(4-sulfamoylphenyl)
butanamide 7.23: Using general procedure B and 3-nitroaniline (138 mg, 1 mmol),
compound 7.23 (117 mg, 29%) was isolated as a yellow solid, m.p. 248 °C. 1H
NMR (500 MHz, DMSO-d6) δ: 2.48 (s, 3H, CH3), 7.31 (br. s, 2H, NH2), 7.65 (t,
1H, J = 8.5 Hz, 1H, ArH), 7.81 (d, J = 8.5 Hz, 2H, ArH), 7.84 (d, J = 8.5 Hz, 2H,
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ArH), 7.91 (d, J = 8.0 Hz, 1H, ArH), 7.95 (d, J = 8.0 Hz, 1H, ArH), 8.32 (s, 1H,
ArH), 11.15 (s, 1H, CONH), 12.92 (s, 1H, NNH); 13C NMR (126 MHz, DMSO-d6)
δ: 25.9, 110.4, 118.5, 120.1, 121.9, 127.2, 131.3, 132.1, 139.8, 140.8, 144.0, 149.0,
161.6, 197.7; MS (ESI-): 404 (100%, M-H)-; HRMS (ESI-) calcd for C16H14N5O6S:
404.0659, found 404.0673.

(E)-2-(2-(3,4-Dimethoxyphenyl)hydrazineylidene)-3-oxo-N-(4sulfamoylphenyl) butanamide 7.24: Using general procedure B and 3,4dimethoxyaniline (153 mg, 1 mmol), compound 7.24 (168 mg, 40%) was isolated
as an orange solid, m.p. 247 °C. 1H NMR (500 MHz, DMSO-d6) δ: 2.52 (s, 3H,
CH3), 3.77 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 7.02 (d, J = 9.0 Hz, 1H, ArH), 7.12
(dd, J = 9.0, 2.5 Hz, 1H, ArH), 7.26 (d, J = 2.5 Hz, 1H, ArH), 7.31 (br. s, 2H, NH2),
7.82 (d, J = 9.0 Hz, 2H, ArH), 7.85 (d, J = 9.0 Hz, 2H, ArH), 11.54 (s, 1H, CONH),
13.99 (s, 1H, NNH); 13C NMR (126 MHz, DMSO-d6) δ: 26.4, 56.2, 56.5, 101.4,
108.6, 113.1, 120.5, 126.1, 127.5, 136.1, 140.0, 140.9, 147.5, 150.3, 162.9, 198.8;
MS (ESI-): 419 (100%, M-H)-, HRMS (ESI-) calcd for C18H19N4O6S: 419.1020,
found 419.1035.

2-Chloro-3-oxo-N-(4-sulfamoylphenyl)butanamide

7.25:

To

a

stirred

suspension of 3-oxo-N-(4-sulfamoylphenyl)butanamide 7.9 (2.56 g, 10 mmol) in
toluene (30 mL) with ice cooling was added dropwise over 1 h sulfuryl chloride
(1.50 g, 11 mmol) and the reaction warmed at 40-50 °C until completion as
analysed by TLC. The toluene was evaporated, and the residue was crystallized
from ethanol to afford 7.25 (1.22 g, 42%) as white crystals, m.p. 140 °C. The
product contains about 32% of enol form as analysed by 1H NMR. 1H NMR (500
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MHz, DMSO-d6) δ: 2.32 (s, 3H, CH3), 2.52 (s, 3H, CH3), 5.42 (s, 1H, CH), 7.31
(br. s, 2H, NH2), 7.34 (br. s, 2H, NH2), 7.74-7.76 (m, 4H, ArH), 7.80-7.82 (m, 4H,
ArH), 7.34 (br. s, 2H, NH2), 10.98 (s, 1H, NH), 10.99 (s, 1H, NH); 13CNMR (126
MHz, DMSO-d6) δ: 24.7, 27.5, 64.2, 84.0, 120.0, 121.3, 127.1, 127.3, 140.0, 140.6,
140.7, 141.3, 162.3, 163.9, 192.3, 197.3; MS (ESI-): 289 (100%, M(35Cl)-H), 391
(30%, M (37Cl)-H); HRMS (ESI-) calcd for C10H1035ClN2O4S: 289.0044, found
289.0058.

General

procedure

C

for

preparation

of

(Z)-2-oxo-N-aryl-2-((4-

sulfamoylphenyl)amino)acetohydrazonoyl chloride 7.26-7.30: To a cold
solution of 2-chloro-3-oxo-N-(4-sulfamoylphenyl)butanamide 7.25 (290 mg, 1
mmol) and sodium acetate trihydrate (408 mg, 3 mmol) in ethanol (10 mL), the
appropriate diazonium chloride solution (15 mmol) was slowly added over a period
30 min at 0-5 °C. The reaction mixture was stirred for further 3 h at 0-5 °C and 3 h
at room temperature. The resulting solid was filtered, washed with water (2 x 10
mL), air dried and recrystallized from EtOH/DMF to afford 7.26-7.30.

(Z)-2-Oxo-N-phenyl-2-((4-sulfamoylphenyl)amino)acetohydrazonoyl chloride
7.26: Using general procedure C and aniline (93 mg, 1 mmol), compound 7.26 (151
mg, 34%) was isolated as a white solid, m.p. 245 °C. 1H NMR (500 MHz, DMSOd6) δ: 7.00 (t, J = 7.5 Hz, 1H, ArH), 7.29 (br. s, 2H, NH2), 7.34 (t, J = 7.5, 8.5 Hz,
2H, ArH), 7.61 (d, J = 8.5 Hz, 2H, ArH), 7.82 (d, J = 9.0 Hz, 2H, ArH), 7.92 (d, J
= 9.0 Hz, 2H, ArH), 10.34 (s, 1H, NH), 10.41 (s, 1H, NH); 13C NMR (126 MHz,
DMSO-d6) δ: 115.4, 118.2, 120.8, 122.6, 127.0, 129.5, 139.5, 141.8, 143.2, 158.1;
MS (ESI-): 351 (100%, M (35Cl)-H)-, 353 (33%, M (37Cl)-H)-, HRMS (ESI-) calcd
for C14H1235ClN4O3S: 351.0319, found 351.0310.
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(Z)-N-(4-Fluorophenyl)-2-oxo-2-((4-sulfamoylphenyl)amino)
acetohydrazonoyl chloride 7.27: Using general procedure C and 4-fluoroaniline
(111 mg, 1 mmol), compound 7.27 (100 mg, 27%) was isolated as a buff solid, m.p.
250 °C. 1H NMR (500 MHz, DMSO-d6) δ: 7.16 (t, J = 8.8 Hz, 2H, ArH 7.28 (br. s,
2H, NH2), 7.61 (dd, J = 8.8, 5.0 Hz, 2H, ArH), 7.82 (d, J = 8.5 Hz, 2H, ArH), 7.91
(d, J = 8.5 Hz, 2H, ArH), 10.32 (s, 1H, NH), 10.42 (s, 1H, NH);

13

C NMR (126

MHz, DMSO-d6) δ: 116.0 (d, J2C−F 23 Hz), 116.8 (d, J3C−F 8 Hz), 118.2, 120.8,
126.9, 139.4, 139.7, 141.7, 157.3 (d, J1C−F 238 Hz), 158.0; MS (ESI-): 369 (100%,
M (35Cl)-H)-, 371 (33%, M (37Cl)-H)-; HRMS (ESI-) calcd for C14H11F35ClN4O3S:
369.0224, found 369.0232.

(Z)-N-(4-Chlorophenyl)-2-oxo-2-((4-sulfamoylphenyl)amino)
acetohydrazonoyl chloride 7.28: Using general procedure C and 4-chloroaniline
(127 mg, 1 mmol), compound 7.28 (154 mg, 40%) was isolated as a yellow solid,
m.p. 255 °C. 1H NMR (500 MHz, DMSO-d6) δ: 7.29 (br. s, 2H, NH2), 7.37 (d, J =
8.3 Hz, 2H, ArH), 7.62 (d, J = 8.3 Hz, 2H, ArH), 7.82 (d, J = 8.5 Hz, 2H, ArH),
7.92 (d, J = 8.5 Hz, 2H, ArH), 10.36 (s, 1H, NH), 10.51 (s, 1H, NH);

13

C NMR

(126 MHz, (CD3)2CO) δ: 123.2, 129.5, 130.0, 131.1, 132.6, 137.0, 139.3, 143.6,
157.0, 163.2; MS (ESI-): 385 (100%, (35Cl) M-H)-, HRMS (ESI-) calcd for
C14H1135Cl2N4O3S: 384.9929, found 384.9935.

(Z)-N-(4-Bromophenyl)-2-oxo-2-((4-sulfamoylphenyl)amino)
acetohydrazonoyl chloride 7.29: Using general procedure C and 4-bromoaniline
(171 mg, 1 mmol), compound 7.29 (137 mg, 32%) was isolated as a yellow solid,
m.p. >260 °C. 1H NMR (500 MHz, DMSO-d6) δ: 7.29 (br. s, 2H, NH2), 7.50 (d, J
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= 9.0 Hz, 2H, ArH), 7.56 (d, J = 9.0 Hz, 2H, ArH), 7.81 (d, J = 9.0 Hz, 2H, ArH),
7.91 (d, J = 9.0 Hz, 2H, ArH), 10.37 (s, 1H, NH), 10.51 (s, 1H, NH);

13

C NMR

(126 MHz, DMSO-d6) δ: 113.5, 116.8, 118.5, 120.2, 126.3, 131.5, 138.9, 141.0,
142.0, 157.2; MS (ESI-): 429 (100%, M-H)-, HRMS (ESI-) calcd for
C14H1179Br35ClN4O3S: 428.9424, found 428.9428.

(Z)-N-(4-Methoxyphenyl)-2-oxo-2-((4-sulfamoylphenyl)amino)
acetohydrazonoyl chloride 7.30: Using general procedure C and 4-anisidine (123
mg, 1 mmol), compound 7.30 (69 mg, 18%) was isolated as a yellow solid, m.p.
250 °C. 1H NMR (500 MHz, DMSO-d6) δ: 3.72 (s, 3H, OCH3), 7.26 (br. s, 2H,
NH2), 7.51 (d, J = 9.0 Hz, 2H, ArH), 7.78 (d, J = 9.0 Hz, 2H, ArH), 7.82 (d, J = 9.0
Hz, 2H, ArH), 7.89 (d, J = 9.0 Hz, 2H, ArH), 10.24 (s, 1H, NH), 10.27 (s, 1H, NH);
13

C NMR (126 MHz, DMSO-d6) δ: 55.7, 114.8, 116.6, 118.2, 120.6, 126.4, 136.9,

139.9, 141.9, 155.3, 158.1; MS (ESI-): 381 (100%, (35Cl) M-H)-, HRMS (ESI-)
calcd for C15H1435ClN4O4S: 381.0424, found 381.0407.

7.4.2

Protein X-ray crystallography

CA II protein was concentrated to 7 mg/mL and set up in SD-2 plates (Molecular
Dimensions) with 200 nL plus 200 nL drops (protein plus reservoir solution) over
50 μL reservoirs and incubated at 8º C. The reservoir conditions consisted of 2.52.8 M ammonium sulfate with 100 mM Tris pH 8.5-9.0. Compounds were soaked
into the crystals for approximately 24 hours and subsequently glycerol (20% final
concentration) was added to cryoprotect the crystals for cryo-cooling. Data were
collected at the Australian Synchrotron MX1 beamline in Oct 2017 and at the MX2
beamline in Nov 2017. Data were auto-processed with XDS23 and then Aimless24
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was used to scale the reflections, Phaser25 was used with model 4cq0 to phase the
data and Coot26 was used to manually place the atoms in electron density. AFITT
(OpenEye Scientific Software) was used to place the ligands into density and
generate the dictionary files. REFMAC27 was used to refine the structures. The 7.13
(high resolution at 1.32 Å) structure used anisotropic refinement whereas the other
structures were refined using isotropic refinement. The models and structure factors
have been deposited at the RCSB with PDB codes: 6UFB (ligand 7.10), 6UFC
(ligand 7.13) and 6UFD (ligand 7.16).

7.4.3

CA Inhibition

An Applied Photophysics stopped-flow instrument was used for assaying the CA
catalyzed CO2 hydration activity.20 Phenol red (at a concentration of 0.2 mM) was
used as indicator, working at the absorbance maximum of 557 nm, with 20 mM
Hepes (pH 7.5) as buffer and 20 mM Na2SO4 (for maintaining constant the ionic
strength), following the initial rates of the CA-catalyzed CO2 hydration reaction for
a period of 10−100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the
determination of the kinetic parameters and inhibition constants. For each inhibitor,
at least six traces of the initial 5−10% of the reaction have been used for
determining the initial velocity. The uncatalyzed rates were determined in the same
manner and subtracted from the total observed rates.
Stock solutions of inhibitor (0.1 mM) were prepared in distilled−deionized water,
and dilutions up to 0.01 nM were carried out subsequently with the assay buffer.
Inhibitor and enzyme solutions were preincubated together for 6 hours at room
temperature prior to assay in order to allow for the formation of the E−I complex.
The inhibition constants were obtained by nonlinear least-squares methods using
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PRISM 3 and the Cheng−Prusoff equation, as reported earlier,28, 29 and represent
the mean from at least three different determinations. All CA isoforms were
recombinant ones obtained in-house as reported earlier. 30, 31

7.4.4

Hypertensive rabbit IOP lowering studies

The experimental procedures were carried out on New Zealand albino rabbits,
following the Resolution of the Association for Research in Vision and
Ophthalmology, the Good Laboratory Practice for the use of animals upon
authorization of Italian Ministry of Health (number 1179/2015-PR), in agreement
with the European Union Regulations (OJ of ECL 358/1, 12/12/1986).32 Male
albino rabbits (body weight 2-2.5 kg) were kept in individual cages, food and water
was provided ad libitum. The animals were maintained on a 12 h-12 h light/dark
cycle in a temperature-controlled room (22-23 °C). Animals were identified with a
tattoo in the ear, numbered consecutively and examined before the beginning of the
study to verify the good general and ophthalmic health condition. All the
compounds were dissolved in pyrogen free sterile 0.9% NACl solution (i.e.
physiologic solution) and 0.1% DMSO, 0.1% EtOH at 1 mM concentration.
Vehicle was 0.9% NaCl + 0.1% DMSO + 0.1% EtOH. The viability of compounds
was evaluated after repeated administration using the Draize Eye Test (Wilhelmus,
2001). Topical delivery into the conjunctival cul-de-sac is the most common route
of ocular drug delivery.
All compounds were given prior to saline injection and the IOP was measured at
the very beginning of the experimental session to establish basal IOP. Ocular
hypertension was induced by the injection of 0.05 mL of sterile hypertonic saline
(5%) into the vitreous bilaterally with local anaesthesia provided by one drop of
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0.2% oxybuprocaine hydrochloride in each eye one minute prior. IOP was
measured using a Pneumotonometer (Reichert Inc. Depew, NY) after hypertonic
saline injection after stabilization (normally 10 minutes) to verify the rise of IOP
into the suitable experimental range (IOP >30 and < 40 mmHg) and after 60, 90,
120, 240 minutes in all groups after drug or vehicle treatment. One drop of 0.2%
oxybuprocaine hydrochloride was instilled in each eye immediately before each set
of pressure measurements
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8.1 The search for anti-CHIKV lead compounds (Chapters 2-4)
8.1.1

Conclusions

Using a multi-disciplinary approach, considerable efforts have been made towards
the development of potential anti-CHIKV. The key findings from this study can be
summarised into two main sections:
a) application of medicinal chemistry concepts to existing inhibitors:
By applying robust medicinal chemistry strategies such as hybridization,
bioisosteric substitution and simplification of existing anti-CHIKV agents, we
devised three series of analogue scaffolds, triazolopyrimidine, thiazolopyrimidine
and 2-anilinopyrimdine, respectively, as shown in Figure 8.1 (Chapter 2 and 3).

Figure 8.1: Summary of the application to medicinal chemistry concepts
Starting from 6-ethyl thiouracil, target compounds 2.14-2.28, 3.29-3.39 and 3.6-3.9
were synthesized using the state-of-art organic chemistry. The first series of (Z)-7ethyl-2-arylidine-5H-thiazolo[3,2-a]pyrimidine-3,5(2H)-diones
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synthesized by optimization of the multi-component reaction conditions via
replacing chloroacetic acid with the more regioselective bromoacetic acid, lowering
reaction temperature and changing the mode of addition. X-ray crystal structure
and computational studies showed that only one regioselective isomer formed with
the Z configuration that is potentially stabilized by two intramolecular hydrogen
bonds. Anti-CHIKV activity evaluation showed the tailed thiazolopyrimidine 2.23
(Figure 8.1) as a promising lead compound for future development with EC50 = 42
µM, with IC50 > 250 µM against the breast cancer cell line MCF-7 and the
endothelial human sapiens cell line EA.hy926.
The triazolopyrimidines 3.29-3.39 and anilinopyrimidines 3.6-3.9, were designed,
synthesised and bioassayed for anti-CHIKV activity and cytotoxicity. Five
derivatives of triazolopyrimidine scaffold 3.29, 3.31, 3.33, 3.34 and 3.39 showed
anti-CHIKV activity spanning from 38-186 µM and compound 3.33 emerged as the
most active and least toxic (EC50 = 42 µM, with IC50 > 300 µM) against the breast
cancer cell lines MCF-7 and MDA-MB-231 and the endothelial human sapiens cell
line EA.hy926). Compound 3.33 showed considerable advantages over the parent
compound 3.1, including the ability of the 3 position in 3.33 to accommodate
substituents and accessibility, low cost and diversities of the hydrazonoyl chlorides
starting materials. Derivative 3.33 may provide new and promising scope for
improved drug design utilising this inexpensive scaffold. Series 3.6-3.9 proved to
only exhibit weak anti-CHIKV activity. Comparisons of the geometries and
Electrostatic Potential-mapped surfaces of minimal pharmacophore models 3.533.56 of anti-CHIKV agents has allowed for a consensus model for effective target
binding. These results place future research into anti-CHIKV agents in better
standing.
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b) Structure-guided drug design (Chapter 4):
In a previous study, eleven potential inhibitors of the CHIKV proteins were
identified by virtual screening of NCI Diversity set II database (1541 compounds)
against three CHIKV proteins (nsP2, nsP3 and envelope glycoprotein) (Figure
8.2).1, 2 Herein, we requested these compounds and sent them to be bioassayed for
their anti-CHIKV activity. Three CHIKV inhibitors were identified out of the 1541
in silico screened database (Figure 8.2).

Figure 8.2: Structure-guided drug design workflow in this dissertation.

Synthesis of a small library of NCI-37168 (4.5 (Figure 8.3) EC50 < 0.8 ug/mL) was
achieved by applying amide coupling conditions to 2-naphthoic acid or 3-hydroxy2-naphthoic acid with different anilines to afford 4.14-4.19. These compounds were
investigated for their anti-CHIKV activity at 20 µg/mL and showed that the
hydroxyl group at position 2 of the naphthalene scaffold and the m-nitro group are
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important for the anti-viral activity.

Figure 8.3: Structure of the active potential leads 4.1, 4.5 and 4.11 and optimization of
4.5.

8.1.2 Future directions
a) application to medicinal chemistry concepts to existing inhibitors:
Antiviral activity evaluation demonstrated the tailed thiazolopyrimidine 2.23 as a
candidate for future development. The rest of the compounds among
thiazolopyrimidines 2.14-2.28, except 2.23, showed no or weak anti-CHIKV,
which indicate that the thiazolo[3,2-a]pyrimidine scaffold is not important for the
antiviral activity (Figure 8.4). Further medicinal chemistry optimization could be
achieved by retaining the tail, while replacing thiazolo[3,2-a]pyrimidine bicyclic
system with thiazolidine scaffold 8.1 (Figure 8.4).
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The most active anti-CHIKV compound 3.33 among the tested 1-aryl[1,2,4]triazolo[4,3-a]pyrimidines 3.29-3.39, could be subjected to another cycle of
optimization by varying R1 and R2 to further explore the structure activity
relationship of this scaffold (Figure 8.4).

Figure 8.4: Future development of the thiazolopyrimidine 2.23 and triazolopyrimidine
3.33.

b) Structure-guided drug design (Chapter 4):
Compounds 4.14-4.19 will be tested for their antiviral activity at lower
concentration to investigate their antiviral activity, while lowering their toxic effect.
Inhibition profile of these derivatives against the protein target nsP3 could be
performed and iterative cycles of optimization could be achieved to decrease their
cytotoxic effect, while retaining the anti-CHIKV activity. The quinoline derivative
4.1 (Figure 8.3) showed a strong inhibitory effect against CHIKV (EC50 = 6.8 ± 0.5
mg/mL, EC90 = 12.0 ± 0.5 mg/mL) and could be considered as a promising hit for
future development. further work will be performed in our lab on compounds 4.1
and 4.11.
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8.2 Fluorescent anion transporters (Chapters 5-6)
8.2.1

Conclusions

An investigation into the design and synthesis of two new classes of fluorescent
anion transporters for pharmacological applications has been undertaken
(Chapters 5-6). The first anion transporters study (Chapter 5) aimed to find
switchable anion reporters that are switched on in the presence of the reducing
agents GSH, DTT and TCEP. We have developed five new anion transporters 5.15.5 and four putative anionophores 5.13, 5.14, 5.16 and 5.17 that are ‘switched on’
in the presence of the reducing agent GSH which is found in higher concentrations
in tumours than in healthy tissue. Biological testing of these compound is currently
undergoing.
A new class of bisurea anion transporters bearing the fluorescent 4-methyl
coumarin has been developed (Chapter 6, 6.1-6.4). The fluorescent anion receptors
elicited a relatively strong chloride binding affinity in DMSO-d6/0.5%H2O with Ka
= 81 - 177 M-1 and superior Cl-/NO3- exchange ability in ISE-based affinity and
H+/Cl- cotransport activity. Transporters 6.1-6.4 showed efficient anion binding and
transport properties than the previously reported fluorescent anion transporters.3, 4
In terms of the biological component of this project the four coumarin-bisurea
compounds 6.1-6.4 synthesised during this work are currently under evaluation in
cell-based assays and cellular fluorescent imaging.
8.2.2

Future directions

Based on the biological evaluation and if the switchable abilities of the gold
complexes 5.13, 5.14, 5.16 and 5.17 could be replicated in a cellular environment,
it would be beneficial to create a larger library of NHC-based bisbenzimidazolepyridine (8.3, Figure 8.5) and investigate their biological properties (Figure 8.5).
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The designed receptors 8.3 could be with a wide variety of substitutions at the R1,
R2 and R3 positions and modifying the coordination metal (gold III) with other
metals such as ruthenium (with anticancer property) whilst retaining the basic
bisbenzimidazole pyridine scaffold present in 5.1-5.5 (Figure 8.5).

Figure 8.5: Future development of the switchable anion transporters 5.13, 5.14, 5.16 and
5.17.

The synthesized coumarin-bisurea conjugates 6.1-6.4 are currently under biological
evaluation, and based on the derived structure activity relationship, further
medicinal chemistry derivatisation could be achieved such as formation of
macrocycle fluorescent probes based on these receptors for fluorescent imaging of
subcellular organelles application.

8.3 Carbonic anhydrase inhibitors (Chapter 7):
8.3.1 Conclusions:
Based on the dual-tailed approach of the CA inhibitors, we designed and
synthesized three series of dual-tailed sulfonamide CA inhibitors 7.10-7.16, 7.177.24 and 7.26-7.30.5 They were tested for their inhibitory profiles against four
carbonic anhydrase isoforms: hCA I, II, IV, and VII. Series 7.10-7.16 emerged as
the most potent CA II inhibitors with low to sub nanomolar Ki values (0.36-6.9
nM) (Figure 8.6). X-ray crystallographic studies of 7.10, 7.13 and 7.16 against CA
II were conducted to further understand and rationalize the strong CA II inhibitory
profile of the compounds. As per our design, the X-ray crystallographic studies
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showed defined moieties within the ligand structures specifically interact with the
hydrophobic and hydrophilic halves of the CA II active site (Figure 8.6). The most
active CA II inhibitors 7.11-7.13 and 7.16 (Ki values of 0.36-2.9 nM) were
evaluated for their IOP lowering action against DRZ as the standard. Compounds
7.11 and 7.13, with IOP reduction of 12.8 and 12.3 mmHg, respectively, emerged
as more potent than the clinically used drug DRZ (IOP reduction = 8.5 mmHg).

Figure 8.6: Drug design of the potent anti-glaucoma derivatives studied in the current
thesis.

8.3.2 Future directions
This study presents compounds 7.11 and 7.13 as potential promising candidates for
the development of therapeutic anti-glaucoma strategies. For further development
on this scaffold, rigidification of the amide group could be done, with a wide variety
of substitutions at the R2 position, whilst retaining the 4-chloro or 4-methoxy
substitutions at R1 (8.4, Figure 8.7).
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Figure 8.7: possible derivatization and development of the CA inhibitors
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B) Binding studies:
a)

b)

c)
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Figure D1: 1H NMR spectroscopic titration of receptor 1 (2 mM) with TBACl in
DMSO-d6 with 0.5% water at 298 K. a) Stack plot. b) Fitplot for NH proton at δ = 13.43
ppm (proton1, Im-NH) and CH protons at δ = 8.33 ppm (proton2, Py-2CH) and δ = 7.29
ppm (proton3, Py-CH), using global analysis with 1:1 (Ka = 92 M-1, error: 13%) and 2:1
host:guest stoichiometry (K11 = 40; K12: 2514 M-1, error 11 and 21%). c) Plot of the
residuals for δ = 13.43 ppm (proton1), δ = 8.33 ppm (proton2) and δ = 7.29 ppm (proton3)
using global analysis. d) Calculated mole fractions.
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Figure D2: 1H NMR spectroscopic titration of receptor 2 (2 mM) with TBACl in
DMSO-d6 with 0.5% water at 298 K. a) Stack plot. b) Fitplot for NH proton at δ = 13.37
ppm (proton1, Im-NH) and CH proton at δ = 8.45 ppm (proton2, Py-CH) using global
analysis with 1:1 host:guest stoichiometry (Ka = 77 M-1, error: 2%). c) Plot of the residuals
for δ = 13.37 ppm (proton1) and δ = 8.45 ppm (proton2) using global analysis. d)
Calculated mole fractions.
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Figure D3: 1H NMR spectroscopic titration of receptor 3 (2 mM) with TBACl in
DMSO-d6 with 0.5% water at 298 K. a) Stack plot. b) Fitplot for NH proton at δ = 14.03
ppm (proton1, Im-NH) and CH proton at δ = 8.50 ppm (proton2, Py-CH), using global
analysis with 1:1 (Ka = 133 M-1, error: 6%) and 2:1 host:guest stoichiometry (K11 = 40;
K12: 259 M-1, error 17% for both of them). c) Plot of the residuals for δ = 14.03 ppm
(proton1) and δ = 8.50 ppm (proton2) using global analysis. d) Calculated mole fractions.
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Figure D4: 1H NMR spectroscopic titration of receptor 1 (2 mM) with TBACl in
DMSO-d6 with 0.5% water at 298 K. a) Stack plot. b) Fitplot for NH proton at δ = 13.15
ppm (proton1, Im-NH) and CH protons at δ = 8.33 ppm (proton2, Py-2CH) and δ = 7.83
ppm (proton3, Py-CH), using global analysis with 1:1 host:guest stoichiometry (Ka = 63
M-1, error: 2%). c) Plot of the residuals for δ = 13.15 ppm (proton1), δ = 8.33 ppm (proton2)
and δ = 7.83 ppm (proton3) using global analysis. d) Calculated mole fractions.
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Figure D5: 1H NMR spectroscopic titration of receptor 1 (1 mM) with TBACl in
CD3CN at 298 K. a) Stack plot. b) Fitplot for NH proton at δ = 11.73 ppm (proton1, ImNH) and CH proton at δ = 8.42 ppm (proton2, Py-CH), using global analysis with 1:1
host:guest stoichiometry (Ka = 4586 M-1, error: 11%). c) Plot of the residuals for δ = 11.73
ppm (proton1) and δ = 8.42 ppm (proton2) using global analysis. d) Calculated mole
fractions.
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Figure D6: 1H NMR spectroscopic titration of receptor 2 (1 mM) with TBACl in
CD3CN at 298 K. a) Stack plot. b) Fitplot for NH proton at δ = 11.85 ppm (proton1, ImNH) and CH proton at δ = 8.49 ppm (proton2, Py-CH), using global analysis with 1:1
host:guest stoichiometry (Ka = 12051 M-1, error: 10%). c) Plot of the residuals for δ =
11.85 ppm (proton1) and δ = 8.49 ppm (proton2) using global analysis. d) Calculated mole
fractions.
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Figure D7: 1H NMR spectroscopic titration of receptor 3 (1 mM) with TBACl in
CD3CN at 298 K. a) Stack plot. b) Fitplot for NH proton at δ = 12.93 ppm (proton1, ImNH) and CH proton at δ = 8.54 ppm (proton2, Py-CH), using global analysis with 2:1
host:guest stoichiometry (K11 = 1987; K12: 2238 M-1, error 15 and 7%, respectively). c)
Plot of the residuals for δ = 12.93 ppm (proton1) and δ = 8.54 ppm (proton2) using global
analysis. d) Calculated mole fractions.
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Figure D8: 1H NMR spectroscopic titration of receptor 4 (1 mM) with TBACl in
CD3CN at 298 K. a) Stack plot. b) Fitplot for NH proton at δ = 11.72 ppm (proton1, ImNH) and CH proton at δ = 8.37 ppm (proton2, Py-CH), using global analysis with 2:1
host:guest stoichiometry (K11 = 0.69; K12: 8.2 x 106 M-1). c) Plot of the residuals for δ =
11.72 ppm (proton1) and δ = 8.37 ppm (proton2) using global analysis. d) Calculated mole
fractions.
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C) Transport studies:
1) HPTS
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Figure D9: Hill plot analysis of H+/Cl- symport or Cl-/OH- antiport facilitated by compound
5.1 using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM), buffered to pH
7.0 with HEPES (10 mM). The test compound was added at 0 s and detergent was added
at 200 s. Ionophore concentrations are shown as ionophore to lipid molar ratios. Error bars
represent SD from at least three repeats.
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Figure D10: Hill plot analysis of H+/Cl- symport or Cl-/OH- antiport facilitated by
compound 5.2 using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM). The test compound was added at 0 s and
detergent was added at 200 s. Ionophore concentrations are shown as ionophore to lipid
molar ratios. Error bars represent SD from at least three repeats.
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Figure D11: Hill plot analysis of H+/Cl- symport or Cl-/OH- antiport facilitated by
compound 5.3 using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM). The test compound was added at 0 s and
detergent was added at 200 s. Ionophore concentrations are shown as ionophore to lipid
molar ratios. Error bars represent SD from at least three repeats.
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Figure D12: : Hill plot analysis of H+/Cl- symport or Cl-/OH- antiport facilitated by
compound 5.4 using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM). The test compound was added at 0 s and
detergent was added at 200 s. Ionophore concentrations are shown as ionophore to lipid
molar ratios. Error bars represent SD from at least three repeats.
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Figure D13: Hill plot analysis of H+/Cl- symport or Cl-/OH- antiport facilitated by
compound 5.5 using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM). The test compound was added at 0 s and
detergent was added at 200 s. Ionophore concentrations are shown as ionophore to lipid
molar ratios. Error bars represent SD from at least three repeats.
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Figure D14: Using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied to determine
the effect of addition of the protonphore cccp at 0.5 mol% (to measure of chloride uniport
solely), oleic acid at 1 mol% (as a source of fatty acid) and BSA-treated lipid (to test if the
transport is fatty acid dependent) on the rate of chloride transport of receptor 5.1 (10
mol%).
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Figure D15: Using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied to determine
the effect of addition of the protonphore cccp at 0.5 mol% (as a measure of chloride
uniport), oleic acid at 1 mol% (as a source of fatty acid) and BSA-treated lipid (to test if
the transport is fatty acid dependent) on the rate of chloride transport of receptor 5.2 (1
mol%).
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Figure D16: Using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied to determine
the effect of addition of the protonphore cccp at 0.5 mol% (as a measure of chloride
uniport), oleic acid at 1 mol% (as a source of fatty acid) and BSA-treated lipid (to test if
the transport is fatty acid dependent) on the rate of chloride transport of receptor 5.3 (1
mol%).
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Figure D17: Using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied to determine
the effect of addition of the protonphore cccp at 0.5 mol% (as a measure of chloride
uniport), oleic acid at 1 mol% (as a source of fatty acid) and BSA-treated lipid (to test if
the transport is fatty acid dependent) on the rate of chloride transport of receptor 5.4 (1
mol%).
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Figure D18: Using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied to determine
the effect of addition of the protonphore cccp at 0.5 mol% (as a measure of chloride
uniport), oleic acid at 1 mol% (as a source of fatty acid) and BSA-treated lipid (to test if
the transport is fatty acid dependent) on the rate of chloride transport of receptor 5.5 (1
mol%).
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Figure D19: Hill plot analysis of H+ flux facilitated by compound 5.1 using KGlu-KOH
assay from POPC vesicles loaded with KGlu (100 mM), buffered to pH 7.0 with HEPES
(10 mM). The test compound was added at 0 s and detergent was added at 200 s. Ionophore
concentrations are shown as ionophore to lipid molar ratios. Error bars represent SD from
at least three repeats.
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Figure D20: Hill plot analysis of H+ flux facilitated by compound 5.2 using KGlu-KOH
assay from POPC vesicles loaded with KGlu (100 mM), buffered to pH 7.0 with HEPES
(10 mM). The test compound was added at 0 s and detergent was added at 200 s. Ionophore
concentrations are shown as ionophore to lipid molar ratios. Error bars represent SD from
at least three repeats.
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Figure D21: Hill plot analysis of H+ flux facilitated by compound 5.3 using KGlu-KOH
assay from POPC vesicles loaded with KGlu (100 mM), buffered to pH 7.0 with HEPES
(10 mM). The test compound was added at 0 s and detergent was added at 200 s. Ionophore
concentrations are shown as ionophore to lipid molar ratios. Error bars represent SD from
at least three repeats.
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Figure D22: Hill plot analysis of H+ flux facilitated by compound 5.4 using KGlu-KOH
assay from POPC vesicles loaded with KGlu (100 mM), buffered to pH 7.0 with HEPES
(10 mM). The test compound was added at 0 s and detergent was added at 200 s. Ionophore
concentrations are shown as ionophore to lipid molar ratios. Error bars represent SD from
at least three repeats.
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Model
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Figure D23: Hill plot analysis of H+ flux facilitated by compound 5.5 using KGlu-KOH
assay from POPC vesicles loaded with KGlu (100 mM), buffered to pH 7.0 with HEPES
(10 mM). The test compound was added at 0 s and detergent was added at 200 s. Ionophore
concentrations are shown as ionophore to lipid molar ratios. Error bars represent SD from
at least three repeats.
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Figure D24: Using KGlu-KOH assay from POPC vesicles loaded with KGlu (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied to determine
the effect of addition of the ionophore valinomycin at 0.05 mol% (as a measure of H+ flux),
oleic acid at 1 mol% (as a source of fatty acid) and BSA-treated lipid (to test if the transport
is fatty acid dependent) on the rate of chloride transport of receptor 5.1 (4 mol%).
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Figure D25: Using KGlu-KOH assay from POPC vesicles loaded with KGlu (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied to determine
the effect of addition of the ionophore valinomycin at 0.05 mol% (as a measure of H+ flux),
oleic acid at 1 mol%AND 10 mol% (as a source of fatty acid) and BSA-treated lipid (to
test if the transport is fatty acid dependent) on the rate of chloride transport of receptor 5.2
(0.1 mol%).
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Figure D26: Using KGlu-KOH assay from POPC vesicles loaded with KGlu (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied to determine
the effect of addition of the ionophore valinomycin at 0.05 mol% (as a measure of H+ flux),
oleic acid at 1 mol% (as a source of fatty acid) and BSA-treated lipid (to test if the transport
is fatty acid dependent) on the rate of chloride transport of receptor 5.3 (0.1 mol%).
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Figure D27: Using KGlu-KOH assay from POPC vesicles loaded with KGlu (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied to determine
the effect of addition of the ionophore valinomycin at 0.05 mol% (as a measure of H+ flux),
oleic acid at 1 mol% (as a source of fatty acid) and BSA-treated lipid (to test if the transport
is fatty acid dependent) on the rate of chloride transport of receptor 5.4 (0.1 mol%).
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Figure D28: Using KGlu-KOH assay from POPC vesicles loaded with KGlu (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied to determine
the effect of addition of the ionophore valinomycin at 0.05 mol% (as a measure of H+ flux),
oleic acid at 1 mol% (as a source of fatty acid) and BSA-treated lipid (to test if the transport
is fatty acid dependent) on the rate of chloride transport of receptor 5.5 (0.1 mol%).
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Figure D29: Observed fluorescence ratio response due to HCl influx in the presence of
compounds 5.1 (10 mol%) into vesicles loaded with KCl (100 mM) and suspended in KCl,
KBr, KI, KNO3 and KClO4 (100 mM). All external and internal solutions were buffered to
pH 7 with HEPES (10 mM).
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Figure D30: Observed fluorescence ratio response due to HCl influx in the presence of
compounds 5.2 (1 mol%) into vesicles loaded with KCl (100 mM) and suspended in KCl,
KBr, KI, KNO3 and KClO4 (100 mM). All external and internal solutions were buffered to
pH 7 with HEPES (10 mM).
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Figure D31: Observed fluorescence ratio response due to HCl influx in the presence of
compounds 5.3 (1 mol%) into vesicles loaded with KCl (100 mM) and suspended in KCl,
KBr, KI, KNO3 and KClO4 (100 mM). All external and internal solutions were buffered to
pH 7 with HEPES (10 mM).
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Figure D32: Observed fluorescence ratio response due to HCl influx in the presence of
compounds 5.4 (1 mol%) into vesicles loaded with KCl (100 mM) and suspended in KCl,
KBr, KI, KNO3 and KClO4 (100 mM). All external and internal solutions were buffered to
pH 7 with HEPES (10 mM).
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Figure D33: Observed fluorescence ratio response due to HCl influx in the presence of
compounds 5.5 (1 mol%) into vesicles loaded with KCl (100 mM) and suspended in KCl,
KBr, KI, KNO3 and KClO4 (100 mM). All external and internal solutions were buffered to
pH 7 with HEPES (10 mM).
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2) Potassium over sodium selectivity:
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Figure D34: Observed fluorescence ratio response due to HCl influx or Cl-/OH- antiport
facilitated by compound 5.2 (1 mol%) using KCl-KOH and NaCl-KOH assays from POPC
vesicles loaded with KCl (100 mM) or NaCl, respectively. All external and internal
solutions were buffered to pH 7.0 with HEPES (10 mM). The test compound was added
at 0 s and detergent was added at 200 s. Ionophore concentrations are shown as ionophore
to lipid molar ratios. Error bars represent SD from at least three repeats.
1.2

DMSO
3 (1 mol%) KCl
3 (1 mol%) NaCl

Fluorescence ratio

1.0

0.8

0.6

0.4

0.2

0.0
0

50

100

150

200

250

300

Time / s
[3] = 5.3
Figure D35: Observed fluorescence ratio response due to HCl influx or Cl-/OH- antiport
facilitated by compound 5.3 (1 mol%) using KCl-KOH and NaCl-KOH assays from POPC
vesicles loaded with KCl (100 mM) or NaCl, respectively. All external and internal
solutions were buffered to pH 7.0 with HEPES (10 mM). The test compound was added
at 0 s and detergent was added at 200 s. Ionophore concentrations are shown as ionophore
to lipid molar ratios.
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3) Calcein leakage assays:
A chloroform solution of POPC was evaporated under vacuum and dried for at least
6 h as reported.1 The thin film was hydrated by the internal solution containing
calcein disodium salt (100 mM) and NaCl (100 mM) buffered to pH 7.4 with
HEPES (10 mM). Then, the lipid suspension was subjected to nine freeze-thaw
cycles followed by extrusion 25 times through a 200 nm polycarbonate membrane.
Size exclusion chromatography using sephadex G-25 column and calcein-free
external solution, containing NaCl (100 mM) and Na2SO4 (100 mM) buffered to
pH 7.4 with HEPES (10 mM).

The resulting suspension of dye-encapsulated LUVs with a mean diameter of 200
nm was diluted with the external solution to obtain 2.5 mL lipid suspension
containing a 0.1 mM lipid concentration. After the tested receptors 5.1-5.5 were
added at 1 mol%, calcein fluorescence (λex = 490 nm, λem = 520 nm) was recorded
at 25 °C. Detergent (25 μL) was added at 200 seconds to lyse the vesicle and to
calibrate the assay.

The fractional calcein release (FR) was calculated as follows (with It = fluorescence
intensity at time t, I0 = fluorescence intensity at time 0 and Imax = fluorescence
intensity after addition of detergent):

𝐹𝑅 =
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Fractional calcein release
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Figure D36: Calcein leakage by 5.1-5.5 (1 mol% carrier-to-lipid) from unilamellar POPC
vesicles loaded with calcein disodium salt (100 mM) and NaCl (100 mM) buffered to pH
7.4 with HEPES (10 mM). At t = 10 s, a DMSO solution of the transporter was added to
start the experiment. At the end of the experiment, detergent was added to lyse the vesicles.
The results are shown as the fraction of calcein leaked from the vesicles.
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4) Ion selective electrode (ISE) assays:
Cl/NO3 exchange assay:
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Figure D37: Chloride efflux mediated by receptor 5.1 (10 mol% w.r.t. lipid), added from
stock DMSO solutions of the receptor at varying concentration with different loading
volume. The compound was added to POPC vesicles containing 489 mM KCl and
suspended in 489 mM KNO3, both buffered to pH 7.2 with phosphate buffer. At the end of
the experiment the vesicles were lysed with detergent to achieve 100% chloride efflux.
Each point represents the average of 3 trials.
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Figure D38: Chloride efflux mediated by receptor 5.2 (1 mol%), added from stock DMSO
solutions of the receptor at varying concentration with different loading volume. The
compound was added to POPC vesicles containing 489 mM KCl and suspended in 489
mM KNO3, both buffered to pH 7.2 with phosphate buffer. At the end of the experiment
the vesicles were lysed with detergent to achieve 100% chloride efflux. Each point
represents the average of 3 trials.
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Figure D39: Chloride efflux mediated by receptor 5.3 (1 mol%), added from stock DMSO
solutions of the receptor at varying concentration with different loading volume. The
compound was added to POPC vesicles containing 489 mM KCl and suspended in 489
mM KNO3, both buffered to pH 7.2 with phosphate buffer. At the end of the experiment
the vesicles were lysed with detergent to achieve 100% chloride efflux. Each point
represents the average of 3 trials.
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Figure D40: Chloride efflux mediated by receptor 5.4 (1 mol%), added from stock DMSO
solutions of the receptor at varying concentration with different loading volume. The
compound was added to POPC vesicles containing 489 mM KCl and suspended in 489
mM KNO3, both buffered to pH 7.2 with phosphate buffer. At the end of the experiment
the vesicles were lysed with detergent to achieve 100% chloride efflux. Each point
represents the average of 3 trials.
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Figure D41: Hill plot analysis of chloride efflux facilitated by compound 5.2 from
unilamellar POPC vesicles that were loaded with a 489 mM KCl solution buffered to pH
7.2 with 5 mM phosphate, and were suspended in a 489 mM KNO3 solution buffered to
pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each point is the average
of three repeats.
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Figure D42: Hill plot analysis of chloride efflux facilitated by compound 5.3 from
unilamellar POPC vesicles that were loaded with a 489 mM KCl solution buffered to pH
7.2 with 5 mM phosphate, and were suspended in a 489 mM KNO3 solution buffered to
pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each point is the average
of three repeats.
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Figure D43: Hill plot analysis of chloride efflux facilitated by compound 5.4 from
unilamellar POPC vesicles that were loaded with a 489 mM KCl solution buffered to pH
7.2 with 5 mM phosphate, and were suspended in a 489 mM KNO3 solution buffered to
pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each point is the average
of three repeats.
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Figure D44: Chloride efflux mediated by different mol% of transporter 5.5, from
unilamellar POPC vesicles that were loaded with a 489 mM KCl solution buffered to pH
7.2 with 5 mM phosphate, and were suspended in a 489 mM KNO 3 solution buffered to
pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each point is the average
of three repeats. The maximim observed solubility of compound 5 in DMSO was 1 mM,
so higher concentration could not be performed to get hill plot.
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Figure D45: Electrogenic or electroneutral transport mediated by compound 5.2 (1 mol%
with respect to lipid) in the presence of monensin or valinomycin (0.1 mol% with respect
to lipid). Unilamellar POPC vesicles were loaded with a 300 mM KCl solution buffered to
pH 7.2 with 5 mM phosphate and were suspended in a 300 mM KGlu solution buffered to
pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each point is the average
of three repeats.
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Figure D46: Electrogenic or electroneutral transport mediated by compound 5.3 (1 mol%
with respect to lipid) in the presence of monensin or valinomycin (0.1 mol% with respect
to lipid). Unilamellar POPC vesicles were loaded with a 300 mM KCl solution buffered to
pH 7.2 with 5 mM phosphate and were suspended in a 300 mM KGlu solution buffered to
pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each point is the average
of three repeats.

307

Appendix D for Chapter 5

100

Chloride efflux (%)

80

60

[4] = 2 mol%
DMSO
4
4 + 0.1 mol% Vlinomycin
4 + 0.1 mol% Monensin

40

20

0
0

50

100

150

200

250

300

Time / s

[4] = 5.4
Figure D47: Electrogenic or electroneutral transport mediated by compound 5.4 (1 mol%
with respect to lipid) in the presence of monensin or valinomycin (0.1 mol% with respect
to lipid). Unilamellar POPC vesicles were loaded with a 300 mM KCl solution buffered to
pH 7.2 with 5 mM phosphate and were suspended in a 300 mM KGlu solution buffered to
pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each point is the average
of three repeats.
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Fluorescence intensity

5) Fluorescence titration studies with TBACl
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Figure D48: Fluorescent changes over 30 minutes (Ex = 285 nm) of compound 5.2 (1.0
μM) upon addition of 100 equivalents of TBACl (100 μM) in DMSO.
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Figure D49: Fluorescent changes over 30 minutes (Ex = 350 nm) of compound 5.3 (1.0
μM) upon addition of 100 equivalents of TBACl (100 μM) in DMSO.
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D) Transport studies upon reduction of complexes 5.13, 5.14, 5.16
and 5.17.
1.0

0.8

0.6

[5.2] and [5.13] = 1 mol%
DMSO
DTT
5.2
5.2+ DTT
5.13
5.13 + DTT 30 m
5.13 + DTT 3h

0.4

0.2

0.0
0

50

100

150

200

250

300

Time / s

Figure D50: Observed fluorescence ratio response due to H+/Cl- symport or Cl-/OHantiport upon reduction of complex 5.13 (1 μM) by dithiothreitol DTT (3 μΜ) using KClKOH assay from POPC vesicles loaded with KCl (100 mM), buffered to pH 7.0 with
HEPES (10 mM) after 30 minutes and 3 hours. The test complex 6 (1 mol%) and KOH
were added firstly, then DTT was added at 0 s. DMSO, DTT (3 mol%), parent anion
transporter 5.2 and complex 5.13 (without addition of DTT) were used as controls.
Detergent was added at 200 s. Ionophore concentrations are shown as ionophore to lipid
molar ratios. Error bars represent SD from at least three repeats.

Normalised HPTS Intensity [F460/F403]

1.0

0.8

0.6

[5.2] and [5.13] = 1 mol%
DMSO
TCEP
5.2
5.2 + TCEP
5.13
5.13 + TCEP 30 m
5.13 + TCEP 3 h

0.4

0.2

0.0
0

50

100

150

200

250

300

Time / s

Figure D51: Observed fluorescence ratio response due to H+/Cl- symport or Cl-/OHantiport upon reduction of complex 5.13 (1 μM) by TCEP (3 mM) using KCl-KOH assay
from POPC vesicles loaded with KCl (100 mM), buffered to pH 7.0 with HEPES (10 mM)
after 30 minutes and 3 hours. The test complex 5.13 (1 mol%) and KOH were added firstly,
then TCEP was added at 0 s. DMSO, TCEP (3 mol%), parent anion transporter 5.2 and
complex 5.13 (without addition of TCEP) were used as controls. Detergent was added at
200 s. Ionophore concentrations are shown as ionophore to lipid molar ratios. Error bars
represent SD from at least three repeats.
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Figure D52: Observed fluorescence ratio response due to H+/Cl- symport or Cl-/OHantiport upon reduction of complex 5.14 (1 μM) by dithiothreitol DTT (3 mM) using KClKOH assay from POPC vesicles loaded with KCl (100 mM), buffered to pH 7.0 with
HEPES (10 mM) after 30 minutes and 3 hours. The test complex 5.14 (1 mol%) and KOH
were added firstly, then DTT was added at 0 s. DMSO, DTT (3 mol%), parent anion
transporter 5.3 and complex 5.14 (without addition of DTT) were used as controls.
Detergent was added at 200 s. Ionophore concentrations are shown as ionophore to lipid
molar ratios. Error bars represent SD from at least three repeats.
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Figure D53: Observed fluorescence ratio response due to H+/Cl- symport or Cl-/OHantiport upon reduction of complex 5.14 (1 μM) by TCEP (3 mM) using KCl-KOH assay
from POPC vesicles loaded with KCl (100 mM), buffered to pH 7.0 with HEPES (10 mM)
after 30 minutes and 3 hours. The test complex 5.14 (1 mol%) and KOH were added firstly,
then TCEP was added at 0 s. DMSO, TCEP (3 mol%), parent anion transporter 5.3 and
complex 5.14 (without addition of TCEP) were used as controls. Detergent was added at
200 s. Ionophore concentrations are shown as ionophore to lipid molar ratios. Error bars
represent SD from at least three repeats.
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Figure D54: Observed fluorescence ratio response due to H+/Cl- symport or Cl-/OHantiport upon reduction of complex 5.16 (1 μM) by dithiothreitol DTT (3 mΜ) using KClKOH assay from POPC vesicles loaded with KCl (100 mM), buffered to pH 7.0 with
HEPES (10 mM) after 5 minutes and 20 minutes. The test complex 5.16 (1 mol%) and
KOH were added firstly, then DTT was added at 0 s. DMSO, DTT (3 mol%), parent anion
transporter 5.2 and complex 5.16 (without addition of DTT) were used as controls.
Detergent was added at 200 s. Ionophore concentrations are shown as ionophore to lipid
molar ratios. Error bars represent SD from at least three repeats.
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Figure D55: Observed fluorescence ratio response due to H+/Cl- symport or Cl-/OHantiport upon reduction of complex 5.16 (1 μM) by TCEP (3 mM) using KCl-KOH assay
from POPC vesicles loaded with KCl (100 mM), buffered to pH 7.0 with HEPES (10 mM)
after 5 minutes, 20 minutes and 3 hours. The test complex 5.16 (1 mol%) and KOH were
added firstly, then TCEP was added at 0 s. DMSO, TCEP (3 mol%), parent anion
transporter 5.2 and complex 5.16 (without addition of TCEP) were used as controls.
Detergent was added at 200 s. Ionophore concentrations are shown as ionophore to lipid
molar ratios. Error bars represent SD from at least three repeats.
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Figure D56: Observed fluorescence ratio response due to H+/Cl- symport or Cl-/OHantiport upon reduction of complex 5.17 (1 μM) by dithiothreitol DTT (3 mM) using KClKOH assay from POPC vesicles loaded with KCl (100 mM), buffered to pH 7.0 with
HEPES (10 mM) after 5 minutes and 20 minutes. The test complex (1 mol%) and KOH
were added firstly, then DTT was added at 0 s. DMSO, DTT (3 mol%), parent anion
transporter 5.2 and complex 5.17 (without addition of DTT) were used as controls.
Detergent was added at 200 s. Ionophore concentrations are shown as ionophore to lipid
molar ratios. Error bars represent SD from at least three repeats.
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Figure D57: Observed fluorescence ratio response due to H+/Cl- symport or Cl-/OHantiport upon reduction of complex 5.17 (1 μM) by TCEP (3 mM) using KCl-KOH assay
from POPC vesicles loaded with KCl (100 mM), buffered to pH 7.0 with HEPES (10 mM)
after 5 minutes and 20 minutes. The test complex 5.17 (1 mol%) and KOH were added
firstly, then TCEP was added at 0 s. DMSO, TCEP (3 mol%), parent anion transporter 5.3
and complex 5.17 (without addition of TCEP) were used as controls. Detergent was added
at 200 s. Ionophore concentrations are shown as ionophore to lipid molar ratios. Error bars
represent SD from at least three repeats.
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B) Binding studies:
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Figure E1: 1H NMR spectroscopic titration of receptor 6.1 (2 mM) with TBACl in DMSOd6 with 0.5% water at 298 K. a) Stack plot. b) Fitplot for 4 NH protons at δ = 8.09, 8.54,
9.00 and 9.46 using global analysis with 1:1 (Ka = 81 M-1, error: 1%). c) Plot of the residuals
for using global analysis. d) Calculated mole fractions.
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Figure E2: 1H NMR spectroscopic titration of receptor 6.2 (2 mM) with TBACl in DMSOd6 with 0.5% water at 298 K. a) Stack plot. b) Fitplot for 4 NH protons at δ = 8.25, 8.64,
9.56 and 9.90 using global analysis with 1:1 (Ka = 146 M-1, error: 3%). c) Plot of the
residuals for using global analysis. d) Calculated mole fractions.
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Figure E3: 1H NMR spectroscopic titration of receptor 6.3 (2 mM) with TBACl in DMSOd6 with 0.5% water at 298 K. a) Stack plot. b) Fitplot for 4 NH protons at δ = 8.23, 8.63,
9.46 and 9.84 using global analysis with 1:1 (Ka = 177 M-1, error: 3%). c) Plot of the
residuals for using global analysis. d) Calculated mole fractions.
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Figure E4: 1H NMR spectroscopic titration of receptor 6.4 (2 mM) with TBACl in DMSOd6 with 0.5% water at 298 K. a) Stack plot. b) Fitplot for 4 NH protons at δ = 8.54, 8.80,
9.90 and 10.37 using global analysis with 1:1 (Ka = 96 M-1, error: 5%). c) Plot of the
residuals for using global analysis. d) Calculated mole fractions.
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C) Transport studies:
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Figure E5: a) Dose response curve and b) Hill plot analysis of chloride efflux facilitated
by compound 6.1 from unilamellar POPC vesicles that were loaded with a 489 mM KCl
solution buffered to pH 7.2 with 5 mM phosphate, and were suspended in a 489 mM KNO3
solution buffered to pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each
point is the average of at least two repeats.
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Figure E6: a) Dose response curve and b) Hill plot analysis of chloride efflux facilitated
by compound 6.2 from unilamellar POPC vesicles that were loaded with a 489 mM KCl
solution buffered to pH 7.2 with 5 mM phosphate, and were suspended in a 489 mM KNO3
solution buffered to pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each
point is the average of at least two repeats.
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Figure E7: a) Dose response curve and b) Hill plot analysis of chloride efflux facilitated
by compound 6.3 from unilamellar POPC vesicles that were loaded with a 489 mM KCl
solution buffered to pH 7.2 with 5 mM phosphate, and were suspended in a 489 mM KNO3
solution buffered to pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each
point is the average of at least two repeats.
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Figure E8: a) Dose response curve and b) Hill plot analysis of chloride efflux facilitated
by compound 6.4 from unilamellar POPC vesicles that were loaded with a 489 mM KCl
solution buffered to pH 7.2 with 5 mM phosphate, and were suspended in a 489 mM KNO3
solution buffered to pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each
point is the average of at least two repeats.
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Figure E9: Electrogenic or electroneutral transport mediated by compound 6.1 (2 mol%
with respect to lipid) in the presence of monensin or valinomycin (0.1 mol% with respect
to lipid). Unilamellar POPC vesicles were loaded with a 300 mM KCl solution buffered to
pH 7.2 with 5 mM phosphate and were suspended in a 300 mM KGlu solution buffered to
pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each point is the average
of at least two repeats.
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Figure E10: Electrogenic or electroneutral transport mediated by compound 6.2 (0.05
mol% with respect to lipid) in the presence of monensin or valinomycin (0.1 mol% with
respect to lipid). Unilamellar POPC vesicles were loaded with a 300 mM KCl solution
buffered to pH 7.2 with 5 mM phosphate and were suspended in a 300 mM KGlu solution
buffered to pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each point is
the average of at least two repeats.
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Figure E11: Electrogenic or electroneutral transport mediated by compound 6.3 (0.05
mol% with respect to lipid) in the presence of monensin or valinomycin (0.1 mol% with
respect to lipid). Unilamellar POPC vesicles were loaded with a 300 mM KCl solution
buffered to pH 7.2 with 5 mM phosphate and were suspended in a 300 mM KGlu solution
buffered to pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each point is
the average of at least two repeats.
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Figure E12: Electrogenic or electroneutral transport mediated by compound 6.4 (0.2 mol%
with respect to lipid) in the presence of monensin or valinomycin (0.1 mol% with respect
to lipid). Unilamellar POPC vesicles were loaded with a 300 mM KCl solution buffered to
pH 7.2 with 5 mM phosphate and were suspended in a 300 mM KGlu solution buffered to
pH 7.2 with 5 mM phosphate salts. DMSO was used as a control. Each point is the average
of at least two repeats.
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Figure E13: a) Dose response curve, b) Hill plot analysis of H+/Cl- symport or Cl-/OHantiport facilitated by compound 6.1 using KCl-KOH assay from POPC vesicles loaded
with KCl (100 mM), buffered to pH 7.0 with HEPES (10 mM). The test compound was
added at 0 s and detergent was added at 200 s. Ionophore concentrations are shown as
ionophore to lipid molar ratios. Error bars represent SD from at least three repeats.
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Figure E14: a) Dose response curve, b) Hill plot analysis of H+/Cl- symport or Cl-/OHantiport facilitated by compound 6.2 using KCl-KOH assay from POPC vesicles loaded
with KCl (100 mM), buffered to pH 7.0 with HEPES (10 mM). The test compound was
added at 0 s and detergent was added at 200 s. Ionophore concentrations are shown as
ionophore to lipid molar ratios. Error bars represent SD from at least three repeats.
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b)

Normalized [F460/F403] at 200 s
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HillFit_normalised (User)
y = y0 + (y1 - y0) * x^n / (k^n + x^n)
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Value
Error
y0
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y1
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Fitted parameters
EC50, k
6.33811E-4 2.69457E-5
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Figure E15: a) Dose response curve, b) Hill plot analysis of H+/Cl- symport or Cl-/OHantiport facilitated by compound 6.3 using KCl-KOH assay from POPC vesicles loaded
with KCl (100 mM), buffered to pH 7.0 with HEPES (10 mM). The test compound was
added at 0 s and detergent was added at 200 s. Ionophore concentrations are shown as
ionophore to lipid molar ratios. Error bars represent SD from at least three repeats.
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a)

Normalised HPTS Intensity [F460/F403]
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b)

Normalized [F460/F403] at 200 s
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Figure E16: a) Dose response curve, b) Hill plot analysis of H+/Cl- symport or Cl-/OHantiport facilitated by compound 6.4 using KCl-KOH assay from POPC vesicles loaded
with KCl (100 mM), buffered to pH 7.0 with HEPES (10 mM). The test compound was
added at 0 s and detergent was added at 200 s. Ionophore concentrations are shown as
ionophore to lipid molar ratios. Error bars represent SD from at least three repeats.
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Figure E17: Using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied including using
BSA-treated lipid (to test if the transport is fatty acid dependent) addition of oleic acid at
1 mol% (as a source of fatty acid), addition of the protonphore cccp at 1 mol% (to measure
of chloride uniport solely), or addition of valinomycin at 0.05 mol% (as a measure of H+
flux), on the rate of chloride transport of receptor 6.1 (0.05 mol%).
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Figure E18: Using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied including using
BSA-treated lipid (to test if the transport is fatty acid dependent) addition of oleic acid at
1 mol% (as a source of fatty acid), addition of the protonphore cccp at 1 mol% (to measure
of chloride uniport solely), or addition of valinomycin at 0.05 mol% (as a measure of H+
flux), on the rate of chloride transport of receptor 6.2 (0.002 mol%).
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Figure E19: Using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied including using
BSA-treated lipid (to test if the transport is fatty acid dependent) addition of oleic acid at
1 mol% (as a source of fatty acid), addition of the protonphore cccp at 1 mol% (to measure
of chloride uniport solely), or addition of valinomycin at 0.05 mol% (as a measure of H +
flux), on the rate of chloride transport of receptor 6.3 (0.001 mol%).
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Figure E20: Using KCl-KOH assay from POPC vesicles loaded with KCl (100 mM),
buffered to pH 7.0 with HEPES (10 mM), different conditions were applied including using
BSA-treated lipid (to test if the transport is fatty acid dependent) addition of oleic acid at
1 mol% (as a source of fatty acid), addition of the protonphore cccp at 1 mol% (to measure
of chloride uniport solely), or addition of valinomycin at 0.05 mol% (as a measure of H +
flux), on the rate of chloride transport of receptor 6.4 (0.01 mol%).
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Appendix F: Supplementary Information to Chapter 7
A) NMR spectra of compounds from chapter 7
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Selected high-resolution mass spectra:
Compound 7.9:

Compound 7.10:

Compound 7.11:

Compound 7.12:
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Compound 7.13:

Compound 7.14:

Compound 7.15:

Compound 7.16:
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Compound 7.17:

Compound 7.18
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Compound 7.19:

Compound 7.22:
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Compound 7.23:

Compound 7.24:

Compound 7.27:
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Compound 7.28:

Compound 7.29:

Compound 7.30:
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B) HPLC purity:
The purity of all tested compounds was determined by High Performance Liquid
Chromatography (HPLC) analysis and was greater than 95%. HPLC was performed
with a Shimadzu CLASS-VP LC10 analytical HPLC system (Shimadzu
Corporation, Kyoto, Japan) equipped with a diode array detector and an autosampler with detection at 254 nm and at a flow rate of 0.5 mL/min. The column
used in HPLC analysis was Luna C18 column (250 × 4.6 mm; 5 μm particle size;
Phenomenex, Australia). Column temperature was not controlled during the
experiment. The mobile phase consisted of (A) water/TFA (99.9:0.1, v/v) and (B)
acetonitrile/TFA (99.9:0.1, v/v).
Table F1: HPLC purity of the synthesized compounds
Compound
Formula
Retention time
7.9
C10H12N2O4S
5.58
7.10
C17H16N2O4S
5.56
7.11
C17H15ClN2O4S
5.79
7.12
C17H15ClN2O4S
5.80
7.13
C18H18N2O5S
5.54
7.14
C17H15N3O6S
5.90
7.15
C17H14ClFN2O4S
5.85
7.16
C15H14N2O4S2
5.48
7.17
C16H16N4O4S
6.74
7.18
C16H15FN4O4S
6.75
7.19
C16H15ClN4O4S
6.75
7.20
C16H15BrN4O4S
6.72
7.21
C17H15N5O4S
6.62
7.22
C17H18N4O5S
6.63
7.23
C16H15N5O6S
6.65
7.24
C18H20N4O6S
6.66
7.26
C14H13ClN4O3S
4.98
7.27
C14H12FClN4O3S
5.63
7.28
C14H12Cl2N4O3S
5.62
7.29
C14H12BrClN4O3S
5.02
7.30
C15H15ClN4O4S
5.02

Purity
98.4%
98.6%
96.1%
97.2%
95.5%
98.0%
95.2%
98.0%
98.0%
95.2%
95.9%
95.6%
98.2%
99.4%
98.7%
97.4%
99.5%
99.5%
97.9%
99.6%
99.4%
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C) Protein X-ray crystallography data:
Table F2: Summary of Data Collection and Atomic Model Refinement
Statistics
PDB

6UFB

6UFC

6UFD

compound

7.10

7.13

7.16

Space group

P21

P21

P21

42.4, 41.5,

42.6, 41.5,

42.6, 41.7,

72.0

72.4

72.3

alpha, beta,

90, 104.5,

90, 104.7,

90, 104.6,

gamma

90

90

90

Resolution

41.5 - 1.67

41.5 - 1.32

41.7 - 1.48

1.70 - 1.67

1.35 - 1.32

1.50 - 1.48

0.091

0.083

0.127

(0.772)

(0.536)

(0.790)

0.036

0.035

0.053

(0.302)

(0.235)

(0.370)

0.999

0.998

0.995

(0.800)

(0.810)

(0.625)

I/sigI

17.2 (2.6)

12.2 (3.2)

10.1 (2.6)

Completeness

97.3 (94.0)

97.7 (88.2)

97.7 (69.4)

7.5 (7.3)

6.7 (6.0)

6.7 (5.3)

resolution (Å)

41.0 - 1.67

40.3 - 1.32

41.3 - 1.48

unique

26,243

52,867

38,441

15.1 / 18.6

11.7 / 14.4

14.9 / 16.7

Cell
dimensions
a, b, c

(Å)
Resolutionhigh (Å)
Rmerge

Rpim

CC ½

(%)
Redundancy

Refinement

reflections
Rwork/Rfree
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(%)
# atoms

2466

2510

2496

Protein

2164

2206

2203

metal (Zn)

1

1

1

ligand

24

26

23

water

258

270

250

B-factors

14.9

9.3

13.8

protein

15.1

14.4

14.0

metal (Zn)

7.9

7.0

6.4

ligand

19.6

20.4

16.5

water

26.0

27.7

25.4

0.010

0.008

0.009

1.628

1.753

1.646

(Å2)

r.m.s.
deviations
Bond
length (Å)
Bond
angle (°)
* values in parenthesis are values in the high-resolution bin
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Figure F1: Graphical depiction of the model fit to experimental electron density of
all instances of 7.10 in hCA II active site (pdb 6UFB). Each fit is shown from
different orientation to approximate a three-dimensional view. 2mFo-DFc (at 0.7
rmsd) in gray mFo-DFc (at 3 Å rmsd) in purple (negative) and green (positive).

379

Appendix F for Chapter 7

Figure F2: Graphical depiction of the model fit to experimental electron density of
all instances of 7.13 in hCA II active site (pdb 6UFC). Each fit is shown from
different orientation to approximate a three-dimensional view. 2mFo-DFc (at 0.7
rmsd) in gray mFo-DFc (at 3 Å rmsd) in purple (negative) and green (positive).
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Figure F3: Graphical depiction of the model fit to experimental electron density
of all instances of 7.16 in hCA II active site (pdb 6UFD). Each fit is shown from
different orientation to approximate a three-dimensional view. 2mFo-DFc (at 0.7
rmsd) in gray mFo-DFc (at 3 Å rmsd) in purple (negative) and green (positive).
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Figure F4: Protein X-ray structure of 7.10 bound to the active site in CA II (pdb
6UFB). The molecular surface of the active site is coloured in blue for the
hydrophilic half and in red for the hydrophobic area.
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